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PlAtelet trAnsfusions: ProDuCts AnD enDPoints  
in rAnDomiZeD ControlleD triAls
Under the assumption that thrombocytopenia correlates with bleeding complications, 
guidelines advise to institute a platelet transfusion policy to prevent and treat bleeding 
complications in haemato-oncology patients with thrombocytopenia due to myelosuppressive 
diseases and/or treatment.1-4 At the start of the research for this thesis platelet transfusion 
therapy appeared to be a fact of life and a point of no return had been achieved, underlining 
the statement by Schiffer in 1992 “unfortunately, it will be scientifically impossible to perform 
studies 20 years after the horse is out of the barn to prove the value of this approach”.5 
Meanwhile clinicians paid only limited attention to the quality of the platelet products as 
long as they were available on demand. The product we tested in our first randomized 
controlled trial (RCT), platelets stored in an additive solution, was just one of the last of several 
modifications since the systematic preventive use of platelets. Studies concerning platelet 
transfusions conducted between the early eighties until the late nineties mainly investigated 
product modifications to reduce adverse reactions, such as (non)-immunological refractoriness 
and febrile transfusion reactions. It was only in the last decade that clinical efficacy became 
an issue, even more to blood bankers than to clinicians.6 The modifications which have been 
performed to improve the safety profile are typically characterised by removing one or more 
components after blood donation (figure 1). This introduction aims to recapitulate platelet 
transfusions from a historical perspective and the development of policy guidelines, mainly 
focussing on the clinical evidence for the several product modifications throughout time.
figure 1: Figure 1 shows the several general modifications in the production of platelet products. 
Not shown is the proces of pooling (possible since the introduction of sterile docking devices in  
the eighties) leading to multidonor Platelet Rich Plasma v.s. Buffy-coat platelet products.
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One of the first physicians investigating the fate of transfused platelets and a potential 
method to treat bleeding was Duke in 1911.7 Using blood from a polycythemic donor 
Duke et al determined that donor platelets survived five to six days following transfusion 
in a young patient probably suffering from congenital thrombocytopenia. In contrast to 
the transfusion of blood of a normal donor, blood of the polycythemic donor resulted 
in a longer lasting rise of the platelet count and a reduction in bleeding time (figure 2).8 
A platelet survival study in 22 patients using a direct transfusion of polycythemic blood 
after a first transfusion using a normal donor to prevent “platelet hunger” suggested a 
survival of 48 – 72 hours, potentially influenced by active bleeding and an enlarged spleen. 
Bleeding time was shortened promptly after transfusion, a beneficial effect which lasted 
approximately 24 hours longer than the platelet survival.9
Klein and Freireich et al developed a technique for platelet separation by differential 
centrifugation to obtain platelets for clinical use and a first study comparing fresh 
versus banked blood in the management of bleeding was performed.10, 11 In one of the 
first reviews platelet transfusions were already considered as a part of the “total care” 
for patients with malignancies, however the difficulty of an objective evaluation of the 
“self-apparent” effects of platelet transfusions and the need for controlled studies was 
also emphasized.12 A state-of-the-art review concerning the development and quality of 
platelet products as well as guidance for clinical use stated that the indication for platelet 
transfusions was haemorrhage associated with severe thrombocytopenia, defined as a 
platelet count less than 10 x 109/l.13 Two autopsy studies showed that fatal haemorrhages 
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figure 2: Figure 2 shows one of the first in vivo experiments studying the survival of transfused 
platelets in a thrombocytopenic patient. PLT= Platelets
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reported a dramatic reduction of fatal haemorrhages after the implementation of platelet 
transfusions.14, 15 The first prospective landmark study in 92 patients with acute leukaemia 
by Gaydos et al showed a relationship between the platelet count as well as a decrease 
in platelet count and the risk of bleeding, although no threshold level could be observed. 
However, it was after this publication that the concept of prophylactic rather than 
therapeutic platelet transfusions emerged (figure 3).16 
Since this publication, several strategies have been studied in clinical trials investigating 
the use of prophylactic transfusions as opposed to therapeutic platelet transfusions, 
platelet transfusion thresholds and platelet transfusion dose. In parallel with these trials 
the manufacturing of platelet products has constantly evolved with the development 
of several ways to harvest platelets, sterile docking device, storage bags and the 
introduction of additive solutions as well as pathogen reduction techniques, driven 
by emerging blood-borne infections and bacterial growth associated with prolonged 
storage of platelets at ambient temperature. Thus far 5 RCTs have studied prophylactic 
platelet transfusions as opposed to therapeutic transfusions.17-21 Based on the three oldest 
studies, the combined relative risk for major or more severe bleeding complications 
was 0.49 (95%CI 0.28 – 0.87) favouring prophylactic platelet transfusions.17, 19, 23, 22 More 
recently, a prophylactic versus therapeutic trial in patients with acute myeloid leukaemia 
reported also that bleeding complications were significantly increased in the therapeutic 
arm. There were 5 minor cerebral haemorrhagic complications and 2 lethal cerebral 
haemorrhages in the therapeutic arm as opposed to zero in the prophylactic arm.21 Four 
RCTs and six observational studies compared different platelet transfusion thresholds 
for prophylactic platelet transfusions from as low as 5 x 109/l to 30 x 109/l.27-32 Despite 
the heterogeneity of the studies, none of these studies has shown a difference with 
regard to bleeding complications, although lowering the platelet transfusion trigger 
led to a significant reduction in the mean number of platelet transfusions.22 Before the 
recent publication of the PLADO and the STOP trial, 4 RCTs and 1 observational study 
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figure 3: Figure 3 shows the number of patients included in randomised trials studying 
platelet transfusions. Policy driven RCTs are trials investigating indication (prophylactic versus 
therapeutic), thresholds and doses. Product related RCTs classically compare an alternative 
platelet product, for instance using additive solutions, with conventional platelet products, usually 
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investigated platelet dose.33-38 These trials were initiated to investigate the “optimal” 
platelet dose. Both economical as well as safety issues, i.e. minimizing donor exposure, 
are the main driving factors to reduce the transfusion threshold as well as the platelet 
dose. Both the PLADO as well as the STOP have made two important points. Firstly and 
most importantly, haemorrhagic complications are very frequent despite the use of 
prophylactic platelet transfusions (the % of patients with WHO ≥ 2 bleeding: PLADO 70%, 
STOP 50% without differences between the study arms with platelet doses reaching from 
± 0.8 x 1011/m2 (lowest dose in the STOP trial) to 4.4 x 1011/m2 (highest dose in the PLADO 
trial) and secondly more transfusions are administered in patients receiving low-dose 
platelet transfusions.37, 38 Although prophylactic platelet transfusions likely prevent severe 
haemorrhages, no definitive quantitative strategy with regard to threshold or doses can be 
made based on these trials.
In contrast to the straight forward search for an “optimal” platelet transfusion strategy, 
the approach to develop the “optimal” platelet product evolved more complicated by 
a diversity of ways to manufacture and store platelet products. Trials studying product 
modifications use an array of endpoints, including transfusion efficacy, haemostatic 
efficacy and the incidence of adverse transfusion reactions. Platelets can be prepared using 
aphaeresis (AP) or a whole-blood method (WBD), of which the platelet-rich plasma (PRP) 
method is mostly used in the United States, whereas the buffy-coat method (BC) is used 
in Europe. On top of these different collection and production methods, a large diversity 
in platelet products arises if we also include a variety of storage bag systems, methods 
for leukoreduction, gamma irradiation, variations in storage time and several additive 
solutions, which all potentially affect efficacy. A simple calculation results in over  
a thousand different currently clinically used platelet products. This diversity resulted in  
the need for defining which requirements should ideally be met by new platelet products 
as stated in a draft guidance of the FDA in 1999 (table 1).39
This manuscript mainly deals with efficacy, although most new platelet products or 
changes in production are driven by safety and economics. An optimal platelet product 
should be easy to produce with constant quality parameters, should be stored for 
preferably longer period than the current 5 – 7 days maintaining this quality, clinically 
efficient in terms of bleeding prevention and without adverse reactions such as febrile 
and allergic transfusion reactions, transfusion related acute lung injury (TRALI), infectious 
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test subcategory type of tests
A Paired in vitro studies Morphology Different levels of resolution, including EM
Biochemical ATP, glucose, lactate, pH and LDH
PLT activation P-selectin (CD62), CD63, fibrinogen binding (PA-
Cl), B-thromboglobulin, Plateletfactor 3 and 4
Physiological respons HSR, aggregation and serotonin release
Microparticles
B Platelet survival Healthy volunteers Radiolabeling of autologous platelets with 
111Indium and/ or 51Chromium
C Clinical haemostatic efficacy Thrombocytopenic patients Transfusion efficacy and haemostatic efficacy
PLT = Platelet; EM = Electron Microscopy; ATP = Adenosine Triphosphate; CD = Cluster of Differentiation;  
HSR = Hypotonic Shock Response; FDA = Food and Dug Administration
table 1: FDA Guidance for industry.
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complications and alloimmunization resulting in refractoriness. Moreover, preferably we 
would have in vitro measures to predict clinical safety and efficacy. However, to date there 
are no in vitro tests predicting viability in terms of recovery and survival or haemostatic 
function after transfusion in patients.40 The suggested performance of recovery / 
survival studies is hampered by the fact that the use of radiolabeling in volunteers is not 
operational in many countries, performed studies are small showing huge variation and 
more important the efficacy in healthy volunteers does not reflect the clinical outcome 
in thrombocytopenic patients. From 1970 to 2005 thirty-four RCTs have been performed 
testing one or more platelet product modifications (table 2).
Apart from studies investigating the clinical effect of storage time or production 
method (PRP, BC, AP), in historical order the following modifications have been subject 
of study: leukoreduction (centrifugation, filtration and UV irradiation), plasmareduction 
(concentration, additive solutions) and pathogen reduction (Amotosalen / UVA) (see also 
figure 1). 
The incentives for leukoreduction, by far the most studied topic in platelet product RCTs, 
were mainly the prevention of alloimmunisation, platelet refractoriness and febrile non-
haemolytic transfusion reactions (FNHTR) and CMV transmission. As the use of prophylactic 
platelet transfusions started to increase exponentially, the induction of HLA-antibodies 
with refractoriness as a consequence posed a major problem. Observations in mice by 
Claas et al supported previous clinical observations that the antibody response to platelets 
was enhanced by contaminating leukocytes acting as professional antigen presenting 
cells directly stimulating recipient T cells.41,42 A first non randomised study subsequently 
showed a significant decrease in the incidence of alloimmunization, from 93% to 24%, 
in patients receiving platelet concentrates, depleted from leukocytes below 2 x 107 by 
centrifugation.42 The first RCT using leukocyte-depleted platelet products was published in 
1983. This study failed to show a reduction of alloimmunisation with leukocyte-depleted 
platelet products using a centrifugation technique, although a trend was noticed in 
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type of modification endpoints n trials
Production (PrP, BC, AP) Alloimmunsation 6
Adverse TRF reactions
Post transfusion recovery
leukodepletion i inactivation Alloimmunisation 11
Post transfusion recovery
Plasmareduction Adverse TRF reactions 6
Post transfusion recovery
HlA or ABo matching Post transfusion recovery 4
Bleeding
Preincubation Post transfusion recovery 2
storage Post transfusion recovery 2
Photochemical pathogen reduction Post transfusion recovery 3
Bleeding
total 34
TRF = Transfusion; Note: all the trials have been counted once, although some trials could have been included in more 
than one category.
table 2: RCTs with different products and/or product modifications up to 2005. 43-55, 57-65, 67-81
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patients who where previously exposed to HLA antigens through pregnancy and or 
transfusions.43 In contrast two other RCTs showed a significant reduction in the rate of 
HLA-alloimmunisation as well as platelet transfusion refractoriness. In these studies the 
platelet products were leukodepleted using a filtration method.44, 45 In a study comparing 
centrifugation and filtration as methods for leukoreduction van Marwijk Kooy et al showed 
that filtration was more efficient in reducing HLA-immunization and refractoriness, 
probably due to a more consistent reduction in leukocytes.46 Apart from the reduction of 
alloimmunization, leukoreduction by filtration was also shown to reduce the number of 
febrile non-haemolytic transfusion reactions (FNHTRs).47 In the end of the eightees when 
sterile docking connecting two plastic tubings became possible, in Europe, the method of 
producing platelet concentrates changed from the PRP-method to the BC-method.  
After filtration BC derived PCs contain less leukocytes as compared to filtered PRP platelets 
and Oksanen et al showed that the use of filtered BC derived PCs (pre- as well as post 
storage alike) as compared to PRP platelets caused significantly fewer and milder adverse 
reactions.48 The first study testing UVB irradiation for the leukocyte inactivation showed 
comparable efficacy in terms of corrected count increments (CCI) but did not show  
a significant reduction of alloimmunization.49 The largest trial studying leukoreduction /  
inactivation is the TRAP trial. Essentially, this study in which 530 alloantibody negative 
patients with AML were randomised to receive standard non-leukodeleted pooled 
platelet concentrates, filtered pooled platelet concentrates, UVB treated pooled platelet 
concentrates or filtered platelets obtained by aphaeresis showed that, regardless the 
method used to reduce/inactivate leukocytes, leukoreduction resulted in a reduction  
of alloantibody-mediated refractoriness.50 A meta-analysis of European studies and  
the TRAP study confirmed that leukoreduction reduced immunological refractoriness  
by almost 80%.51
 
In 1994 Heddle et al showed that the supernatant plasma component of stored leukocyte-
containing PCs was more likely to cause severe reactions as compared to the platelet 
concentrates itself, and a strong correlation was observed between the reactions and 
the concentration of interleukin-1β an interleukin-6.52 Chalandon et al showed that 
cytokines arise during storage of leukocyte-containing PCs, supporting that pre storage 
leukoreduction favours over post storage leukoreduction.53 Another trial suggesting 
that plasma removal is more effective in preventing adverse transfusion reactions, 
despite cytokines accumulate during storage also in additive solutions, gave rise to the 
development of platelet additive solutions.54 Up till 2005 only 1 RCT reported on the 
clinical efficacy of BCs stored in additive solution (AS). This study showed a significantly 
decreased transfusion efficacy of platelets stored in AS, however AS stored BCs significantly 
reduced the incidence of adverse transfusion reactions. No comments were made 
regarding the haemostatic efficacy.55 Despite the reduced transfusion efficacy the results of 
this trial as well as similar results in a subanalysis of another trial led to the introduction of 
this platelet additive solution (PAS) in clinical practice in the Netherlands.55, 56 
Platelets have to be stored in ambient temperature and small inocula of bacterial 
contaminants sometimes grow exponentially beyond 4 days. Moreover, emerging new and 
still occurring known transfusion transmittable infections have led to the development 
of pathogen reduction (PR) techniques using a photoactive substance in conjunction 
with UV irradiation. Up till the start of the trials reported in this thesis 3 RCTs investigated 
the clinical efficacy of platelets treated with amotosalen HCl (S-59) and ultraviolet A light 
(UVA), at that time point the only clinically available photochemical pathogen reduction 
technique.57-59 These trials have shown a reduced transfusion efficacy of PR-treated 
platelets, but only one of these trials used haemostatic efficacy as a primary endpoint as 
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proposed by the FDA. Although this trial reported a high but similar proportion of patients 
with grade 2 or higher bleeding complications, patients supported with amotosalen-UVA 
treated platelets had a mean of 3.2 days with grade 2 or higher bleeding as opposed to  
2.5 days in the control group (p = 0.02) and experienced more refractoriness not explained 
by lymphocytotoxic antibodies or significantly increased platelet consumption.58 
Apart from leukoreduction / inactivation to prevent alloimmunization and 
plasmareduction to reduce adverse transfusion reactions, two items need to be discussed 
as they were cause for debate and trials the past two decennia: the effect of platelet 
storage and the clinical effects of the differently collected/produced platelets (Whole blood 
derived BC or PRP versus single donor AP). The incentive to use single donor aphaeresis 
platelets (AP) is to reduce the exposure to alloantigens and micro organisms. The first 
RCTs conducted before leukoreduction of PC, to study the effect on alloimmunisation 
comparing AP with whole blood derived, multi donor platelets were published in the early 
eighties. In contrast to a stable recovery of AP transfusions the recovery of multi donor 
platelet products declined each subsequent transfusion resulting in refractoriness after 
a mean of nine transfusions and it turned out that alloimmunisation was postponed, but 
not prevented.60, 61 The first trial to compare the clinical effectiveness of the three available 
production techniques was published in 1995 by Bishop et al. The corrected count 
increment (CCI) after 24 hours was not different between the three products, although 
the 1-hour CCI was higher with single donor AP.62 A similar trial published in 1996 did not 
find a significant difference in the 1- and 20 hour CCI of BC platelets as compared to AP, 
although the CCI of BC platelets declined with 30% during storage in contrast with AP, 
which did not show a significant reduction during storage.63 Although the 1- and 20-hour 
CCIs of BCs, APs and PRPs did not differ significantly, transfusions with PRPs resulted in 
more FNHTRs.64 A recent meta-analysis comparing the efficacy and safety of AP with WBD 
platelets concluded that AP platelets compared with PRP have better increments post 
transfusion and comparable increments as compared to BC. There was no difference in the 
occurrence of alloimmunization and refractoriness. Moreover provided the products were 
leukoreduced there were no differences in the occurrence of adverse transfusion reactions. 
More importantly there are no data comparing AP and WBD platelets with regard to 
haemostatic efficacy.65 To date there are no RCTs comparing production techniques with 
regard to bacterial contamination, but in a recently published large non-randomised 
multicenter study bacterial contamination of pooled whole blood-derived platelets versus 
AP was studied. In this study the rate of confirmed-positive units was 0.06 and 0.09%, 
respectively p = n.s.).66 
In these last three decades of technical advantages in the production of platelets has 
allowed for an increase in storage from 1 day in the late sixties to as long as 7 days 
nowadays provided that an adequate screening tool for bacterial contamination is 
instituted. Up till 2005 only three RCTs were published investigating the effect of storage 
time on clinical efficacy.63, 67, 68 In the study of Shanwell et al 39 patients were randomised to 
receive either fresh single donor AP or APs stored for 2 – 5 days. No difference was shown.67 
In a study of 25 patients Rosenfeld et al studied platelet function as well as efficacy 
comparing 1-day stored APs with 4-day stored APs and showed an immediate increase  
in number and function of platelets post transfusion independent of storage time.68  
As compared to single donor APs, although keeping within an acceptable range, BCs 
showed a larger decrease in post transfusion recovery with increasing storage.69 
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During the design of our first RCT using corrected count increments as a primary endpoint, 
we used a non-inferiority model accepting a fairly large decrease in transfusion efficacy 
without really knowing what would be the biological or clinical relevance. The main 
concept was to convince haematologists in our regional academic centre to shift from 
plasma stored platelet products to platelets stored in additive solution as these had shown 
to reduce FNHTRs.55 The trial used platelets produced with the BC method, were prestorage 
leukoreduced and patients were transfused at the conventional guidelines with regard 
to dose and threshold, in compliance with the evidence so far. The trial and its design do 
reflect the leading question today: should we keep improving safety at the expense of 
efficacy? Adverse transfusion reactions are rare and difficult to classify.82 Alloimmunisation 
keeps occurring at a low level despite leukoreduction, moreover the far more frequent 
problem of non-immunological refractoriness (that may also be related to reduced product 
quality) seems to be an increasing issue in need for a solution. Last but not least the risk 
of transmittable infectious diseases is very low, making randomised studies testing the 
efficacy of preventive measures virtually impossible. With regard to efficacy as an endpoint 
for platelet transfusion recent years have shown increasing doubts and problems with the 
commonly used endpoints: (corrected) count increments and bleeding. 
The (corrected) count increment is a ratio correcting for a measure of blood volume and 
the number of transfused platelets. This method has been challenged by several authors 
in the field with as main arguments a bias in favour of a preparation technique with fewer 
platelets combined with a not adequately estimated blood volume and doubts regarding 
the usefulness of the CCI as a surrogate outcome measure as it does not predict the clinical 
outcome bleeding.83, 84 However the CCI is an easy quantitative and objective measure and 
far more standardized than the more obvious outcome measure bleeding. Apart from the 
lack of a validated tool for the scoring and grading of bleeding, measurement of bleeding 
is hampered by difficulties with regard to the methods, persons and timing of the bleeding 
observation in thrombocytopenic patients.85, 86 
This thesis encompasses two RCTs encountering many challenges with regard to the 
studies endpoints but more importantly raises novel and old unsolved questions to be 
resolved in the near future. 
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A B s t r AC t
Background
The introduction of platelet (PLT) additive solutions (PASs) and pathogen reduction (PR) 
technologies possibly allow extension of PLT shelf life. It was our aim to compare in vitro 
quality of white cell (WBC)-reduced PLT concentrates stored in various PASs with those 
in plasma during 8 days of storage. Also, the effect of PR was investigated. The study was 
performed in a nationwide, multicenter study design, where each center tested 4 of  
the 6 study conditions.
study design and methods
In paired experiments (n= 12 per center), 20 AB0-identical buffy coats were pooled and 
divided into 4 products, to which various storage media were added. Plasma was used 
as reference in all 4 centers. Two centers used InterSol followed by PR (InterSol+PR) and 
InterSol without PR; other investigated PASs were T-sol, SSP+ and Composol. A rating 
system was used to judge PLT quality based on CD62P expression, annexin A5 binding  
and lactate production: a rating of 6 for good quality and 0 for poor quality. 
results
All PLT concentrates fulfilled release criteria (pH37°C>6.6; swirl present) until Day 8.  
Marked differences were seen for other in vitro parameters, including CD62P expression, 
which was 28±5; 31±7; and 39±9% for T-sol, Intersol+PR and without PR, respectively, 
which was significantly higher as the values found for Composol (12±3%), SSP+ 
(15±5%) and plasma (15±6%). Three in vitro parameters (CD62P, Annexin A5, and lactate 
concentration) were collapsed into one rating value; PLTs stored in plasma had a rating of 
2.8±1.0, which was significantly higher as for PLTs in T-Sol (1.5±0.5), InterSol+PR (1.3±0.6) 
and without PR (1.7±0.5; all p<0.001 versus plasma). PLTs stored in potassium- and 
magnesium-containing PASs showed higher ratings as plasma, 4.3±0.5 for Composol  
and 3.8±0.8 for SSP+ (p<0.05).
Conclusion
PLT concentrates in plasma, SSP+ and Composol scored better using an arbitrary rating 
system as PLTs stored in T-Sol or InterSol; PR further impaired rating parameters.  
The applicability of these differences in rating for clinical effects needs a clinical study.
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In vitro comparison of platelet storage in plasma and in four 
platelet additive solutions, and the effect of pathogen reduction2
i n t r o D u C t i o n
Plasma is still the most widely-used medium for storage of platelet (PLT) concentrates. 
CPD plasma contains high levels of glucose as nutrient for the PLTs, and citrate to prevent 
clotting.1 Other constituents are at near-physiological ranges, with the exception of a very 
low free calcium level, and a phosphate level approximately 3 times higher as in normal 
plasma.2 Initially, a main motivation to investigate the use of PLT additive solutions (PASs) was 
an increased availability of plasma for fractionation of Factor VIII and other plasma-derived 
products. However, the use of PASs has more benefits. These include the fact that PASs can be 
manufactured sterile and pathogen-free, and have a standardized composition in contrast to 
donor-variations of plasma. Moreover, PLT concentrates in PAS contain less plasma proteins, 
reducing allergic reactions3, 4, and have a lower titer of AB0 antibodies, thereby easier allowing 
AB0-mismatched PLT transfusions.5 Theoretically, for the same reason of a 3- to 4-fold antibody 
dilution, PASs could decrease the risk of antibody mediated transfusion related acute lung 
injury (TRALI).6, 7 Finally, PASs facilitate some pathogen reduction (PR) technologies that are 
inhibited by the presence of plasma proteins.8 PASs can be introduced in currently used, 
plasma-based processing methods. PASs were initially developed in conjunction with the 
buffy coat method, where multiple (usually four to six) buffy coats are pooled, and instead of 
adding one unit of plasma, one bag with about 300 mL of PAS is added to this pool. After low 
speed centrifugation the PLT-rich supernatant is expressed to a PLT storage container. Due to 
the lower viscosity9, PLT yield is generally a little less than when plasma is used. With apheresis, 
a highly concentrated PLT concentrate is collected which is diluted with PAS to produce a 
single-donor PLT concentrate that can be stored for 5 to 7 days.10 With the PLT-rich plasma 
(PRP) method, the use of PASs is less easy to incorporate, although specific methods have been 
described.11 All PASs require some residual plasma to maintain PLT quality and functionality.12, 13
Initial developments of PASs were done with PlasmaLyte-A, an infusion fluid licensed for 
use14, and still under consideration for platelet storage.15 One of the most widely used PAS in 
blood banks is T-sol, often referred to as PAS-II (Fenwal, Mont Saint Guibert, Belgium).16 This 
solution is licensed for in vivo infusions in Europe, and it was developed for 5-day storage of 
PLT concentrates. With introduction of bacterial screening assays extension of the PLT storage 
time to seven days was allowed, but T-Sol could not always maintain the pH within acceptable 
limits.17 Moreover, transfusions of PLTs stored in T-Sol resulted in lower increments compared 
to PLTs stored in plasma.3, 4, 18 After T-Sol, a number of PASs have been developed that fulfilled 
in vitro quality requirements after 7-days PLT storage. Potassium and magnesium were added 
to some PASs to preserve PLT integrity throughout storage.19 Also, specific PASs have been 
developed for PR technologies.8 We compared a number of these newly marketed solutions, 
including: T-Sol, Composol-PS (Fresenius HemoCare, Emmer-Compascuum, The Netherlands), 
SSP+ (MacoPharma, Tourcoing, France) and InterSol (Cerus, Amersfoort, The Netherlands); 
plasma was used as reference. Because InterSol was specifically intended in combination with 
PR, we included PLT concentrates in InterSol after inactivation with amotosalen (Cerus, Concord, 
CA, USA). For this study, PLT concentrates derived from buffy coats were used. This in vitro study 
was conducted in conjunction with a phase III clinical trial in hemato-oncological patients, 
investigating the clinical effectiveness and safety of white cell (WBC)-reduced pooled random 
donor PLT concentrates, stored up to seven days in either PAS with and without PR, or in 
plasma.20 For this preparative study many laboratory tests were applied to evaluate the quality 
of the new storage medium for PLTs in vitro, and run as a paired comparison with PLTs stored 
in approved containers.21, 22 The benefits and pitfalls of such comparisons have been outlined 
before for recovery/survival studies23; in line with defining objective acceptance criteria for 
recovery and survival, we propose a rating system for in vitro PLT studies, which may allow a 
more objective interpretation of laboratory results. 
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m At e r i A l s  A n D  m e t H o D s
All four blood centers in the Netherlands participated in this study, designated center 1, 
2, 3 and 4. Each center used their own materials and methods compliant with the Dutch 
guidelines for preparation of platelet products, unless indicated otherwise.
 
Blood collection and processing
Blood was collected in quadruple bag bottom-and-top systems with an inline red cell 
filter (from Fresenius HemoCare or from Baxter) on Day 0, and after rapid cooling to room 
temperature stored overnight at this temperature. On Day 1, after hard spin centrifugation, 
the units were separated into a unit of plasma, a buffy coat and a red cell concentrate using 
an automated separation device (Compomat, Fresenius HemoCare, or Optipress II, Baxter). 
Each center prepared 4 paired PLT concentrates by pooling 20 buffy coats in  
a large container, mixed well, and split in equal parts over four buffy coat pooling sets 
(from Terumo (Tokyo, Japan), Fresenius HemoCare, or from Baxter). All connections were 
made with a sterile connection device (Terumo). Each center prepared one unit PLT  
in plasma (derived from one of the whole blood units used for the buffy coat pool),  
and 3 others by adding one container of PAS to the content of the pooling bag according 
to the following scheme:
The addition of the PASs resulted in a 35/65% ratio for plasma and PAS, respectively.  
After soft spin centrifugation (adapted to the use of plasma or PAS) the PLT rich 
supernatant was expressed through the WBC-reduction filter to the PLT storage container, 
both part of the buffy coat pooling set. The units A through E were placed on a flat bed 
shaker at room temperature in a climate-controlled cabinet at 60 strokes per minute. 
Units F underwent PR with Amotosalen according to the manufacturer’s instructions, 
as described elsewhere.24 These units were transferred to a storage container with a 
Compound Adsorption Device (CAD) and placed on the flat bed shaker. On Day 2,  
units F were transferred to the final storage containers present in the PR bag system.  
At that time, all units A through F were weighed, and sampled for in vitro analysis. 
Weighing and sampling was repeated on Day 6 and Day 8.
in vitro analysis
The volume of the units was calculated from the net weight and specific gravity of the 
resuspension fluid (1.026 g/mL for plasma, 1.006 g/mL for PAS). The number of PLTs was 
counted on a hematology analyzer; residual WBCs were counted by flow cytometry. pH 
(measured and reported at 37°C), PO2, and PCO2 were measured with a blood gas analyzer, 
glucose and lactate were measured on a blood gas analyzer or enzymatically. CD62P 
expression25 and annexin A5 binding26 were determined with a flow cytometer. Swirl was 
judged visually on a scale from 0 to 3. Regular surveys with identical specimens were 
Center 1 Center 2 Center 3 Center 4
A. plasma m m m m
B. T-Sol (300 mL) m - - m
C. Composol (300 mL) m m m -
D. SSP+ (300 mL) m m - -
E. InterSol (280 mL) - m m m
F. InterSol, followed by a PR step - - m m
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performed between the labs to estimate intra- and inter-laboratory agreement (PLTs, WBCs, 
pH, blood gases). Specific optimizations were done to reduce intra- and inter-laboratory 
variations for CD62P and annexin A5.25
 
Dutch product specifications required that the units had a volume between 150 and  
400 mL, contained >250 x109 PLTs/unit in >95% of the units and <1 x106 WBCs/unit  
in >90% of the units. pH37°C should remain between 6.6 and 7.2 throughout storage.
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in vitro rating system
For the in vitro rating system we selected assays that could be performed shortly before 
transfusion of the PLTs, as endpoint measurement and to allow clinical evaluation of the 
rating system. We included three parameters in this rating system, each of which could 
play an independent role in predicting in vivo effectiveness of stored PLTs for reasons 
discussed below. First, we considered CD62P expression. This parameter of activation is, 
albeit contradicting, linked to PLT clearance28-32 and there is evidence that a higher CD62P 
expression causes a faster PLT clearance. Impaired PLT survival in animals was found to be 
associated with the apoptosis marker annexin A5 binding33,34 thus warranting inclusion of 
this parameter in our rating system. The third assay is the lactate concentration.  
The lactate production rate is considered as a good indicator of mitochondrial quality.35 
However, to calculate a lactate production rate over multiple days of storage, an additional 
baseline sample has to be taken immediately after production. In routine such sterile 
sampling before storage is not performed, making this (currently) unsuitable as endpoint 
measurement. The starting levels between units in plasma and PASs were slightly different 
(see Results), but the different production rates resulted in very different endpoint lactate 
concentrations, and so the lactate concentration prior to transfusion can be used as marker 
for lactate metabolism.
 
The in vitro outcomes of each of these three parameters were scored from 0 to 2, where  
0 points would indicate a poor quality and 2 points a good quality. The combined rating 
then results in a value between 0 (poor quality) and 6 (excellent quality). For CD62P 
expression a value of 2 points was arbitrarily attributed to an expression <20%, 1 for  
20-30% and 0 points for an expression >30%. For annexin A5, a value of 2 points for  
a binding <10%, 1 for 10-20% and 0 for all PLT concentrates with a binding >20%.  
Finally, lactate level >20 mM are known to indicate poor PLT quality [36], and we scored  
2 points for a level <10 mM, 1 for concentrations between 10-20 mM and 0 points for  
a value >20 mM. 
statistical analysis
The results were analyzed with Instat (version 3.06, GraphPad software, San Diego,  
CA, USA). Results between groups were compared with a repeated measures analysis 
of variance (ANOVA) followed by a Tukey Kramer post test, or, if data were not normally 
distributed, with Dunn’s post test. Differences between storage days were also compared 
with a repeated measures ANOVA, followed by Dunnett’s test to compare with Day 2 
values. A p value <0.05 was considered to indicate a statistically significant difference.
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r e s u lt s
Composition of platelet concentrates
The composition of the PLT concentrates on Day 2 is summarized in Table 1. The volumes of 
the PLT concentrates were significantly different amongst the groups, which was caused by 
the different volumes of plasma (current routine, approx. 330 mL) or PAS (T-sol, Composol 
and SSP+, 300 mL, InterSol, 280 mL) that had been added to the buffy coat pool. Additional 
volume loss due to the PR procedure was observed. The number of PLTs per unit differed 
significantly amongst the groups. The highest PLT counts were found in PLT concentrates 
in plasma, while the lowest were found in PLT concentrates in pathogen reduced InterSol 
concentrates. Though some units contained fewer than the required 250 x109 PLTs per unit 
(see Table 1), still >95% conformed to this requirement; these units were not excluded from 
evaluation. 
None of the PLT concentrates in PAS contained >1 x106 WBCs/unit. On average, more 
residual WBCs were seen in the units in plasma. This was caused by one center that 
detected more WBCs in the units in plasma, but not in the units in PAS. Overall, 3/47 (6.4%) 
of the units in plasma contained >1 x106 WBCs per unit, and therefore standard product 
requirements were met. 
In vitro comparison of platelet storage in plasma and in four 
platelet additive solutions, and the effect of pathogen reduction
Plasma t-sol Composol ssP+ lntersol lntersoi+ 
Pr
A B C D E F
n 47 23 23 35 36 24
Volume, mL* 380±30 354±23 367±16 352±16 303±17 275±11
PL Ts, x109 † 380±64 373±28 344±52 330±41 319±45 300±47
PL T concentration, x109/ml ‡ 1.03±0.16 1.06±0.12 0.94±0.11 0.94±0.10 1.06±0.17 1.09±0.16
PL Ts <250x109/U 0 (0%) 0 (0%) 0 (0%) 1 (3%) 1 (3%) 3 (13%)
WBCs, 106 | 0.23±0.43 0.03±0.06 0.04±0.05 0.06±0.06 0.05±0.05 0.08±0.06
Storage data
Glucose consumption, mmol/1011 PLT/d || 0.08±0.05 0.08±0.03 0.05±0.01 0.06±0.02 0.09±0.02 0.10±0.02
Lactate production, mmol/1011 PLT/d** 0.13±0.04 0.14±0.02 0.10±0.02 0.11±0.03 0.17±0.03 0.18±0.04
* all differences p<0.001 except A vs. CD, C vs. BD: n.s.
† B vs. D, C vs. F: p<0.05; A vs. C, B vs. E: p<0.01; A vs. DEF, B vs. F: p<0.001; all other differences n.s.
‡ B vs. CD, C vs. E: p<0.05; C vs. F, D vs. E: p<0.01; D vs. F: p<0.001; all other differences n.s
| A vs. BD: p<0.05; A vs. E: p<0.01; all other differences n.s.
|| A vs. CD: p<0.05; C vs. EF, D vs. EF: p<0.001; all other differences n.s.
** A vs. C: p<0.05; B vs. D: p<0.01; A vs. EF, C vs. BEF, D vs. EF: p<0.001; all other differences n.s.
table 1: Composition (on Day 2) and storage parameters of PLT concentrates in plasma and 
in four different additive solutions (one with additional pathogen reduction), used to compare 
storage characteristics (expressed as mean ± SD).
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figure 1: Figure 1 shows the various in vitro parameters of PLT concentrates in plasma and in 
4 different additive solutions (one with additional pathogen reduction), stored for up to 8 days 
(shown as mean±SD; n: see Materials and Methods). Plasma , T-sol , Composol , SSP+ , 
Intersol , InterSol with pathogen reduction .
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in vitro quality during 8-day storage 
The results of various parameters during 8 days of storage are shown in Figure 1. All PLT 
concentrates were well able to maintain pH37°C >6.6. Plasma and the potassium- and 
magnesium-containing PAS (Composol and SSP+) showed constant pH throughout 
storage, while the others showed a decline over time. The PO2 increased during storage 
under all conditions, plasma having the lowest and InterSol+PR having the highest 
absolute levels (not shown). PCO2 decreased over time; throughout storage the PCO2 
was highest for the units in plasma, while units in InterSol after PR had the lowest levels 
(not shown). Glucose levels in plasma were considerably higher in the PLT concentrates 
prepared with CPD-plasma as those made with PAS; all PLT concentrates showed a steady 
decline of glucose over the storage time.
The PASs with potassium and magnesium, Composol and SSP+, showed the lowest glucose 
consumption rates and lactate production rates, while InterSol (without and with PR) 
showed the highest. With respect to PLT activation, shown as CD62P expression, plasma, 
Composol and SSP+ had much lower expression rates throughout the storage period as 
the other three PASs tested. The initial PS expression (measured as annexin A5 binding) 
was similar for all tested conditions, but showed a steady incline for InterSol (without and 
with PR), T-Sol and for plasma; while PS exposure hardly changed for Composol and SSP+ 
over the whole storage time. Swirl remained present in all tested units irrespective of the 
storage solution used.
rating results
The rating results for the PLT concentrates stored in various solutions are given in Table 2. 
After overnight storage following PLT processing, on Day 2 the PLT concentrates in plasma, 
Composol and SSP+ had a similar rating, while PLT stored in T-Sol, InterSol without or with 
PR had already significantly lower scores. These differences were mainly due to higher 
CD62P expression in the latter groups. From Day 6 onwards these differences between 
products became more pronounced, as the lactate concentrations increased more in 
the T-Sol and InterSol groups. By Day 6, Composol and SSP+ ended with higher scores 
over plasma, reaching statistical significance by Day 8, mainly as a result from to lactate 
production and higher annexin A5 expression for PLTs stored in plasma (compare with 
Figure 1).
In vitro comparison of platelet storage in plasma and in four 
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n Day 2 Day6 Day 8
Plasma 37 5.6± 0.6 3.7±1.0 2.8±1.0
T-Sol 17 4.2±0.6* 2.2±0.4† 1.5±0.5†
Composol 12 5.7±0.5 5.1 ±0.7 4.3±0.5*
SSP+ 25 5.4±0.6 5.0± 1.0* 3.8±0.8*
InterSol 31 3.9± 0.6† 2.0± 0.5† 1.7±0.5†
InterSol+PR 24 4.0±0.8† 2.1 ±0.5† 1.3± 0.6†
* p<0.05 as compared with plasma
† p<0.001 as compared with plasma
table 2: Results of a rating system, based on CD62P expression, annexin A5 binding and lactate 
concentrations during storage. Results are shown as mean±SD.
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D i s C u s s i o n
This nationwide, multicenter comparison of PLT storage solutions revealed that all tested 
solutions maintained in-vitro PLT quality, allowing release to hospitals, for at least 8 days after 
blood collection: pH37°C was maintained above 6.6, and the swirling phenomenon continued 
to be visible. PLT concentrates in InterSol, and those that had undergone additional PR also 
fulfilled these criteria at day 8 with this limited set of requirements, but occasionally had 
low glucose levels. Though most preparation conformed to Council of Europe guidelines37, 
additional assays displayed probably relevant differences in in vitro parameters between the 
storage solutions, underscoring the FDA instructions21 for additional assays to be performed 
when evaluating new processing or storage methods. Unfortunately, the lack of correlation 
between a particular test result with clinical efficacy remains a significant limitation of most in 
vitro parameters. In the current study, PLT yield amongst the products differed; units in plasma 
had higher PLT numbers per unit than those in PASs. We explain this by the lower viscosity of 
the PASs which hampers to find good centrifugation conditions.9 PR did not cause a decrease 
in the number of PLTs (since lower numbers would suggest PLT lysis), the lower PLT numbers in 
the final product were caused by volume loss alone. 
When comparing between the PASs, a clear difference emerged between presence and 
absence of potassium and magnesium on the in vitro parameters. PLTs stored in PASs without 
potassium and magnesium (T-sol and InterSol) and had a lower pH, showed higher glucose 
and lactate metabolism, had a higher CD62P expression and higher annexin A5 binding as 
compared to solutes containing potassium and magnesium (Composol and SSP+).  
These results are consistent with other publications.19, 38
Glucose consumption and lactate production are stimulated by the presence of phosphate in 
the storage medium.36 Consequently, plasma, T-Sol and InterSol showed significantly higher 
conversion rates as compared with Composol or SSP+. Because of the lower starting value for 
glucose in InterSol-units, this resulted in depletion of all glucose in part of the units on day 8. 
Composol contains no phosphate and showed lower conversion rates. Despite the presence of 
phosphate in SSP+, low conversion rates were seen similarly to those with Composol, indicating 
that presence of potassium and magnesium in this solution can counteract the effects of 
phosphate.39 In T-Sol and in InterSol the higher production rate of lactate resulted in lower pH 
values during storage.
 
The units that underwent a PR procedure had lower pH, higher lactate levels, and higher CD62P 
and annexin A5 binding as control units that had not undergone this procedure suggesting 
additional PLT activation. 
In general, all PLT preparations conformed to the requirements for release, despite detectable 
differences among other in vitro parameters. Usually, requirements are applied as pass/
fail criterion, such as PLT number per pool above or below 250 x109 PLTs, pH at the end of 
storage below 6.6.27 There is clinical support that some parameters are indeed dichotomous, 
for example a pH22°C value below 6.2 will result in poor recovery and survival of PLTs
40, 41, while 
any pH value above that level does not. However, other in vitro measures could have a more 
gradual effect. We therefore propose a rating system. This rating system is based on three 
parameters, reflecting different aspects of PLT storage, i.e. activation, apoptosis/cell death, and 
metabolism: CD62P expression, annexin A5 binding and lactate production. We considered all 
in vitro measures for inclusion into the rating model, but most were rejected. Blood gases were 
not included, because the levels are dependent both on PLT quality and on gas permeability of 
the storage container. For example, low CO2 levels can indicate poor PLT quality, where little or 
no CO2 is produced, but can also indicate that the gas permeability of the container is very high. 
The same applies for oxygen levels. As indicated earlier, pH is a dichotomous parameter, and 
thus not suitable for our rating. Furthermore, with current-generation PLT storage containers, 
In vitro comparison of platelet storage in plasma and in four 
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pH values <6.2 are rarely seen. As bicarbonate levels in blood are directly related to pH and CO2, 
this parameter was also not included. For PLT storage, it is important that glucose becomes not 
depleted, and thus we considered glucose informative for inclusion in the rating. However, only 
levels <1 mM would indicate poor PLT quality39, while any level above that is not indicative as 
quality marker. Moreover, as glucose is normally converted into lactate in a 1:2 ratio (as was the 
case in the current study), and lactate was already included, we decided not to include glucose. 
Swirl is believed to be a good predictor of PLT quality32, and therefore in Dutch guidelines all PLT 
concentrates are checked for presence of swirl at the time of issue. We would therefore never 
find a PLT concentrate without swirl being transfused and thus it is not a useful marker in the 
PLT rating. Finally, hypotonic shock response shows good correlation with in vivo recovery  
and survival.2 In the current study, two centers included HSR but we found large differences  
in absolute values, and therefore, before being included in our proposed rating system,  
further standardization of the test is necessary. 
In our rating system all study groups were compared with PLT stored in plasma. As proposed 
by AuBuchon et al.23, this gold standard was used to circumvent a “downward creep” when 
methods were compared amongst each other for recovery/survival studies. Validation of our 
proposed rating system against clinical outcomes is necessary, and this validation should 
indicate whether a trichotomous distribution is a good indicator of clinical efficacy, or that a 
continuous distribution is feasible. At this time, our rating system is based on conjecture and 
assumptions, and includes only a limited number of in vitro tests. It is intended as a starting 
point for discussing a combination of parameters, that are collapsed into one composite 
outcome. So far, there is no “ultimate in vitro test” for predicting in vivo recovery, survival and 
functionality, but possibly a combination of in vitro tests, as summarized in our rating system, 
may provide such a helpful tool. 
In summary, this study shows that PLTs in plasma or in 4 different PASs, of which one included 
a PR step, all conformed to release requirements after 7 days of storage; additional biochemical 
and functional measurements do demonstrate differences amongst PLT preparations.  
The results were reproducible and comparable amongst 4 different blood centers. 
A rating system is proposed to incorporate additional in vitro measures to judge PLT quality 
with the aim to predict in vitro quality. This rating system summarizes multiple (activation, 
apoptosis/cell death, and metabolism) PLT storage characteristics into a single score, and 
facilitated interpretation of an otherwise complex study. For example, the outcome of the 
rating clearly demonstrated the benefit potassium and magnesium in the PAS. On the other 
hand, a number of questions remain: there is some evidence that the chosen parameters for 
the rating are related to platelet survival, recovery and functionality, but no formal prospective 
evaluation has taken place so far. Also, based on that evidence we postulate that there is a 
relation between the rating score and PLT recovery, survival and effectiveness, but we have to 
provide data to support this hypothesis. Therefore, validation studies for this rating system will 
be initiated; until that time, the rating system should be considered as a proposal that needs 
further support from clinical studies. 
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A B s t r AC t
Randomized studies testing the clinical efficacy of platelet additive solutions (PASs)  
for storage of platelets are scarce and often biased by patient selection. We conducted  
a multicenter, randomized study to investigate clinical efficacy of platelets stored in PAS II 
versus plasma, also including patients with clinical complications associated with increased 
platelet consumption. A total number of 168 evaluable patients received pooled buffy coat 
derived platelet concentrates (PC) suspended in either plasma (n = 354) or PAS II (n = 411), 
stored up to 5 days. Both univariate as well as multivariate analysis showed a significant 
effect of used storage medium in regard to 1- and 24 hour count increments and corrected 
count increments, in favour of plasma PCs. However, there were no significant differences 
between the groups regarding bleeding complications and transfusion interval. Adverse 
transfusion reactions occurred significantly less after transfusions with PAS II PCs (p = 0.04). 
Multivariate analysis showed no significant effect of the used storage medium on the 
incidence of 1- and 24-hour transfusion failure. We showed safety and efficacy of PAS II PCs 
in intensively treated patients, however plasma PCs show superior increments.
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i n t r o D u C t i o n
The use of platelet concentrates (PC) for the prevention and treatment of bleeding 
complications in patients with thrombocytopenia, due to cytotoxic therapy or 
malignancies of the bone marrow, is generally accepted. Despite the use of prophylactic 
platelet transfusions, bleeding is a frequent complication and recommendations regarding 
the preferred transfusion regimen, the quantity and quality of transfused platelets and 
strategies to monitor efficacy differ and only a minority is evidence based.1, 2 
In recent decades storage of platelets suspended in non-plasma media (additive solutions) 
evolved as a growing field of interest. Possible advantages of using additive solutions 
instead of plasma are an increase of plasma available for plasma products, a reduction of 
plasma related adverse reactions, improvement of storage conditions in order to increase 
the shelf-life of PCs and allowing photochemical pathogen reduction techniques.  
In the Netherlands the National Blood Supply aims for harmonization of blood products 
used throughout the country. Currently, except when selected donors are required, all 
platelet products are prepared using the buffy coat (BC) method. On historical grounds 
two platelet products are used: Plasma stored platelet concentrates (Plasma PC) and 
platelet concentrates stored in Platelet Additive Solution II (PAS II PC, Trombosol, Baxter). 
However, there are no informative studies for a strong selection for one of these products. 
Although in vitro studies showed significant differences suggesting inferior quality in 
metabolic, functional and flowcytometric parameters in platelets stored in PAS-II as 
compared to plasma, platelets stored up to five days in PAS II stay within the range of 
minimal quality requirements.3-6 The correlation of these in vitro parameters with clinical 
efficacy is inconsistent.7-9 One paired radiolabelled platelet survival study showed a 
significant decrease in both recovery as well as survival of PAS II PCs compared to plasma 
PCs and PCs stored in PlasmaLyte A.10 Data regarding the clinical transfusion response of 
platelets stored in PAS II are also limited. A small, non-randomized clinical trial did not show 
a significant difference between PAS II PCs and plasma PCs, and one small prospective, 
randomized study reported that corrected count increments (CCIs) after transfusion with 
PAS II PCs were significantly lower.11, 12 Despite lower CCIs bleeding complications did 
not differ and the latter study reported a significant reduction in transfusion reactions.11 
Observational analysis of the transfusion response of PAS II PCs and plasma PCs, used 
in the control arm of a randomized trial evaluating pathogen inactivated platelets 
(EuroSPRITE), did not show significant differences.13, 14 Major drawback of these studies was 
the exclusion of patients with clinical factors known to increase platelet consumption.12-14 
Because several studies show the importance of patient related factors in relation to 
platelet transfusion response we performed a randomized, controlled, double-blinded 
study to evaluate the therapeutic efficacy and safety of PAS II PCs in a non-selected patient 
population.15-19
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Patients and study design
The study protocol was approved by the hospital ethics committees and conducted 
according to the Guidelines of Good Clinical Practice. All patients > 18 year, who needed 
or were expected to need more than 2 platelet transfusions, were eligible. After informed 
consent patients were randomized to receive PAS II PCs or plasma PCs. Patients with HLA- 
and/or HPA-alloantibodies, active immune thrombocytopenia or an indication for CMV-
negative blood products (CMV negative patients receiving stem cells of CMV negative, 
unrelated or HLA-mismatched donors) were excluded. Patients were enrolled at the 
Hematology departments of two hospitals. Inclusion was restricted to a period of maximal 
30 days after the first PC transfusion or a maximum of 8 PC transfusions, whichever 
occurred first. The inclusion period ended in case of informed consent withdrawal, the 
occurrence of immunological refractoriness, after request of the patient or the treating 
physician, or in case of reaching 30 days after the first PC or 8 PC transfusions. In case of 
the latter two a second randomization was allowed. After randomization age, gender, 
length, weight, diagnosis, intended treatment, existence of an enlarged spleen (by physical 
exam and/or imaging techniques), medical history, transfusion history and medication 
were recorded. Blood samples were tested for ABO-RhD blood group, irregular red blood 
cell antibodies, hemoglobin, hematocrite, white blood count, platelets, HLA- and HPA- 
alloantibodies and anti-platelet autoantibodies. During the inclusion period platelet and 
red cell transfusions, transfusion-related adverse reactions (skin reactions, fever > 2˚C, 
dyspnoea, hypotension), bleeding complications, mucosal damage, fever, infections, and 
used medication were recorded. Bleeding complications were graded according to the 
World Health Organization criteria and mucosal damage was graded according to the 
Common Toxicity Criteria (version 2.0).20, 21 Both parameters were reviewed on a daily basis. 
Infections were scored positive in case of positive cultures or if a focus was likely as shown 
by radiologic examination. 
Platelet concentrates (PCs) 
PCs were prepared from five-pooled whole blood BCs with the same ABO blood group.22, 23  
After collection of a unit of whole blood, BCs were prepared through high-speed 
centrifugation. Five BCs together with one unit of PAS II or one unit of plasma from one 
of the BC donors were coupled to a BC pool set (containing a transfer bag, leukocyte 
filter and a PL-2410 storage container, Baxter) through a sterile connection device. After 
connecting, the five BCs were pooled in the transfer bag together with the unit of PAS II 
or plasma. A low speed differential centrifugation was used to separate the platelet rich 
supernatant from erythrocytes and leucocytes, which subsequently was pressed through 
the leukocyte-filter into the storage container. A sample was obtained prior to storage to 
measure platelet content, pH and bacterial culture. The platelet content was measured 
using a Beckman Coulter Act-10 (Coulter Corp., Miami Florida, USA). The PCs were stored 
at 20-24˚C on a flatbed shaker up to 5 days. The PCs were γ irradiated with 25 Gy at time of 
issue in case of specific patient requirements for the prevention of transfusion-associated 
graft-versus-host disease.
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Platelet transfusions and monitoring
The treating physician ordered platelet transfusions according to local hospital guidelines. 
In general, indications were divided in prophylactic trigger-based transfusions, prophylaxis 
prior to an intervention or treatment of bleeding complications. The transfusion trigger for 
uncomplicated prophylaxis was ≤ 10 x 109/l. In case of serious infections, anti-coagulant 
medication or administration of anti-thymocyte globulin (ATG) a trigger of ≤ 30 x 109/l 
was used. In case of surgical interventions or bleeding complications a platelet trigger 
of ≥ 50 x 109/l was used. Pre transfusion platelet count was measured one hour prior to 
transfusion. Platelet counts were measured from 10 minutes to 2 hours after transfusion 
and from 16 to 24 hours after transfusion to determine the 1- and 24-hour increment, 
respectively. Platelet counts in the participating hospitals were measured using a Sysmex 
XE-2100 (Sysmex Corp., Kobe, Japan). In case of a second PC transfusion within 4 hours, 
both transfusions were considered to be part of one transfusion. If the 24-hour increment 
exceeded the 1-hour increment, combined with other signs of haematopoietic recovery, 
then the 24-hour increment value was excluded from analysis. PC transfusion failure was 
defined as a 1-hour CCI < 7.5 and/or a 24-hour CCI < 4.5. Patients experiencing repeated 
episodes (≥ 2 subsequent PC transfusions) of PC transfusion failure, without an apparent 
non-immunological cause were tested for the existence of HLA- and/or HPA-antibodies.  
If available, PCs of ABO-identical donors were used, although both minor ABO 
incompatible (i.e. potential donor anti-A and/or B antibodies directed to the platelets/red 
cells of the patient) and major ABO incompatible PCs (i.e. potential patient anti-A and/or B 
antibodies directed to the donor platelets) were not excluded. 
study endpoints
The primary endpoints of the study protocol were the 1- and 24-hour CCI, calculated as 
follows: CCI1/24 h = [(post transfusion count (x 10
9 /l) 1/24 h – pre transfusion count (x 10
9 /l)) 
x Body surface area (m2)]/ Platelet dose (x 1011). Secondary endpoints were transfusion 
interval, transfusion-related adverse reactions and bleeding complications.
The transfusion interval was defined as the calculated administrative time of two 
consecutive PC transfusions. 
statistical methods
The study was designed as a two-armed non-inferiority study. The sample size calculation 
was based on data of patients enrolled in the two randomized trials concerning non-
plasma storage media.12, 13 The standard deviation of the mean 1- and 24-hour CCI was 
estimated as 6.0. To detect a difference of 30% between the 1- and 24-hour CCI of PAS 
II PCs and plasma PCs using a 0.05 level 2-sided test, a sample size of 360 transfusions 
in each study arm provided a power of 90%. The statistical comparison of the CCIs of 
the two products was performed both as independent transfusion events as well as in a 
mixed linear model, assuming biological interdependence of consecutive PC transfusions 
in a patient (SPSS/PC+, Chicago, IL). Fisher-exact tests were used to compare patient 
characteristics. A multivariate analysis testing the effects on both count increments and 
CCIs as well as the occurrence of transfusion failure was performed including storage time, 
storage medium, gender, age, bodyweight, body surface area, diagnosis, therapy, history 
of prior platelet transfusions, fever (body temperature > 38˚C) at the time of transfusion, 
infection, splenomegaly and ATG, using a random effects logistic regression model 
(EGRET).
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Patient population
Between October 2003 and April 2005, 195 patients were randomized (plasma PC n = 95; 
PAS II PC n = 100). A total of 11 patients were excluded (plasma PC n = 7; PAS II PC n = 4)  
of which 6 patients had HLA-alloantibodies and 1 patient had HPA-alloantibodies prior to 
the first transfusion, 1 patient developed refractoriness with proven HLA-alloantibodies 
after the second transfusion, 2 patients acquired an indication for CMV-negative blood 
products and 1 patient was transferred to another department. Although patients 
were randomized based on expected platelet transfusions, 16 patients did not receive 
any platelet transfusion during the inclusion period (plasma PC n = 4, PAS II PC n = 12), 
resulting in 168 patients, in which platelet transfusions could be evaluated (plasma PC 
n = 84; PAS II PC n = 84). There were no significant differences between the two study 
arms (i.e. patients with evaluable transfusions) regarding demographic characteristics, 
diagnosis, treatment and transfusion history (table 1). The same applied for the excluded, 
non-transfused patients in both groups. Splenomegaly was present in 17 patients (10.1%). 
The mean time on study for patients receiving PAS II PCs and plasma PCs was 20.7 +/- 7.1 
and 21.5 +/- 8.6 days (p = 0.54), respectively. Twenty-one patients were randomized more 
than once (plasma PC n = 11; PAS II PC n = 10). There were no significant differences in 
the occurrence of febrile episodes, proven infections and mucosal damage, most often 
localised to the digestive system (painful oral lesions and diarrhoea).
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Plasma PC PAs ii PC p-value
(n = 84) (n = 84)
Male / female 53/31 56/28 0.85
Age (Years ± sd ) 51.4 ± 13.1 50.1 ± 14.6 0.54
Body surface area (m2 ± sd) 1.94 ± 0.22 1.92 ± 0.24 0.57
Enlarged spleen 6 (7.1)1 11(13.1) 0.31
Diagnosis AML / MDS 43(51) 44(52) 1.00
ALL 7(8.3) 5(5.9) 0.77
CML 5(5.9) 3(3.6) 0.72
CLL 1(1.2) 3(3.6) 0.62
Myeloma 14(17) 6(7.1) 0.09
NHL 13(15) 21(25) 0.18
Other 1(1.2) 2(2.4) 1.00
therapy Remission Induction 31(37) 31(37) 1.13
Consolidation 9(11) 12(14) 0.64
Allogenic transplant 18(21) 20(24) 0.58
Autologous transplant 23(27) 19(23) 0.59
TBI 17(20) 14(17) 0.69
ATG 5(5.9) 7(8.3) 0.77
Other 3(3.6) 2(2.4) 1.00
transfusion history RBCs2 66(79) 62(74) 0.59
PCs 58(69) 52(62) 0.42
Transplants 10(12) 5(5.9) 0.28
1Number of patients (percentage of patients in study arm. 2RBCs = red blood cell concentrates.
table 1: Patient characteristics.
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Platelet transfusions: product parameters and increments
A total number of 765 PCs were transfused (plasma PC n = 354; PAS II PC n = 411). A total of 
684 PC transfusions could be evaluated (89%; Plasma PC n = 311, PAS II PC n = 373).  
In the PAS II PC group the 1-hour and 24-hour CCI could be calculated in 337 (90%) and  
334 (90%) transfusions, respectively. In the plasma PC group this was the case in 274 (88%) 
and 282 (91%) transfusions. The missing CCIs were a result of missing data regarding pre 
count, 1- and/or 24-hour post count.
In table 2 product parameters, dosage, count increments and CCIs are shown.  
Although the mean platelet content of PAS II PCs was significantly lower than of plasma 
PCs, there was no significant difference in the mean dose per kilogram body weight per 
transfusion between the two groups. There was a significant difference regarding the pH. 
However, all products had a pH well above 6.8. Univariate analysis, assuming each platelet 
transfusion as independent event, showed a mean difference in 1-hour and 24-hour CCI 
between plasma PCs and PAS II PCs off 19.7% (95% CI 11.7 – 27.2%, p < 0.0001) and 17.8% 
(95% CI 5.9 – 31%, p = 0.004), respectively. We also analysed the CCIs in a mixed linear 
model for biological interdependence of consecutive PC transfusions (data shown in table 
2). This analysis resulted in the same mean difference in 1-hour and 24-hour CCI between 
plasma PCs and PAS II PCs, but confidence intervals and p-values differed. In respect to the 
difference in 1-hour CCI the analysis showed a 95% CI between 6.5 and 32.9% (p = 0.004), 
and the difference in 24-hour CCI resulted in a 95% CI between –2.4 and 38.1% (p = 0.09).  
A multivariate analysis as described in the methods section showed an independent  
effect of the used storage medium with regard to both count increments and CCIs.  
Plasma PCs and PAS II PCs resulted in a sufficient 1-hour CCI in 81.3%and 69.1% 
respectively (p < 0.0001). The 24-hour CCI was sufficient in 70.7% and 65.7% (p = 0.16). 
Considering the difference in platelet content of plasma PCs and PAS II PCs, we also 
performed a linear regression analysis of count increments and platelet dose confirming 
significant lower 1- and 24-hour count increments after transfusion of PAS II PCs (data not 
shown). Gamma irradiation had no significant effect on the transfusion responses  
of both PCs.
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Plasma PC PAs ii PC p-value
(n = 311) (n = 373)
numbers of platelets/product 109 ± sd 412 ± 93 391 ± 119 p = 0.01
storage time days ± sd 3.5 ± 1.3 3.5 ± 1.1 n.s.
pH ± sd 7.12 ± 0.04 7.08 ± 0.04 p < 0.0001
Product volume ml ± sd 356 ± 19 316 ± 11 p < 0.0001
Precount 109/l ± sd 13.3 ± 8.7 13.7 ± 10.5 n.s.
Platelet dose/kg body weight1 109/l ± sd 5.5 ± 1.7 5.3 ± 2.0 n.s.
transfusion response2
1-hour n = 274 n = 337
Ci 32.2 ± 17.1 24.6 ± 14.8 p = 0.001
CCi 13.9 ± 7.0 11.2 ± 6.4 p = 0.004
24-hour n = 282 n = 334
Ci 20.6 ± 16.0 16.3 ± 14.1 p = 0.028
CCi 8.4 ± 6.9 6.8 ± 6.4 p = 0.09
n = number of transfusions. 1Per transfusion. 2General linear mixed model acounting for within-patient-correlation  
of observations (repeated measurements).
table 2: Platelet product parameters, dosage and transfusion response.
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Bleeding complications, transfusion reactions and transfusion interval 
The overall incidence of bleeding complications was 32.1%, consisting of 16.1% grade I,  
14.3% grade II and 1.8% grade III. Grade IV bleeding was not observed. There were no 
differences between the two study groups. As a surrogate marker for bleeding we also 
calculated the mean transfused red cell concentrates per patient, no difference was 
observed.
A total number of 26 mild transfusion reactions were observed in 21 patients. Of these, 
17 (5.5%) transfusion reactions were related to plasma PCs and 9 (2.4%) related to PAS II 
PCs (p = 0.04). Eight patients receiving PAS II PCs experienced transfusion reactions versus 
thirteen receiving plasma PCs (p = 0.35). One patient, receiving plasma PCs, complicated 
with repeated dyspnoea and wheezing, decided to end the study protocol and was further 
treated with plasma reduced hyper concentrated platelet products. 
Table 3 shows an overview of platelet and red cell transfusions and the calculated 
transfusion interval. There were no significant differences with regard to transfused PCs, 
interval and required red cell transfusions per patient. However, the platelet transfusion 
interval is substantially determined by timing of blood sampling and varying (logistic) 
delays in PC administration after reaching a transfusion trigger.
effects of storage
Storage time had a significant effect on the transfusion response of both PCs (figure 1). 
Stored PAS II PCs as well as stored plasma PCs showed a decrease in 1-hour CCI compared 
to fresh PCs. For both PCs this difference became significant after two days of storage. 
Stored plasma PCs show a gradual decrease in 24-hour CCI, however no significance is 
reached compared to fresh PCs. The same is true for PAS II PCs, although after 4 days of 
storage the deterioration was significant (p = 0.02), showing that the effects of storage 
time were more pronounced in PAS II PCs.
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Plasma PC PAs ii PC p-value
(n = 84) (n = 84)
number of rBC transfusions 452 475
mean rBC /patient (± sd) 4.8 ± 4.1 5.1 ± 3.8 0.62
number of PC transfusions 354 411
PC transfusion interval (days ± sd) 2.0 ± 1.0 2.1 ± 1.0 0.52
mean PC/patient (± sd) 4.2 ± 2.7 4.9 ± 2.8 0.10
Cumulative platelet dose/kg (x 1011/kg ± sd) 0.22 ± 0.15 0.23 ± 0.16 0.68
table 3: Platelet transfusions, red cell transfusions and transfusion interval.
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figure 1: Figure 1 A and B shows the comparison of 1- and 24-hour CCI,respectively, related 
to storage time of plasma PCs and PAS II PCs. Both PCs show a significant decrease in 1- and 
24-hour CCI during storage. Figure 2 A showes a significant difference between plasma PCs and 
PAS II PCs after 3 days of storage. Figure 2 B showes a significant difference beween the two 
products after 5 days of storage. SEM = Standard Error of the Mean; n = number of transfusions. 
day 1/2 day 3 day 4 day 5
 Plasma (mean) 15,6 13,2 14,4 13,2
 PAS II (mean) 13,8 11,3 10,0 9,8
 p-value 0,11 0,07 0,0001 0,0001
 Plasma (n) 71 66 55 79
 PAS II (n) 83 76 84 87
storage time (days)
day 1/2 day 3 day 4 day 5
 Plasma (mean) 9,9 7,8 7,9 8,2
 PAS II (mean) 8,3 7,8 5,9 6,4
 p-value 0,14 0,96 0,055 0,030
 Plasma (n) 73 66 53 87
 PAS II (n) 82 73 81 87
storage time (days)
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effect factors of increased platelet consumption
Refractoriness, both immunological as well as non-immunological, remains an important 
clinical problem. In our study 34.5% of patients experienced one or more transfusions  
with a 1-hour CCI < 7.5, while 25% of all transfusions resulted in a 1-hour CCI < 7.5%.  
Of all transfusions 25 were major ABO incompatible (plasma PC n = 12, PAS II PCs  
n = 13), mostly patients with blood group O receiving a blood group A product. A 1-hour 
transfusion failure after two or more subsequent transfusions occurred in 34 patients 
(plasma PC n = 14, PAS II PC n = 20), in 7 patients (plasma PC n = 4, PAS II PC n = 3) not 
explained by obvious non-immunological factors. Testing these patients revealed only 
one patient with HLA-antibodies and none with HPA-antibodies. Two patients, without 
detectable HLA-antibodies, received a HLA-matched test transfusion, both without success.
A number of non-immunological factors have been associated with an increase in platelet 
consumption. Most patients with haematological malignancies experience complex 
clinical conditions and in our study only 25% of the transfusions were administered in  
the absence of factors known to increase platelet consumption. A multivariate analysis  
to evaluate transfusion efficacy in terms of 1- and 24-hour transfusion failure is shown in 
table 4. Factors independently influencing 1-hour transfusion failure were splenomegaly, 
ATG, fever and infection. Storage time showed a trend towards an effect, but the used 
storage medium did not significantly influence the occurrence of 1-hour transfusion failure. 
The 24-hour transfusion failure was determined by splenomegaly, ATG, fever and the age 
of the patient significantly contributed to the occurrence of 24-hour transfusion failure, 
whereas both storage time and used medium dissappeared as independent factors.
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odds ratio 1-hour  
CCi < 7.5
odds ratio 24-hour 
CCi < 4.5
(95% CI) p (95% CI) p
storage time 1.93 (0.95 – 3.93) 0.069 1.51 (0.82 – 2.79 ) 0.18
storage medium 0.60 (0.25 – 1.42) 0.25 0.72 (0.30 – 1.69 0.46
fever 1.41 (0.97 – 2.04) 0.071 1.88(1.33 – 2.66) < 0.001
infection 0.38 (0.17 – 0.84) 0.02 1.08 (0.57 – 2.05) 1.08
enlarged spleen 26.7 (8.13 – 87.7) < 0.001 7.55(2.35 – 24.2) < 0.001
Atg 39.6 (7.81 – 201) < 0.001 4.83 (1.14 – 20.5) 0.03
Age 1.01 (0.98 – 1.04) 0.47 1.04 (1.01 – 1.07) 0.023
gender 0.59 (0.18 – 1.93) 0.39 0.71 (0.21 – 2.42) 0.58
Diagnosis 0.71 (0.71 – 1.31) 0.96 1.09 (0.82 – 1.43) 0.56
therapy 1.16 (0.85 – 1.58) 0.36 1.06 (0.79 – 1.44) 0.68
transfusion history 1.10 (0.41 – 2.90) 0.85 0.68 (0.46 – 3.35) 0.68
Bodyweight 0.97 (0.86 – 1.11) 0.69 0.90 (0.79 – 1.04) 1.04
1Random effects binary logistic model for distinguisable data (odds ratios and p-values are corrected for within-patient-
correlation of observations).
table 4: Multivariate analysis1 of 1- and 24-hour transfusion failure.
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D i s C u s s i o n
With the intention to harmonise platelet products in the Netherlands and in anticipation 
to future product changes, we performed a randomised controlled trial comparing plasma 
PCs and PAS II PCs. With the exception of immunological refractoriness due to HLA- and 
HPA-antibodies no exclusion criteria regarding factors of increased platelet consumption 
were used. There is general agreement that changes in platelet products should be 
validated for their clinical quality. Because major bleeding complications are rare,  
platelet count increments and CCIs have been accepted as surrogate endpoints.24  
A draft guidance for testing and evaluating platelet components advises an array of in vitro 
tests, the use of in-vivo autologous radio labelled platelet survival studies and clinical trials, 
including haemostatic efficacy.25 Currently, in Europe the requirements defined for quality 
control of platelet transfusion are minimal. In our study swirl, pH and platelet content  
were determined as in vitro parameters. Swirl was present in all transfused products.  
The platelet content of the products was measured directly after production as a previous 
study has shown a limited decline in platelet number during 5 days of storage.4, 23  
We found significant differences with regard to pH and platelet content of the two PCs.  
The lower pH of PAS II PCs is due to a lower intrinsic pH of PAS II, lower buffering capacity 
and higher lactate production.23, 26 The lower platelet content of PAS II PCs can be explained 
by a viscosity-related difference in the platelet distribution during centrifugation, resulting 
in a less efficient separation.23 
We showed that the 1- and 24-hour CCIs of PAS II PCs were lower as compared to plasma 
PCs, with a mean difference of 19.7% and 17.8%, respectively. This effect remained after 
correcting for possible confounders in a multivariate analysis. Although the platelet 
content in PAS II PCs was significantly (approximately 5%) lower as compared to plasma 
PCs, this small difference is not clinically relevant and the transfused dose per kilogram  
(or per square meter) in both groups was similar. Univariate analysis of the effect of storage 
time showed a significant decrease in 1-hour and 24-hour CCI in both products, more 
pronounced in stored PAS II PCs, in contrast to the results of the study of de Wildt-Eggen.12 
The mechanism of this storage effect is unknown. Increased P-selectin expression and 
structural changes have been suggested as possible mechanisms.5, 6 Whether such in vitro 
changes explain for the inferior increments of PAS II PCs remains unclear.8, 9 
To investigate the clinical relevance of the inferior CCI of PAS II PCs we compared the 
incidence of bleeding, transfusion interval, red cell concentrate usage and the occurrence 
of transfusion failure, the latter also in relation to patient factors. We did not observe 
significant differences with regard to bleeding complications or the consumption of PCs 
and red cell concentrates. Univariate analysis of transfusion failures showed a significant 
effect of PAS II PCs on the occurrence of 1-hour transfusion failure, but not on the 24-hour 
transfusion failure. A multivariate analysis showed that patient related factors overruled 
product defined factors as determinants of transfusion failure at 1- and 24-hour, with the 
exception of storage time, which showed a trend towards 1-hour transfusion failure.  
The only other randomised study conducted by de Wildt-Eggen12 used a different 
transfusion threshold (> 20 x 109/l) and excluded sick patients. It is likely that the 
differences in CCIs and transfusion failure between the two studies are caused by factors of 
increased platelet consumption in our study population, as several studies demonstrated 
the impact of patient factors on the occurrence of transfusion failure.15-19 In our study over 
75% of all PCs were transfused during episodes with clinical complications associated with 
increased platelet consumption and multivariate analysis showed that patient related 
factors annihilated the effects of the used storage medium in relation to transfusion failure. 
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Compared to other studies we found a relatively low percentage of transfusion reactions, 
although significantly less after transfusions with PAS II PCs (p = 0.04), confirming the 
results of de Wildt-Eggen.12 Probably this percentage underestimates the real frequency 
due to the fact that most reactions are mild, whereas fever and chills are common 
symptoms in this category of patients. 
In conclusion we showed that transfusion responses with PAS II PCs are inferior as 
compared to plasma PCs. The biological significance of this observation is not significantly 
exceeding a 30% deterioration. A multivariate analysis showed that patient related factors 
annihilated the observed differences and there were no significant differences with regard 
to bleeding complications or PC consumption. Transfusion reactions were mild, infrequent 
and significantly lower with PAS II PCs. As most patients in need of supportive care 
temporarily experience factors leading to increased platelet consumption, we propose that 
future clinical trials studying experimental platelet products should include these patients. 
We showed safety and efficacy of PAS II PCs in intensively treated patients, however plasma 
PCs show superior increments. To prevent a downward creep in future developed platelet 
products, we advise storage of platelets in plasma should be included as a reference in 
future trials. 
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s u m m A ry
Pathogen reduction (PR) of platelet products increases costs and available clinical studies 
are equivocal with respect to clinical and haemostatic effectiveness. We conducted  
a multicentre, open-label, randomised, non-inferiority trial comparing clinical effectiveness 
of buffy-coat derived leukoreduced platelet concentrates (PC) stored up to seven days 
in plasma with platelets stored in platelet additive solution III (PASIII) without and with 
treatment with amotosalen-HCl/UVA photochemical pathogen reduction (PR-PASIII). 
Primary endpoint of the study was 1-hour corrected count increment (CCI). Secondary 
endpoints were 24-hour CCI, bleeding, transfusion requirement of red cells and PC, platelet 
transfusion interval and adverse transfusion reactions. Compared to plasma-PC, in the 
intention to treat analysis of 278 evaluable patients the mean difference for the 1-hour 
CCI of PR-PASIII-PC and PASIII-PC was -31% (p < 0.0001) and -9% (p = n.s.), respectively. 
Twenty-seven patients (32%) had bleeding events in the PR-PASIII arm, as compared to 19 
(19%) in the plasma arm and 14 (15%) in the PASIII arm (p = 0.034). Despite the potential 
advantages of pathogen (and leukocyte) inactivation of amotosalen-HCl/UVA-treated 
platelet products, their clinical efficacy is inferior to platelets stored in plasma, warranting  
a critical reappraisal of employing this technique for clinical use.
keywords:
Platelet, Buffy-coat, Amotosalen/UVA Pathogen Reduction, Efficacy.
Clinical effectiveness of leukoreduced, 
pooled donor platelet concentrates, 
stored in plasma or additive solution 
with and without pathogen reduction
4
58
For the generally accepted indications for treatment and prevention of bleeding, millions 
of platelet products are transfused yearly, warranting vigilance towards emerging logistical 
problems and safety issues (Slichter, 2007; Stroncek & Rebulla, 2007). Donor counselling 
and screening, including molecular techniques, have reduced the risk of transmission 
of hepatitis B, hepatitis C, HIV, HTLV-I and –II. However, despite the bacterial culture of 
platelet products, a risk of 1 in 25,000 platelet transfusions for transfusion-related sepsis 
still remains (Goodnough et al, 1999; Kuehnert et al, Dodd et al, 2002; Blajchman et al, 2005; 
Schrezenmeier et al, 2007). Availability of platelets and reduction of costs due to reduced 
outdating would benefit from extending the storage time of platelet products, which is 
hampered mainly by the risk of bacterial growth beyond 5 days of storage (Lee et al, 2003). 
Pathogen reduction (PR) has been shown to be very effective for the inactivation of several 
viruses and bacteria (Lin et al, 2004; Lin et al, 2005). Moreover, PR might also comprise 
a solution for emerging pathogens, CMV and an alternative for γ-irradiation for the 
prevention of graft-versus-host-disease (Grass et al, 1999; Lin et al, 2001). Several countries 
consider implementing PR as a standard for all platelet products, but concerns still exist 
with regard to clinical efficacy, potential long-term toxicity as well as uncertainty whether 
PR- platelet products can be stored longer than 5 days (Council of Europe, 2001; Simonsen 
et al, 2006). Although PR platelet products using amotosalen-HCl and UVA fulfil standard 
release criteria up to 7 days of storage, this treatment results in considerable metabolic 
deterioration, increased platelet activation during storage and inconsistent findings by  
in-vitro haemostatic assessment (van Rhenen et al, 2000; Picker et al, 2004; Janetzko  
et al, 2004; Jansen et al, 2004; Lozano et al, 2007; Apelseth et al, 2007; van der Meer  
et al, 2009). Nevertheless, transfusion in thrombocytopenic patients corrected prolonged 
bleeding times (Slichter et al, 2006). Radiolabeled, autologous 5 days stored amotosalen-
HCl/UVA-treated platelets showed a significant lower recovery and reduction in survival 
time as compared to platelets stored in PASIII additive solution (Snyder et al, 2004).  
Three randomised controlled trials have been performed using amotosalen-HCl/UVA-
treated platelet concentrates (PC) (van Rhenen et al, 2003; McCullough et al, 2004;  
Janetzko et al, 2005). In the SPRINT trial (645 patients), using aphaeresis PC stored in 
plasma as control, significantly lower post transfusion platelet increments were found, 
combined with a reduced transfusion interval and an increased rate of transfusion failure 
(McCullough et al, 2004). The EuroSPRITE trial (103 patients) reported no significant 
differences with regard to transfusion efficacy, however the control arm of this study used 
buffy-coat derived platelets stored in plasma as well as in additive solution (PASII) for 
approximately half of the transfusions (van Rhenen et al, 2003). In a previous RCT we have 
shown that PASII PC have a 20% lower corrected count increment as compared to plasma 
PC, which might have masked a relevant difference (Kerkhoffs et al, 2006). A third small 
trial with 43 patients showed a borderline significant reduction in transfusion efficacy 
(Janetzko et al, 2005). None of these trials reported inferior haemostatic efficacy. Before the 
implementation of pathogen reduced platelet products, extending storage time to 7 days 
while maintaining clinical efficacy is an important aspect to compensate for the additional 
costs of the procedure. We performed a multicentre open-label, randomised clinical trial 
to study the clinical efficacy in terms of transfusion response of pooled, random donor 
PC stored up to seven days in platelet additive solution (Intersol, Fenwal, Inc., Lake Zurich, 
IL, USA) without additional PR (PASIII) and with amotosalen-HCl/UVA photochemical PR 
(PR-PASIII, Intercept Blood System, Cerus Corporation, Concord, CA, USA), compared to 
platelets stored in plasma.
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study design
The study was designed as a prospective, randomised open-label non-inferiority 
trial in haemato-oncological patients with thrombocytopenia or expected to be 
thrombocytopenic caused by myelosuppression. Patients were included at the 
haematology wards of eight Dutch hospitals. The study protocol and consent forms were 
approved both by a central ethics committee as well as local institutional review boards. 
The study was conducted according to the ICH-GCP guidelines and the declaration of 
Helsinki. During the study all centres were audited and trial conduct was monitored by an 
independent organisation. All patients older than 18 years, having a haemato-oncological 
disease, were eligible for inclusion if they were expected to receive 2 or more platelet 
transfusions. Exclusion criteria were immunological refractoriness to random platelet 
transfusions due to HLA- and/or HPA-antibodies or clinical relevant auto-antibodies, 
pregnancy (or lactating) and previous inclusion in this study. After informed consent 
eligible patients were registered and randomised, stratified by centre, before start of 
platelet transfusions in a 1:1:1 ratio to receive per protocol up to a maximum of 5 platelet 
transfusions with Plasma-PC, PASIII-PC or PR-PASIII-PC in a period of maximal 42 days. 
Off protocol platelet transfusions were allowed during the study period in case of non-
availability of the correct component. Apart from normal completion, reasons to go off 
study were refusal to continue by the patient or treating physician, intercurrent death  
and immunological refractoriness. 
Platelet products, transfusions and monitoring
All products were produced by the Sanquin Blood Bank. PCs were prepared from 5 pooled 
whole-blood buffy-coats (BC) with the same ABO-blood group using standard procedures 
and with regard to pathogen reduction using manufacturer’s instructions (van Rhenen  
et al, 2003; Kerkhoffs et al, 2006). Samples were obtained prior to storage to measure 
platelet content. Samples of all products were cultured for 7 days using the BacT/Alert 
culturing system (BioMerieux, Boxtel, the Netherlands). All products were stored with 
gentle agitation at 20–24˚C up to seven days. The PCs were γ-irradiated if requested by  
the hospital. 
Indications for platelet transfusions were divided into platelet count-based prophylaxis, 
intervention related prophylaxis and treatment of bleeding. Generally accepted guidelines 
were used as guidance for the indication of platelet transfusions. If or when a transfusion 
was ordered was determined by the treating physician. In summary, in stable, non-
bleeding patients a platelet transfusion was advised to maintain the platelet count  
≥ 10 x 109/l and ≥ 40 x 109/l when these patients receive anti-coagulant therapy 
or treatment with anti-thymocyte globulin. A transfusion trigger of 40 x 109/l was 
recommended in endoscopic evaluation of the gastrointestinal or respiratory tract,  
when no biopsies are performed, diagnostic pleural or peritoneal puncture with a thin 
needle, lumbar puncture, extraction of a central venous catheter and minor surgical 
interventions. A trigger of 60 x 109/l was recommended in case of bleeding, endoscopic 
evaluation with biopsies, dental extractions, placement of a central venous catheter and 
major surgical interventions, with the exception of neurosurgery and cardiac surgery.  
In case of cerebral bleeding, diffuse alveolar haemorrhage, neurosurgery and cardiac 
surgery a trigger of 100 x 109/l was recommended. A pretransfusion platelet count 
was preferably measured just before transfusion up till a maximum of 6 hours before 
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transfusion. A 1-hour posttransfusion platelet count was measured between 10 and  
120 minutes after transfusion and a 24-hour post transfusion platelet count was measured 
between 16 and 28 hours after transfusion. The CCI was calculated as follows: CCI1/24 h 
= [(post transfusion platelet count1/24 h – pre transfusion platelet count (x 10
9/L)) x body 
surface area (m2)] / platelet dose x 1011. Transfusions given shortly after one another 
without platelet counts between the transfusions are referred to as multi-dose transfusions 
and analysed as a single transfusion. If available, ABO-identical PC were used, although 
minor- and major incompatible PC were not excluded. Platelet transfusion failure was 
defined as a 1-hour corrected count increment (CCI) below 7.5 and/or and 24-hour 
CCI below 4.5 (Kerkhoffs et al, 2006). Immunological refractoriness was defined as the 
occurrence of transfusion failure of two consecutive ABO-matched random platelet 
transfusions combined with existence of HLA- and/or HPA-alloantibodies.
study endpoints
The primary endpoint was the 1-hour CCI. Secondary endpoints were 24-hour CCI, 
bleeding, the transfusion requirement of red cells and PCs, platelet transfusion interval and 
adverse transfusion reactions. The following characteristics were recorded at entry: gender, 
age, blood group, haematological disease and treatment phase, WHO performance status, 
existence of enlarged spleen, transfusion history, treatment with anti-coagulation, medical 
history, medication, bleeding and presence of active infection. The following characteristics 
were recorded at each transfusion: the reason of the transfusion (trigger, bleeding or 
intervention), the blood group of the PC, presence of fever, presence of infection (graded 
according to the CTCAE), presence of mucosal damage, and use of acetaminophen, 
steroids or antihistamines. Patients were evaluated daily by trained personnel to observe, 
describe and grade bleeding complications at 8 defined sites according to the CTCAE 
under supervision of the local investigator (http://ctep.info.nih.gov/reporting/ctc.html). 
In short grade 1 or minor bleeding comprises petechiae, minimal or microscopic bleeding 
not requiring interventions. Grade 2 bleeding is defined as gross, symptomatic bleeding 
for which minimal intervention (i.e. aspiration, cauterisation, irrigation of the urinary 
tract) is indicated. Grade 3 is severe bleeding requiring red cell transfusions and/or major 
interventions. Generalized petechiae/purpura as well as retinal bleeding with visual 
impairment also is classified as grade 3. Catastrophic bleeding defines grade 4, as does CNS 
bleeding causing neurologic deficit or disability. Lethal bleeding is classified as grade 5. 
All major bleeding complications were reviewed centrally. Infections were scored in case 
of positive cultures or if a focus was likely as shown by clinical or radiological examination. 
Apart from haematological parameters, PT, aPTT and fibrinogen, were measured regularly. 
Some centres performed routine periodic serological testing of HLA- and/or HPA-
alloantibodies, whereas other centres performed these tests only on indication. 
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reporting of serious adverse events and Data safety monitoring Board
Serious adverse events (SAE) for the purpose of this study were defined as any untoward 
medical occurrence that resulted in death, a life-threatening event or any other medical 
condition which might jeopardize the patient or required intervention to prevent more 
serious sequelae. SAE reporting was mandatory within 24-hours of the initial observation. 
An independent Data Safety Monitoring Board (DSMB) was installed before the start of the 
study. An interim analysis was planned after 300 transfusions. All serious adverse events 
(SAEs) were reviewed by the DSMB. Two criteria for early stopping of an experimental 
arm were defined: 1. A negative 24-hour CCI (decrement) not caused by immunological 
factors in more than 20% of the transfusions; 2. Statistically significant more bleeding 
complications (CTCAE ≥ 2) compared to the Plasma arm. 
Power calculation and statistical analysis
The study was designed as a one-sided, non-inferiority study comparing the 1-hour CCI of 
the transfusions in the PR-PASIII arm and in the PASIII arm with the Plasma arm. Inferiority 
of an experimental arm was defined as a 20% lower mean 1-hour CCI compared to the 
Plasma arm. A mean 1-hour CCI of 15.6 and a standard deviation of 6.0 were used based 
on a previous study (Kerkhoffs et al, 2006). For a power of 90% and an alpha of 0.025 
(multiple testing) 100 patients per arm were required. In case of multi-dose transfusions, 
the sum of the platelet content of the PC was used. If one of the PC products differed 
from the allocated arm, the multi-dose transfusion was considered as not according to 
protocol. The mean of the storage times of the PC in a multi-dose transfusion was used as 
the storage time. The 1 and 24 hour counts after the infusion of the last PC of a multi-dose 
transfusion were used for analysis. To account for the hierarchical structure of the data 
with a variable number of transfusions per patient, the data were analysed using mixed 
regression models with random effects for patient and transfusion number. Besides the 
CCIs, 1 and 24 hour posttransfusion counts were used as endpoints in regression models 
with as additional covariates besides arm, platelet dose, pretransfusion counts and body 
surface area of the patient (Davis et al, 1999). The data were analysed by intention to treat 
(ITT) as well as per protocol (PP). To assess safety, the incidence of bleeding complications 
and adverse reactions were analysed through tabulation. Pearson’s chi-square test was 
used to compare categorical patient characteristics by arm and the Kruskal-Wallis test to 
compare ordinal or continuous characteristics by arm. A relation between storage time and 
the post transfusion counts and CCIs was assessed by adding this factor as covariate to the 
regression models. The association between the patient and transfusion characteristics 
mentioned above was assessed by adding each of these variables separately as covariate 
to the regression models. All statistical analyses were performed using Stata.
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Patients and platelet transfusions
Inclusion of patients started March 2007. The inclusion of patients in the PR-PASIII group 
was halted after 92 patients in January 2009 on advice of the DSMB because of lower CCI’s 
(p<0.0001) and more bleedings (p=0.045) compared to the plasma group. Inclusion of 
patients in the plasma and PASIII group ended May 2009 and overall 295 patients were 
randomised. There were 17 non-evaluable patients, resulting in a total of 278 evaluable 
patients and 1129 transfusion events (fig 1). There were no significant differences in the 
patient characteristics of the study groups (table 1). 302 transfusion events (27%) were not 
according to the allocated study arm, more frequent in both study arms. 85% of the off 
protocol PC were platelets stored in PASII, 15% were platelets stored in plasma. The study 
products had a lower platelet content, with a mean difference of 6% and 11% for PASIII-PC 
and PR-PASIII-PC as compared to plasma PC, respectively (table 1, p < 0.001).
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figure 1: Figure 1 shows the randomisation scheme together with evaluable patients, 
transfusions and endpoints. n = number of patients, n PC = number of single platelet 
concentrates, n TRF = number of PC transfusion events (includes pooled transfusions).  
Of the 17 non-evaluable patients 4 patients were non-eligible due to anti-HLA antibodies and 
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Platelet transfusion efficacy
All efficacy analyses were done ITT as well as PP. The 1-hour CCI and 24-hour CCI were evaluable 
in 1004 (88.9%) and 1013 (89.7%) of the transfusion events, respectively. The single reason 
for a non-evaluable CCI-1/24 was failure to perform a platelet count after transfusion and 
with respect to these missing evaluations there were no significant differences between the 
study groups or between the per- and off-protocol transfusion events. All transfusion efficacy 
parameters show inferiority of transfusions with PR-PASIII-PC. There were no significant 
differences in transfusion responses between PASIII-PC and Plasma-PC (table 2). The proportion 
of 6 and 7 days stored PC was equally distributed across the arms, being 24%, 21% and 26% of 
transfused PC in the plasma arm, the PASIII arm and the PRPASIII arm, respectively.
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Plasma PAs iii Pr-PAs iii
No. of patients 99 94 85
Male / Female 52 / 47 53 / 41 47 / 38
Age, years ± SD 54 ± 12 55 ± 12 53 ± 12
Body surface area, m2 ± SD 1.93 ± 0.22 1.94 ± 0.19 1.96 ± 0.25
Enlarged spleen N (%)1 10 (10) 5 (5) 6 (7)
Diagnosis n (%)
 AML / MDS 42 (42) 52 (55) 44 (52)
 ALL 9 (9) 4 (4) 3 (4)
 Lymphoma 22 (22) 14 (15) 18 (21)
 Multiple myeloma 22 (22) 21 (22) 17 (20)
 Other 4 (4) 3 (3) 3 (4)
therapy n (%)
 Remission induction 47 (47) 46 (49) 39 (46)
 Consolidation 5 (5) 6 (6) 3 (4)
 Autologous transplantation 32 (32) 31 (33) 33 (39)
 Allogeneic transplantation 12 (12) 5 (5) 6 (7)
 Other 3 (3) 6 (6) 4 (5)
transfusion history n (%)
 RBC concentrates 55 (56) 59 (63) 43 (51)
 PCs 48 (48) 61 (65) 41 (48)
no. of PC transfusion events 357 381 391
Product type according to protocol (%) 292 (82) 278 (73)2 257 (66)2
Multi-dose transfusion (%) 14 (4) 12 (3) 11 (3)
PC transfusion indication n (%)
 Prophylactic, trigger based 304 (85) 334 (88) 327 (84)
 Intervention 38 (11) 25 (7) 44 (11)
 Treatment of bleeding complication 11 (3) 19 (5) 16 (4)
 Unknown 4 (1) 3 (1) 4 (1)
Platelet product content, mean x 1011 ± SD 3.9 ± 1.0 3.6 ± 0.82 3.4 ± 0.82
Storage time, mean days ± SD 4.0 ± 1.8 3.8 ± 1.8 4.0 ± 1.6
Pre transfusion PLT count x 109/L ± SD 18 ± 13 17 ± 13 16 ± 113
1Number (%) of evaluable patients and transfusions; 2p < 0.001 as compared to plasma; 3p = 0.04 as compared to plasma; 
AML = Acute myeloid leukaemia; MDS = Myelodysplastic syndrome; ALL = Acute lymphoblastic leukaemia; RBC = Red 
blood cell; PC = Platelet concentrate. Major ABO-incompatibility occurred in only 6 PC transfusions.
table 1: Platelet transfusions, red cell transfusions and transfusion interval.
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Plasma PAs iii Pr-PAs iii
No. of patients 99 94 85
itt analysis 
 CCI-1 hour, mean ± SD 17.1 ± 7.3 15.3 ± 6.5 11.4 ± 5.35
 Mean diff (97.5% CI)1 -9% (-22%; 4%) -31% (-43%; -18%) 
 CCI-24 hour, mean ± SD 12.8 ± 7.8 11.6 ± 7.6 7.9 ± 5.35
 Mean diff (97.5% CI)1 -7% (-26%; 12%) -34% (-52%; -17%)
PP analysis 
 CCI-1 hour, mean ± SD 17.1 ± 7.3 15.3 ± 6.7 10.6 ± 5.05
 Mean diff (97.5% CI)1 -10% (-23%; 4%) -36% (-49%; -24%)
 CCI-24 hour, mean ± SD 12.5 ± 7.7 11.7 ± 7.6 6.8 ± 5.95
 Mean diff (97.5%CI)1 -4% (-24%; 16%) -42% (-61%; -23%)
other response parameters (itt)
 CI-1 hour, mean x 109/L ± SD 34 ± 15 29 ± 13 20 ± 104
 CI-24 hour, mean x 109/L ± SD 25 ± 15 21 ± 13 14 ± 103
 PC transfusions / patient, mean ± SD 4 ± 2 4 ± 3 5 ± 32
 TRF interval (hours), mean ± SD 81 ± 47 77 ± 44 61 ± 473
transfusion failure (itt)
N of Evaluable CCI-1 314 340 350
CCI-1 hour < 7.5 (%)6 48 (15) 66 (19) 97 (28)5
N of Evaluable CCI-24 319 343 351
CCI-24 hour < 4.5 (%)6 72 (23) 94 (27) 125 (36)3
The mean CCI and CI values were calculated as the mean of the average CCI/CI of all transfusions per patient.  
1Mean difference with 97.5% confidence interval of PAS III and PR-PAS III compared to Plasma derived from mixed model 
regression analyses. 2p < 0.05, 3p < 0.01, 4p < 0.001, 5p < 0.0001 as compared to plasma; 6percentage of evaluable CCIs.
table 2: Transfusion response parameters: ITT and according to protocol (PP).
table 3: Linear regression analysis 1- and 24-hour PLT counts.
1-hour Plt count 24-hour Plt count
Beta1 p-value Beta p-value
PASIII -2.29 0.377 1.79 0.507
PR-PASIII -9.63 0.001 -8.95 0.003
Storage time (days) -1.55 <0.001 -1.24 <0.001
Body surface area (m2) -15.4 <0.001 -10.1 0.002
Transfusion sequence number -0.38 0.047 -0.08 0.686
Platelet product content (x 109) 0.09 <0.001 0.06 <0.001
Precount (x 109/l) 0.96 <0.001 0.96 <0.001
1Random effects binary logistic model for distinguisable data (odds ratios and p-values are corrected for within-patient-
correlation of 1Beta: regression coefficient. Multivariate linear regression analyses with patient as random factor and as 
dependent variables the 1-hour platelet (columns 2 and 3) and the 24-hour platelet count (columns 4 and 5). The factors 
included in the models are shown in the first column. The estimated regression coefficients are shown in the Beta -columns. 
The regression coefficients measure the strength of the effect per unit change of the corresponding factor; e.g the 1-hour 
platelet count decreases on average with 1.55 x 109/l with each additional day of storage, while an increase of the content of 
the platelet product with 1 x 109 results on average in an increase of 0.09 x 109/l of the 1-hour platelet count. The regression 
coefficients for PAS III and PR-PAS III indicate the average difference in the post transfusion counts as compared to Plasma.).
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Both the 1-hour CCI as well as the 24-hour CCI decreased with longer storage time in all 
study groups. However both CCIs were significantly less in PR-PASIII-PC at each day of 
storage as compared to plasma PC (figs 2A&B). The 1- and 24-hour CCIs of PASIII-PC did 
not differ significantly to plasma PC up to 7 days of storage. Linear regression analysis of 
1- and 24-hour platelet count showed a platelet dose independent effect of pathogen 
reduction (figs 2C&D, table 3). A number of product and patient related covariates were 
tested for an association with CCIs adjusted for arm (table 4). Storage time, enlarged spleen 
and fever were highly significantly associated with lower CCIs, while the use of steroids 
as premedication was associated with a higher 1-hour CCI and transfusion for a bleeding 
indication was associated with a lower 24-hour CCI.
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figure 2: Figure 2 shows the fitted lines from linear regression analyses restricted to per 
protocol transfusions. Black, blue and red, respectively represent Plasma, PAS III and PR-PAS III. 
(2A/B) The 1-hr and 24-hr CCI as function of storage time for the three treatment groups. Point 
estimates with 95% confidence intervals and number of transfusions are indicated. The lines are 
the fitted lines assuming a linear relation between CCI and storage time for each group. (2C/D) 
Fitted 1-hr and 24-hr increments as linear functions of storage time for the three treatment 
groups for a patient with surface area 1.93, precount 12 and storage time of 4 days. Standard 
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Bleeding and other clinical complications 
Sixty-seven new bleeding episodes (CTCAE grade 1-3) were observed in 60 patients during 
the on study period from the start of the first transfusion with significantly more (p=0.034) 
and higher grade (p=0.044) bleeding in the PR-PASIII group (table 5). 
Distribution of bleeding sites was not different between the study groups. 14 of the 
bleeding patients were on anticoagulant therapy at the time of bleeding, without 
differences between the groups. We did not observe lethal bleeding complications in the 
on protocol period; however, one patient in the PR-PASIII arm deceased due to intracranial 
bleeding after going off protocol. We did not find an association between platelet dose, 
storage time or γ-irradiation and the occurrence of bleeding (all grades). There were no 
differences between the groups with regard to number of RBC transfusions received.  
The mean number of RBCs in the plasma group was 4±3 as compared to 5±3 and 4±3  
in the PASIII and PR-PASIII group, respectively. Twenty-eight mostly mild transfusion 
reactions occurred in 25 patients, without significant differences between groups  
(table 5). Incidences of infections and SAE’s were equally distributed among the groups. 
Three SAE’s were possibly related to PC transfusion, one in each group. In the plasma group 
a patient developed a severe, generalized skin reaction, in the PASIII arm a possible TRALI 
was reported and in the PR-PASIII arm a patient developed acute glottis oedema treated 
successfully with antihistamines and steroids.
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table 4: Relation between covariates and the CCI-1 and CCI-24 adjusted for arm.
1-hour CCi 24-hour CCi
Beta1 (SE) p-value Beta (SE) p-value
Storage time (days) -0.9 (0.1) <0.00001 -0.9 (0.1) <0.00001
Spleen enlargement -5.7 (1.4) <0.00001 -6.5 (1.5) <0.00001
Fever -1.7 (0.4) <0.00001 -1.5 (0.4) 0.0003
Steroids 2.6 (1.1) 0.02 1.0 (1.3) 0.43
Indication bleeding 1.1 (1.0) 0.29 -2.5 (1.1) 0.02
Indication Intervention -0.6 (0.8) 0.39 -0.4 (0.8) 0.64
Age (years) 0.2 (0.3) 0.49 0.0 (0.3) 0.97
Sex 1.1 (0.8) 0.17 0.3 (0.8) 0.76
Prior PLT TRF -1.0 (0.8) 0.22 -1.0 (0.8) 0.24
Prior RBC TRF -0.9 (0.8) 0.25 -0.7 (0.8) 0.42
Prior TRF reactions -2.4 (1.5) 0.12 -0.3 (1.7) 0.84
Infection -0.5 (0.5) 0.33 -0.5 (0.5) 0.27
Mucosal damage -0.1 (0.5) 0.82 0.1 (0.5) 0.82
ABO mismatch 0.2 (0.4) 0.68 0.4 (0.4) 0.33
Anti-histamines -1.6 (1.3) 0.21 -1.8 (1.3) 0.16
Anti-coagulation -1.3 (1.3) 0.31 -2.1 (1.4) 0.14
Acetaminophen 1.1 (1.3) 0.39 -1.3 (1.3) 0.31
Univariate random effects regression analysis adjusted for arm. 1Beta: regression coefficient; SE = Standard error;  
TRF = Platelet transfusion; RBC = Red blood cell concentrate. All covariates, with the exception of storage time  
and patient age, are no/yes covariates.
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Plasma PAs iii Pr-PAs iii
No. of patients 99 94 85
Bleeding after first PC transfusion
No of patients (%) 19 (19) 14 (15) 27 (32)1
No of episodes 19 16 32
Maximum grade (%)
 Grade 1 12 (12) 10 (11) 16 (19)
 Grade 2 6 (6) 4 (4) 6 (7)
 Grade 3 1 (1) - 5 (6)
Patients with transfusion reactions, n (%) 11 (11) 8 (9) 6 (7)
no. of transfusion reactions 13 8 7
Severity of events
 No or minor morbidity 11 7 6 
 Moderate morbidity 1 - 1 
 Serious morbidity 1 1 -
Patients with infectious complications, n (%) 40 (40) 39 (41) 42 (49)
Maximum grade (%)
 Grade 1 (%) 1 - -
 Grade 2 (%) 3 5 6 
 Grade 3 (%) 30 29 28 
 Grade 4 (%) 6 4 8 
 Grade 5 (%) - 1 -
immunological refractoriness, n (%) 2 (2) - 2 (2)
serious adverse events, n 7 3 5
SAE related to PC transfusion 1 1 1
Death, n 32 1 3
Except for the number of bleeding episodes, the numbers in the table reflect numbers (percentage) of patients.  
For the grades of bleeding and infections the maximum grade is used in case of more than one bleeding episode or more 
than one infection. 1p = 0.034 as compared to plasma; 21 patient died in the plasma arm 24 days after the last transfusion 
(the fifth) without SAE report. The cause of death was reported on the off study form as related to the treatment of  
the underlying disease, with fever presumably due to sepsis.
table 5: Bleeding, transfusion reactions, infections and SAE’s
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D i s C u s s i o n
In a non-selected population of thrombocytopenic haematology patients we studied  
the transfusion efficacy of PR-PASIII-PCs and PASIII-PCs in terms of increments, transfusion 
failures, PC consumption and transfusion interval as well as bleeding occurrence and 
adverse transfusion reactions, compared to plasma-PC. In accordance with the SPRINT 
trial but in contrast to the EuroSPRITE trial, we observed inferiority of transfusions with 
PR-PASIII-PC with regard to all transfusion efficacy-related endpoints (van Rhenen et al, 
2003; McCullough et al, 2004). Moreover more patients in the PR-PASIII-PC arm experienced 
bleeding complications. As reported previously, both study products contained less 
platelets due to loss of platelets during the production process (McCullough et al, 2004; 
Kerkhoffs et al, 2006; Murphy et al, 2006; Pineda et al, 2006). As CCI might not adequately 
correct for dose differences between arms, we performed linear regression analysis of 
the posttransfusion platelet counts with covariates treatment arm, platelet content and 
storage time, also showing an independent effect of PR-PASIII PC (Davis et al, 1999). 
Using the linear regression analysis we estimate that a PR-PASIII-PC should on average 
contain 200 x 109 platelets extra (i.e. approximately 3 BCs) to achieve a comparable 
count increment. The relationship between storage time with both CCIs showed a 
constant difference at each incremental day of storage, suggesting a decreased viability 
of a fixed number of platelets and a normal disappearance of surviving platelets after 
treatment with this PR technique. To the same extend as plasma PC, PASIII PC show a 
decrease in transfusion efficacy up to seven days of storage and no difference in bleeding 
complications. Our results with regard to lower increments are in agreement with the 
SPRINT study. The discordance with the EuroSPRITE as well as with a large phase IV trial 
may be due to the usage of PC stored in PASII in approximately half of the reference group 
attenuating the results of the reference groups in these other studies (van Rhenen et al, 
2003; Osselaer et al, 2009). 
Patients in the PR-PASIII group experienced more and more grade ≥ 2 bleeding compared 
with both the other arms. The EuroSPRITE and the other smaller European RCT reported no 
differences between the study arms with regard to bleeding complications (van Rhenen 
et al, Janetzko et al, 2005). However in the extended safety report of the SPRINT trial the 
frequency of grade 2-4 bleeding appeared significantly higher in the PR-arm, 43% as 
compared to 34% in the control arm (p = 0.02) (Snyder et al, 2005). It is unlikely that the 
difference in bleeding complications is solely explained by a lower platelet dose resulting 
in lower post transfusion platelet peak levels. Estimating approximately one-third non-
viable platelets in PR-PC, the platelet dose is still comparable with the low to medium dose 
applied in a recently presented platelet dose trial showing that bleeding complications 
did not differ between low, medium or high dose levels of platelets transfused (Slichter 
et al, 2010). Possibly, damage of platelet mitochondrial nucleic acids by PR may not only 
result in loss of viability of a proportion of platelets, but may impair haemostatic capacity 
as well (Keuren et al, 2006; Apelseth et al, 2007). We did not find significant differences in 
transfusion reactions as observed in larger trials using PR-PASIII PC (Osselaer et al, 2008a; 
Osselaer et al, 2008b). 
This study has some shortcomings. The number of off-protocol transfusions in the PR-PASIII 
arm can be regarded as an important limitation of our study. However, performances of 
both an ITT as well as a PP analysis lead to similar conclusions.
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The open label aspect of our study is not expected to influence platelet counts,  
the primary endpoint of our study, although we cannot completely exclude bias  
with regard to evaluation of bleeding. 
In conclusion, although there are clear advantages and arguments in favour of pathogen 
reduction techniques to increase transfusion safety, our results warrant a reappraisal of 
pathogen reduction techniques prior to routine implementation. The process of PR using 
amotosalen-HCl/UVA likely leads to decreased platelet viability and perhaps compromises 
haemostatic function, the primary goal of platelet transfusions in high risk patients.  
A comprehensive survey on the nature and consequences of amotosalen-HCl/UVA-induced 
platelet damage is needed to understand how this damage can be compensated for  
in routine transfusion practise.
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The development and introduction of additives for the storage of platelet concentrates 
(PC) is proceeding steadily. In the Netherlands platelets stored in PAS II (T-Sol) up to 5 days 
are allowed for transfusion in contrast to platelets stored in plasma, which are allowed to 
be stored up to 7 days. A recent study suggested an adequate transfusion efficacy with 
platelets stored in PAS III (Intersol) up to 7 days. 
method 
We reanalysed the data of the two RCTs in which plasma PC had been used as control arm 
and either PAS III PC or PAS II PC as study arms, respectively in order to compare the clinical 
efficacy of both additive solutions in relation to storage. Moreover, we calculated  
a combined Odds Ratio for adverse transfusion reactions.
results 
The CCI-1 of PAS II (stored up to 5 days) was 23.6% (95%CI 10.6; 36.5) lower as compared 
to plasma, whereas PAS III (stored up to 7 days) showed a reduction of 10.9% (95%CI -1.3; 
23.2). The same effect was observed with regard to the 24-hour CCIs. Adverse transfusion 
reactions occurred less frequent after transfusion with platelets stored in an additive 
solution resulting in a risk reduction of 50% as compared to plasma (95%CI 10 – 72%,  
p = 0.025).
Conclusion 
The use of additive solutions reduce the incidence of mild adverse transfusion reactions,  
an important advantage for patients, and the use of PAS III PCs, stored up to 7 days,  
for routine transfusion practice is an alternative for PAS II PCs. 
keywords:
platelet concentrates additive solution, efficacy, and adverse reactions
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Since the first publication by Rock et al, the development and clinical use of synthetic 
additive solutions for the storage of platelets gained interest in many countries with 
as main incentives the recovery of plasma for other purposes, reduction of adverse 
transfusion reactions and the improvement of storage conditions to increase the platelet 
shelf-life.1, 2 In the Netherlands, the vast majority of platelet products are pooled buffy-
coat derived prestorage leukoreduced platelet concentrates (PC), stored either in plasma 
(Plasma PC) or in PAS II (PAS II PC, Trombosol, Baxter, Lessines, Belgium). Based on a study 
showing adequate in vitro characteristics and clinical efficacy, storage of plasma PC is 
allowed up to seven days.3 Storage of platelets in PAS II is limited to a maximum of five 
days.6 In a randomised study, comparing 1 - 5 days versus 6 - 7 stored PAS II PC in transplant 
recipients a significant decrease in transfusion efficacy of 6 - 7 days stored platelets was 
shown, without differences in hemorrhagic complications.9 Although in vitro studies show 
acceptable quality parameters for PAS II PC during storage up to seven days and the in 
vivo autologous recovery and survival of 7 days stored PAS II platelets has been reported 
to be in acceptable ranges this illustrates the limited information of pre-clinical studies.4 
However, it is virtually impossible to compare all different platelet additive solutions 
in clinical studies. To improve storage conditions other additive solutions have been 
developed, using differing concentrations of acetate and phosphate, with or without the 
addition of potassium and magnesium.10, 11 One of these solutions, PAS III (Intersol, Fenwal 
Inc., Lake Zurich, Il, USA), differs from PAS II only in the addition of phosphate, which 
besides increasing buffering capacity, may be superior to PAS II by protection against low 
adenine nucleoside levels during storage.12, 13 PAS III PCs as well as PAS II PCs both fulfilled 
the standard release criteria (pH, swirling) stored up 8 days.6 We have previously performed 
two randomised controlled clinical studies, one comparing 1-5 days stored platelets in PAS 
II with plasma PC and showing an approximately 20% lower efficacy of PASII PC, without a 
difference in bleeding complications and halving of transfusion reactions. A second RCT, 
a three-arm study, included Plasma PCs and PAS III PCs both stored up to seven days as 
control arms.14 In this study, PAS III PC showed a minor reduction in transfusion efficacy. 
Instead of conducting a clinical study comparing PAS II with PAS III stored PC for their 
storage capacity, we analysed the data of these two RCTs in which plasma PC had been 
used as control arm and either PAS III PC or PAS II PC as study arms.8, 14
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study design
The study design of both trials was very similar with respect to included patients, platelet 
transfusion policy and study endpoints. The first trial (Trial 1), conducted between October 
2003 and April 2005, studied the clinical efficacy of pooled blood, buffy-coat derived platelet 
products, comparing plasma PCs and PAS II PCs stored up to 5 days.8 The second trial (Trial 2), 
conducted between March 2007 and May 2009 compared PAS III PCs treated with pathogen 
reduction with plasma PCs and PAS III PCs without pathogen reduction.14 For a detailed 
description of both trials we refer to the original publications. For both trials all products were 
produced by the Sanquin Blood Bank, prepared from five pooled buffy-coats with the same 
ABO-group. Samples of all products were obtained prior to storage to measure platelet count 
and culture using the BacT/Alert culturing system (Biomerieux, Boxtel, the Netherlands). 
PCs were stored with gentle agitation at 20 – 24 °C and γ-irradiated at request. There were a 
number of relevant differences between both trials (table 1). Most importantly, in Trial 1  
patients were allowed to be randomised more than once, also more study transfusions 
were allowed in this trial. The primary objective of this analysis is an indirect comparison of 
the transfusion efficacy of platelets stored in PAS II (PAS II PC, Trombosol, Baxter, Lessines, 
Belgium) and platelets stored in PAS III (Intersol, Fenwal Inc., Lake Zurich, Il, USA). For the 
purpose of this comparison we abstracted the main patient characteristics as well as product 
characteristics and transfusion efficacy parameters (count increment, corrected count 
increment) of the first 5 according to protocol transfused PCs from the databases of both 
studies. We only included the first inclusions in trial 1 (figure 1). Adverse reactions were 






- Transfusion sequence 
nr > 5
- off protocol PC TRF
exclusion:
- Transfusion sequence 
nr > 5
- off protocol PC TRF
Plasma
Patients: n = 84
PCTRF: n = 311
Plasma
Patients: n = 99
PC TRF: n = 357
Plasma
Patients: n = 62
PC TRF: n = 198
Plasma
Patients: n = 96
PC TRF: n = 269
PAs ii
Patients: n = 84
PC TRF: n = 373
PAs iii
Patients: n = 94
PC TRF: n = 381
PAs ii
Patients: n = 67
PC TRF: n = 226
PAs iii
Patients: n = 91
PC TRF: n = 248
figure 1: Figure 1 schematically shows the selection of patients and transfusions included for  
this analysis. PC = Platelet concentrate; TRF = Transfusion; n = number of patients or transfusions.
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statistical analysis
Chi-square tests were used to compare categorical patient characteristics by arm, ordinal 
and continuous patient were compared using ANOVA. For the statistical comparison 
of pre- and post transfusion platelet count, count increments (CI) and corrected count 
increments (CCI) we used an averaged mean per patient to correct for interdependence of 
consecutive platelet transfusions within a patient. For each of both trials, we performed a 
multivariate analysis for the effect of several patient variables (sex, age, body surface area, 
enlarged spleen, pre transfusion platelet count and therapy) and product factors (storage 
medium, product platelet content and storage time) on post transfusion platelet count. 
Adverse transfusion reactions were analysed intention-to-treat both on patient as well on 
transfusion level using the full data set of both trials through tabulation and compared 
using a chi-square test. All statistical analyses were performed using SSPS (version 15.0  
for Windows, Chicago, Il, USA). P-values < 0.05 were considered significant.
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table 1: Trial and trial design overview.
trial 1 trial 2
Period Oct 2003 – Apr 2005 Mar 2007 – May 2009
Type of trial RCT, blinded RCT, non-blinded
Stratification Yes Yes
N of study arms 2 3
N of participating centers 2 8
Primary endpoints CCI-1 and 24-hour CCI-1 hour
N of evaluable patients 168 278
Type of patients Hemato-oncology Hemato-oncology
Age ≥ 18 ≥ 18
Exclusion criteria (main) Auto- and/or alloimmunisation Auto- and/or alloimmunisation
Multiple inclusions Yes No
N of PC transfusions 765 1129
Type of platelet products BC BC
Reference product Plasma Plasma
Study product PAS II PAS III +/- PR
Storage 1 – 5 days 1 – 7 days
N of study transfusions/patient Maximal 8 Maximal 5
N = number; RCT = Randomised Controlled Trial; PC = Platelet concentrate; BC = Buffy coat; PR = Pathogen Reduction
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PC transfusion characteristics and transfusion efficacy
Randomisation in both RCTs led to well balanced patient characteristics in both studies 
(table 2). The inclusion of only the PC transfusions of the first inclusion episode of a patient 
in trial 1 and including only the first 5 on protocol PC transfusions in both trials resulted 
in 424 PC transfusions to 129 patients in trial 1 and 517 to 187 patients in trial 2. By design 
PCs in trial 1 had a mean storage time of 3.5 ± 1.2 days as opposed to 4.0 ± 1.9 in trial 2 
(p<0.001). Comparison of the transfusion efficacy of both plasma PC arms showed several 
significant differences. As opposed to trial 1, PCs in trial 2 were transfused at a higher pre 
transfusion platelet count (mean difference 4.2 (1.3 – 6.9)), plasma PCs contained less 
platelets (mean difference 32 (14 – 51)) and resulted in a significantly higher 24-hour 
post transfusion platelet count (mean difference 7.3 (2.5 – 12.1)) and 24-hour CCI (mean 
difference 2.3 (0.3 – 4.4)). For this reason, we decided not to combine the plasma control 
arms, but to compare both PASs to their respective controls (table 3, figure 2). Both the 
1-hour and 24-hour CIs and CCIs of PAS II PCs were significantly lower as compared to 
plasma. In contrast, only the 1-hour CI of PAS III was significantly lower than plasma. 
Despite all PCs show a decreased efficacy with increasing storage time, in a multivariate 
analysis storage interval was a non-significant futile factor in both trials. Only PAS II had  
an independent negative effect on the 1-hour transfusion efficacy. As is shown in table 4,  
pre transfusion platelet count and product platelet content are consistently associated 
with higher post transfusion platelet increment. Body surface area and acute myeloid 
leukaemia were associated with a decreased post transfusion platelet increment in both 
trials, whereas an enlarged spleen remarkably only negatively affected the increments in 
trial 1. Unfortunately we were not informed about the magnitude of the splenomegaly. 
5
table 2: Patient and transfusion characteristics
trial 1 trial 2
Plasma PAS II Plasma PAS III
n Patients 62 67 96 91
sex M/F 39 / 23 45 / 22 50 / 46 52 / 39
Age Years ± SD 53 ± 14 49 ± 14 54 ± 13 54 ± 13
Body surface area M2 ± SD 1.9 ± 0.2 1.9 ± 0.2 1.9 ± 0.2 1.9 ± 0.2
Acute myeloid leukemia N (%) 29 (47) 30 (45) 42 (44) 51 (56)
remission induction Ctx N (%) 28 (45) 28 (42) 46 (48) 44 (48)
enlarged spleen N (%) 5 (8) 8 (12) 10 (11) 5 (6)
n Platelet transfusions 198 226 269 248
storage time Days ± SD 3.5 ± 1.1 3.5 ± 0.8 4.0 ± 1.5 3.7 ± 1.4
Platelet content 109 ± SD 408 ± 62 390 ± 88 376 ± 50 355 ± 431
Ctx = Chemotherapy; 1p < 0.05 as compared to the respective plasma arm.
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table 3: Transfusion efficacy.
figure 2: Figure 2 shows the estimated mean difference and 95% confidence interval for  
the 1- and 24-hour CCIs comparing both PASs to their own Plasma control. The dashed lines 
represent the non-inferiority margins as were used in both Trials.
trial 1 24-hour CCi
Plasma PAS II p-value1 Plasma PAS III p-value1
Pre count 13 ± 7 14 ± 9 0.425 17 ± 11 15 ± 9 0.174
1-hour
Ci (109/l) 33 ± 15 25 ± 12 0.001 34 ± 15 28 ± 13 0.012
CCi 15.7 ± 5.9 12.0 ± 5.5 <0.001 17.0 ± 7.4 15.2 ± 6.6 0.079
24-hour
Ci (109/l) 21 ± 11 16 ± 11 0.017 24 ± 14 21 ± 13 0.189
CCi 10.0 ± 5.0 8.0 ± 5.0 0.026 12.3 ± 7.8 11.7 ± 7.7 0.605
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Adverse transfusion reactions
Transfusion reactions were a secondary endpoint in both RCTs. In both trials the vast 
majority of adverse transfusion reactions were mild without significant morbidity.  
An intention-to-treat analysis, combining the results of both trials showed that 9.0%  
of the patients randomised to receive platelets stored in additive solution experience 
transfusion reactions, without differences between the type of PAS, as compared to 13.1% 
of patients randomised to receive plasma stored platelets (OR 0.7, 95%CI 0.3 – 1.3).  
In the combined additive arms 2.2% of the PC transfusions resulted in an adverse 
transfusion reaction as compared to 4.5% in the plasma arms (OR 0.5, 95%CI 0.3 – 0.9). 
Limiting this analysis to the selection of patients and transfusions evaluated in this study 
the OR for patients treated with additive stored platelets to experience a transfusion 
reaction is 0.4 (95%CI 0.2 – 1.0) and the OR for additive stored PCs to result in an adverse 
reaction 0.6 (95%CI 0.3 – 1.1).
5
table 4: Multivariate analysis of post transfusion PLT count.
trial 1 trial 2
Post count 1-hour 24-hour 1-hour 24-hour
Additive solution -7.07 (-11.1; -3.00) -3.02 (-6.72; 0.69) -2.95 (-6.93; 1.02) -2.31 (-6.36; 1.73)
Pre count 0.72 (0.46; 0.97) 0.90 (0.66; 1.13) 0.80 (0.59; 1.00) 0.90 (0.69; 1.11)
Storage time -2.19 (-4.50; 0.11) -0.609 (-2.69; 1.48) -1.02 (-2.35; 0.31) -0.49(-1.91; 0.93)
PLT content 0.05 (0.02; 0.08) 0.04 (0.02; 0.07) 0.08 (0.04; 0.12) 0.00 (-0.04; 0.05)
BSA -20.2 (-28.9; -11.5) -11.0 (-19.0; -3.06) -24.2 (-34.1; -14.3) -12.7 (-22.9; -2.58)
Female -2.28 (-7.42; 2.87) 0.63 (-4.10; 5.35) 2.76 (-1.86; 7.38) -0.90 (-5.82; 4.01)
Enlarged spleen -11.4 (-18.2; -4.51) -7.37 (-13.7; -1.09) -1.22 (-3.26; 0.81) -1.22 (-3.31; 0.87)
AML -2.21 (-6.31; 1.90) -4.16 (-7.87; -0.44) -4.71 (-8.65; -0.77) -4.37 (-8.47; -0.27)
RI Chemotherapy 3.04 (-2.04; 8.12) 1.65 (-3.00; 6.30) 1.87 (-2.65; 6.39) -0.65 (-5.33; 4.03)
Beta: regression coefficient. Multivariate linear regression of the 1- and 24 post transfusion PLT count (averaged mean per 
patient in both trials). The estimated regression coefficient is shown in the columns, measuring the strength of the effect per unit 
of change of the corresponding factor. BSA = Body Surface Area; AML = Acute Myeloid Leukaemia; RI = Remission Induction.
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For blood bank logistical and economical reasons, the use of an additive solution allowing 
for storage up to 7 days would be very attractive. By analysing the data of two trials,  
we have compared the transfusion efficacy of PAS II PCs and PAS III PCs relative to their own 
plasma PC controls. Because comparison of both control arms showed several significant 
differences we did not choose to pool the plasma controls, which would have enabled  
a direct comparison. The CCI-1 of PAS II (stored up to 5 days) was 23.6% (95%CI 10.6; 36.5) 
lower as compared to plasma, whereas PAS III (stored up to 7 days) showed a reduction of 
10.9% (95%CI -1.3; 23.2). The same effect was observed with regard to the 24-hour CCIs. 
As was previously reported there were no haemostatic consequences of the observed 
decrease in transfusion efficacy, nor did the decreased efficacy lead to differences in 
transfusion interval or number of PC transfused.8, 14 Mild adverse transfusion reactions 
occurred less frequent after transfusion with platelets stored in an additive solution  
in both trials and combining both trials results in an estimated risk reduction of 50% 
(95%CI 10 – 72%, p = 0.025). 
A trial, comparing PAS II PCs stored 1-5 days with PAS II PCs stored 6-7 days in a paired 
fashion, showed that the mean 1- and 24-hour CCI of 6-7 day stored PAS II PCs was 7.4 ± 3.8 
and 2.6 ± 2.6, respectively.9 Both these mean CCI values could be conceived as transfusion 
failures. We did not study 6-7 days stored PAS II platelets, but we estimate by extrapolation 
of our data (estimated mean CCI-1 and CCI-24 for 6 – 7 day stored platelets in PAS II of 
6.1 and 4.9 respectively), consistency with the data from Diedrich et al.9 The results of 
our analysis strongly suggest that platelets stored in PAS III have superior clinical efficacy 
compared to PAS II stored PC and enable extension of storage time to 7 days without  
a clinically relevant decrease in transfusion efficacy.
The main limitation of this study is the indirect nature of the comparison; despite at 
first glance both trials appear very similar, there are a number of important differences 
potentially affecting efficacy such as pre-transfusion platelet count and platelet content of 
the product and these could not be corrected for by better matching and thus prohibited 
pooling of the plasma PC arms from the two RCTs. 
Nevertheless the results support to replace PASII PC by PAS III PCs, stored up to 7 days,  
as an acceptable alternative for plasma PCs for routine transfusion practice.  
The development of additives with the addition of potassium and magnesium to PAS III  
are expected to further improve platelet storage conditions.16 Lacking informative  
pre-clinical methods however, new platelet products need to be tested for their efficacy 
as well as haemostatic properties compared to plasma PCs, still gold standard, in clinical 
studies to avoid as formulated by Scott Murphy a downward creep. 
Clinical efficacy in thrombocytopenic patients of platelets  
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Despite supportive care with platelet transfusions bleeding complications occur in 
a substantial number of patients with thrombocytopenia due to cytotoxic therapy. 
Moreover, refractoriness to platelet transfusions remains a frequently encountered 
problem. We investigated the clinical impact of platelet transfusion failure in 117 patients, 
part of a randomised platelet transfusion trial, which excluded patients with HLA- and/or 
HPA-alloantibodies.
study design and methods
Between October 2003 and April 2005 a multicenter randomized controlled trial, testing 
the clinical efficacy of platelets stored in plasma as compared to PAS II, was performed. 
Using multiple regression analysis of observational data of patients randomised in one of 
the participating centres, the occurrence of platelet transfusion refractoriness was analysed 
for a relation with bleeding complications and patient survival.
results
Platelet transfusion failure occurred at least once in 49.6% of the patients. Mild to moderate 
bleeding complications occurred in 19% of the patients. Platelet transfusion failure was, 
independently from thrombocytopenia, positively associated with bleeding complications 
(OR 3.4, 95%CI 1.1 - 11). Other independent risk factors were non-transplant related 
chemotherapy, severe mucosal damage and age. Moreover, patients experiencing one  
or more 24-hour platelet transfusion failures had, as compared to patients always showing 
a sufficient 24-hour increment, a significantly reduced median survival of 491 days (IQR 
156-858) versus 825 days (IQR 355-996), respectively. In a Cox regression model the effect 
on survival was independent of therapy, diagnosis and age.
Conclusion
Our results suggest that platelet transfusion failure might be a sensitive clinical marker 
for the occurrence of bleeding and impaired patient survival. Platelet transfusion failure, 
bleeding complications and decreased survival could be manifestations of a more severe 
degree of endothelial damage. This poses a challenge to develop potential markers and 
improved treatment options in relation to the clinical efficacy of platelet transfusions.
Abbreviations
AML = Acute Myeloid Leukemia; ATG = Anti Thymocyte Globulin; CCI = Corrected Count 
Increment; CI = Confidence Interval; CTC = Common Toxicity Criteria; HLA = Human 
Leukocyte Antigen; HPA = Human Platelet Antigen; IQR = Inter-Quartile range; OR = Odds 
Ratio; NHL = Non Hodgkin Lymphoma; PAS = Platelet Additive Solution; PC = Platelet 
Concentrate; RBC = Red Blood cell Concentrate; RCT = Randomized Controlled Trial;  
TBI = Total Body Irradiation; TRAP = Trial to Reduce Alloimmunization to Platelets;  
WHO = World Health Organization.
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Transfusion support with PCs is widely applied and accepted for the prevention and 
treatment of bleeding in patients with thrombocytopenia, due to bone marrow diseases or 
cytotoxic therapy, and thrombocytopathy.1 Although not without limitations, the efficacy 
of platelet transfusions usually is expressed as count increment, adjusted for platelet 
dosage and patient size, resulting in recovery, survival or CCI.2 Applying internationally 
accepted, but arbitrary definitions, platelet transfusion failure occurs in 25 – 70% of 
multiple transfused patients and up to 30 – 50% of platelet transfusions.3-9 An analysis 
of the outcome of 6379 transfusions in the TRAP study showed that prior pregnancies, 
male gender, an enlarged spleen, bleeding, fever, infection, disseminated intravascular 
coagulation, increasing height and weight, lymphocytotoxic antibody positivity, number of 
platelet transfusions, heparin therapy or amphotericin treatment were related to decreased 
posttransfusion platelet responses.10, 11 The potential role of endothelial damage in relation 
to increased platelet consumption in non-immunological platelet transfusion failure has 
been suggested by several authors.3, 8, 11 In a large study comprising 1402 patients after 
bone marrow transplantation Nevo and colleagues found bleeding was significantly 
associated with reduced survival, independent of type of transplantation, stem cell 
source and diagnosis.12 They conclude that the bleeding complications may be regarded 
as a marker of multifactorial clinical deterioration. Interestingly, in a study evaluating 
a restrictive platelet transfusion threshold, this group showed an association between 
profound thrombocytopenia and reduced survival also in non-bleeding patients.  
Exposure to profound thrombocytopenia was significantly increased when a restrictive 
prophylactic threshold was used. A relation with increased platelet consumption due  
to endothelial damage was argued.13 These findings underline the need for the 
identification of more specific risk factors for the occurrence of thrombocytopenia, 
bleeding and survival, in order to improve supportive care strategies.14, 15 We evaluated 
whether platelet transfusion failure is associated with bleeding complications and 
decreased survival and could serve as a signal for additional diagnostic tests and/or 
adjustment of supportive care treatment .
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m At e r i A l s  A n D  m e t H o D s
Between October 2003 and April 2005 a RCT, testing the clinical efficacy of platelets stored 
in plasma as compared to PAS II, was performed.16 For the current analysis only patients 
randomised in the Leiden University Medical Centre were evaluated. All patients older 
than 18 years who needed or were expected to need more than two PC transfusions 
were eligible. Patients with HLA- and/or HPA- alloantibodies and active immune 
thrombocytopenia were excluded. An inclusion cycle was restricted to a maximum of 
30 days and/or 8 platelet transfusions, whichever occurred first. In the RCT, patients 
were allowed to participate several cycles (i.e. during a remission-induction course, 
consolidation chemotherapy or stem cell transplantation). For the current analysis only  
the events during the first inclusion were used. 
After randomisation, age, sex, height, weight, diagnosis, existence of an enlarged spleen,  
WHO performance status, medical history (including transfusion history), prior bleeding 
and medication (including treatment schedule) were recorded. During the inclusion 
periods platelet and red cell transfusions were monitored as well as transfusion related 
adverse reactions, mucosal damage (CTC, version 2.0, http://ctep.info.nih.gov/reporting/
ctc.html), fever (defined as body temperature > 38˚C), infections (defined as a positive 
culture and/or radiologic evidence for infection) and the occurrence of bleeding 
complications. Bleeding was graded according to the WHO criteria.17 All parameters  
were reviewed on a daily basis by the attending physician and recorded on case report 
forms. Hospital records were used in regard to survival. The first day of the first inclusion 
cycle was considered day zero. 
 
All PCs were prepared from 5 pooled whole-blood buffy coats, leukocyte depleted  
and subsequently stored up to 5 days in plasma or PASII. The treating physician ordered 
platelet transfusions according to hospital guidelines either for prophylactic or therapeutic 
indications, using a restrictive policy with a threshold of 10 x 109/l in non-bleeding, stable 
patients. The 1- and 24-hour CCIs were calculated according to the method described in 
our previous study.16 Platelet transfusion refractoriness or failure was defined as a 1-hour 
CCI below 7.5 and/or a 24-hour CCI below 4.5. In patients experiencing repeated episodes 
of refractoriness without an apparent clinical cause, tests for the existence of HLA- and/or 
HPA- allo antibodies (PAK12, GTI Waukesha, USA) were performed. 
statistical methods
Fisher exact tests were used to compare the categorical variables. Continuous variables 
were tested using ANOVA or, when non-normally distributed, Mann-Whitney tests. 
Univariate analysis was performed to identify factors at randomisation and during the 
study cycle associated with the occurrence of bleeding complications. Factors with  
a p-value of ≤ 0.20 combined with known factors from the literature, e.g. prior bleeding, 
were included in a multivariate analysis.11, 18 The data are presented as Odds ratios,  
with 95% confidence intervals. We performed a sequential analysis according to Wald  
and Barnard to investigate the temporal relationship of bleeding complications and 
platelet transfusion failure.19
 
To study the relation between platelet transfusion failure and survival, we performed  
a backward conditional Cox regression analysis initially correcting for patient age, 
diagnosis, and treatment schedule. All analyses were performed using SPSS/PC+ (version 
14.0, Chicago, IL).
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Patient characteristics
117 patients were randomized for a total of 151 inclusion cycles to receive either  
plasma stored or PAS II stored PCs (n = 93 one cycle, n = 24 more than one cycle).  
Table 1 summarizes the main characteristics, including events and complications during 
the first inclusion cycle. The non-AML group consisted of patients with NHL (n = 26), 
multiple myeloma (n = 14), acute lymphatic leukaemia (n = 10), chronic myeloid leukaemia 
(n = 8), chronic lymphatic leukaemia (n = 3), aplastic anemia (n = 2) and one patient with 
carcinoma of the testes. The vast majority of the remission-induction and consolidation 
courses were anthracycline based, in patients with AML combined with cytarabine. 
Most included patients with NHL were treated with busulfan, etoposide, cytarabine and 
melphalan, followed by autologous stem cell transplantation. Patients with myeloma were 
conditioned for autologous stem cell transplantation using high dose melphalan. A total of 
31 allogeneic stem cell transplantations were performed, using both related and unrelated 
stem cell donors, with a myeloablative scheme (cyclophosphamide / total body irradiation) 
in 22 patients and 9 using a reduced intensity scheme based on ATG and fludarabine. 
All allogeneic stem cells were in-vitro treated with alemtuzumab. Acute Graft versus 
host disease was seen in 6% of the allogeneic transplantations. Most of the infectious 
complications were bacterial (49%). 15% of the patients had a fungal infection of which 
2 patients had pulmonary aspergillosis. Only one of these patients eventually received 
amphotericine B. Combined infections were not infrequent. Severe mucosal damage was 
encountered in 15% of the patients.
red cell and platelet transfusions
During the first inclusion cycle the total number of transfused RBCs and PCs was 678 
and 486, respectively. The mean consumption of RBCs and PCs per patient in the first 
cycle is shown in Table 1. ABO major incompatibility was present in only 3.6% of the PC 
transfusions. PC transfusion failures occurred at least once in 58 patients (49.6%). Of the 
patients with PC transfusion failure, 31% experienced only one PC transfusion failure, 
whereas in 69% failure occurred more then once. The mean use of both PCs as well as RBCs 
was significantly higher in patients with PC transfusion failures, 6.4 ± 2.5 and 7.2 ± 3.6 as 
compared to 2.9 ± 1.8 and 4.5 ± 3.7, respectively. Patients with prior bleeding, bleeding 
complications, febrile and infectious complications were more likely to experience 
PC transfusion failure. On the other hand, patients undergoing autologous stem cell 
transplantation were less likely to experience PC transfusion failure (table 1, p < 0.05).
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Patients without failure with failure
n = 117 n = 59 n = 58
At inclusion
Male/female 78 / 39 38 / 21 40 / 18
Age (Years, mean ± sd) 48.9 ± 13.4 47.8 ± 14.1 49.9 ± 12.3
Age categories
 < 40 years 29 15 14
 40 – 60 years 63 31 32
 ≥ 60 years 25 13 12
Body surface area (m2, mean ± sd) 1.94 ± 0.23 1.94 ± 0.23 1.94 ± 0.23
Prior bleeding 17 4 13
Enlarged spleen 11 4 7
Number of inclusions
 1 inclusion 93 49 44
 > 1 inclusion 24 10 14
Inclusion time (days, mean ± sd) 20.5 ± 7.6 20.4 ± 7.8 20.6 ± 8.0
Diagnosis
 AML 53 22 31
 Non AML 64 37 27
Chemotherapy 60 24 36
Stem cell transplant 57 35 22
 Allogeneic transplantation 31 17 14
 Autologous transplantation 26 18 8
ATG 10 3 7
TBI 22 15 7
During follow up
Complications
 Fever 71 28 43
 Infections 68 27 41
 Mucosal damage 88 43 45
 Severe mucosal damage (grade III-IV) 18 5 13
 Bleeding complications 22 5 17
n days with Plt counts ≤ 10 x 109/l
 0 days 35 16 19
 1-3 days 58 39 19
 ≥ 4 days 24 4 20
red cell and platelet transfusions (mean ± sd)
 Red cell transfusions 5.8 ± 3.9 4.5 ± 3.7 7.2 ± 3.6
 Platelet transfusions 4.3 ± 2.4 2.9 ± 1.8 6.4 ± 2.5 
follow up and survival
 Follow up (months, mean ± sd) 20.9 ± 12.5 22.9 ± 11.8 19.0 ± 13.0
 Lost to follow up 2 1 1
 Survival 56 33 23
Numbers of patients, unless otherwise specified. 
table 1: Patient characteristics, events and complications during first inclusion.
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Bleeding complications
During the first inclusion cycle bleeding occurred in 22 patients (19%), mostly grades I  
and II. No lethal bleeding occurred during the first inclusion cycle, however during follow 
up 4 patients died with severe bleeding complications. Two patients died of an intracranial 
haemorrhage and two with recurrent AML and graft versus host disease, with concomitant 
severe bleeding. 45% of our study population consisted of patients with AML, mostly 
receiving remission-induction chemotherapy. In this category bleeding incidence was 
39%. Although we could not find a direct correlation between platelet count and bleeding 
complications, patients with bleeding had more days of mean platelet counts below 
30 x 109/l (p < 0.01, figure 1). In the PC transfusion failure group there were significantly 
more patients with a platelet count of ≤ 10 x 109/l for ≥ 4 days. Table 2 shows the risk for 
bleeding complications according to patient characteristics. In the multivariate analysis PC 
transfusion failure remained significantly associated with bleeding complications (OR 3.4, 
95% CI 1.1 – 11), as were non-transplant related chemotherapy, severe mucosal damage 
and age. The level of thrombocytopenia was not significant in the multivariate analysis. 
Sequential analysis showed no temporal pattern between the occurrence of PC transfusion 
failure and bleeding complications (data not shown). The mean RBC consumption was  
7.9 ± 4.0 in bleeding patients, versus 5.3 ± 3.7 in non bleeding patients (p < 0.01). The mean 
PC consumption was 6.0 ± 2.1 and 3.9 ± 2.3, respectively (p < 0.01).
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figure 1: Figure 1 shows the distribution of daily mean platelet count expressed as a percentage 
of all daily mean platelet counts over different strata of platelet counts for bleeding (285 days in  
22 patients) and non-bleeding patients (1202 days in 95 patients). The same distribution was seen 
in the daily minimal platelet counts. The median number of days with minimal platelet counts  
≤ 10 x 109/l was 1 day(0 – 8 days) in non-bleeding patients as compared to 3 days (0 – 10 days)  
in bleeding patients (p = 0.034). The median number of days with minimal platelet counts  
≤ 30 x 109/l was 4 days (0 – 18 days) and 7 days (0 – 17 days), respectively (p = 0.12).
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PC transfusion failure and survival
For this analysis we only used the 24-hour CCIs. In 5 of the 117 patients there were 
insufficient PC transfusion data to calculate the percentage of 24-hour transfusion 
failure. Two other patients were lost to follow up. Of the remaining 110 patients 61 did 
not experience 24-hour transfusion failure versus 49 patients, experiencing one or more 
episodes of transfusion failure. The 100-day survival in both groups was 98% versus 83%, 
respectively (p < 0.01). The median survival in both groups was 825 (IQR 355 – 996) days 
and 491 (IQR 156 – 858) days, respectively (p = 0.032). Figure 2 shows the survival curves of 
patients with and without 24-hour transfusion failure. The difference between both groups 
remained significant, using backwards conditional Cox Regression analysis correcting for 
age, diagnosis, treatment and level of thrombocytopenia.
The effect was more pronounced in patients with acute myeloid leukemia. If we perform 
the analysis for the effect of 1-hour transfusion failure, there was only a less outspoken 
trend towards reduced survival (p = 0.11).
figure 2: Figure 2 shows the survival of patients with and without 24-hour platelet transfusion 
failure, during the first inclusion cycle. A Cox regression model was used to adjust for age, 
diagnosis, treatment and level of thrombocytopenia.
table 2: Relative risk for bleeding according to patient characteristics.
univariate analysis multivariate analysis
OR 95% CI P OR 95% CI P
Chemotherapy1 5.7 (1.8-18) 0.003 12.5 (2.4-65) 0.003
PC transfusion failure 4.5 (1.5-13) 0.006 3.4 (1.1-11) 0.04
Severe mucosal damage 3.6 (1.2-11) 0.023 5.0 (1.3-19) 0.021
Age ≥ 60 years 1.6 (0.8-3.2) 0.194 2.7 (1.1-6.7) 0.038
Fever 3.6 (1.1-11.3) 0.031 2.2 (0.6-8.5) 0.243
Enlarged spleen 2.8 (0.7-11) 0.130 2.2 (0.39-12) 0.369
AML 2.0 (0.8-5.1) 0.154 0.3 (0.1-1.2) 0.091
Male sex 1.4 (0.5-4.0) 0.505 1.7 (0.5-5.9) 0.401
Prior bleeding 1.3 (0.4-4.4) 0.687 0.5 (0.1-2.3) 0.381
≥ 4 days PLT < 10 x 109/l 3.7 (1.3-10.2) 0.012 1.1 (0.3- 4.0) 0.867

















D i s C u s s i o n
We analyzed the relationship between the occurrence of platelet transfusion failure(s), 
bleeding complications and patient survival. Our results confirm the frequent occurrence 
of non-immunological platelet refractoriness. In the first analysis of this study we already 
showed that patient-related factors were the main determinants of transfusion failure, 
independent of product factors such as storage medium and storage time.16 This is in 
agreement with a recently published study showing that storage duration of both buffy-
coat PCs as well as apheresis PCs only explained for less then 4% of the variation in CCI  
and transfusion interval.20 
The relationship between platelet count and bleeding has been reported with conflicting 
results. A large study in 2,942 patients did not show a relationship with platelet counts 
and bleeding.24 Until now, only one previous study reported an association between PC 
transfusion failures and bleeding complications. In that study bleeding complications were 
significantly associated with an increased risk of 1- and 24-hours PC transfusion failure 
(Hazard ratio 2.0).11
The overall bleeding incidence in our study is less than reported in the literature, 
presumably related to the relatively short observation period including only the first 
randomisation cycle.12, 21-23 We could confirm an association between PC transfusion 
failures and bleeding complications. As shown in figure 1, bleeding patients had more 
pronounced thrombocytopenia as compared to non-bleeding patients, consistent with 
other studies, although this difference is relatively small.22, 23 In the multivariate analysis the 
level of thrombocytopenia did not independently correlate with bleeding complications. 
Pathophysiological mechanisms as to how clinical factors contribute to decreasing 
transfusion efficacy and bleeding complications are not unravelled, but endothelial 
vascular damage caused by cytotoxic treatment or disease-related complications has 
been proposed as a potential mechanism.8, 11, 24 This vascular damage could at least in part 
explain the not hitherto reported association of PC transfusion failure and patient survival. 
Impaired patient survival was previously observed in patients experiencing bleeding 
complications after stem cell transplantation and profound thrombocytopenia in non-
bleeding patients.12, 13 
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In our study, we found no correlation between patient survival and bleeding complications 
or profound thrombocytopenia in non-bleeding patients. The most likely explanation 
for this discrepancy is the small number of patients and transfusion events in our study. 
Moreover our study not only included transplant procedures, but also remission-induction 
and consolidation chemotherapy. It might be that PC transfusion failure stronger predicts 
systemic platelet destruction caused by epithelial and endothelial cell damage, as 
compared to bleeding complications or the occurrence of profound thrombocytopenia.
Both in vitro, as well as in vivo evidence of endothelial cell damage and/or activation due 
to cytotoxic and irradiation therapy exists.25-29 Clinically, endothelial cell damage can be 
the cause of bleeding complications, capillary leakage and proteinuria, as opposed to 
endothelial activation, which may be more related to thrombotic complications.  
All of these complications occur in patients treated with cytotoxic therapy. For instance, 
treatment with VEGF-inhibitors in oncology patients resulted in an increased incidence of 
both bleeding as well as thrombosis.30, 31 Alas, all of these studies lack details on platelet 
transfusions and transfusion efficacy. 
Recognizing the small sample size and retrospective nature of our study, we have shown 
an association between PC transfusion refractoriness and the occurrence of bleeding and 
a reduced survival. Obviously, neither PC transfusion failure nor bleeding is causally related 
to death. Rather the associations found could be related to the level of endothelial cell 
damage, which in turn contributes, by an unknown mechanism, to decreased survival. 
Incorporation of markers for endothelial damage or activation may be helpful to explain 
transfusion refractoriness and may ultimately lead to treatment options.
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The reported percentage of patients experiencing bleeding complications is highly 
variable, ranging from 5 – 70%, posing a major problem for designing clinical platelet 
transfusion trials using bleeding complications as a primary endpoint. A pilot study was 
performed to access the percentage of patients with WHO grade 2 or higher bleeding  
in preparation of a large randomised controlled trial.
study design and methods
We performed a prospective, observational study using a rigorous bleeding observation 
system. Endpoints of the study were the percentage of patients and days with bleeding 
WHO grade ≥ 2. The results were compared the previously reported HOVON study. 
Moreover, the impact of scoring successive days with stable skin bleeding was assessed.
results
Bleeding grade ≥ 2 occurred in 37 patients (54%). The percentage of days with 
bleeding of grade > 2 was 18%. The administration of chemotherapy was the strongest 
predictor of grade > 2 bleeding. The vast majority of bleeding complications occurred 
mucocutaneously, largely explaining the difference with the HOVON trial. Censoring for 
stable skin bleeding had a profound effect on bleeding incidence per day.
Conclusion
The results of this study confirm the bleeding frequency reported in literature reporting 
on platelet transfusion studies provided a rigorous bleeding observation strategy is used. 
However, the clinical relevance of bleeding as an endpoint remains a matter of debate.
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i n t r o D u C t i o n
Patients with hemato-oncological diseases receiving myelosuppressive chemotherapy 
or undergoing haematopoietic stem cell transplantation are supported with platelet 
transfusions to prevent or treat bleeding complications.1 Despite several policy-driven 
trials the prophylactic platelet transfusion strategy has remained stable without major 
changes in the last four decades. In contrast, safety as well as economical concerns has 
led to several changes in the production of platelet products. Although several endpoints 
have been used as an endpoint for platelet transfusion trials, the Guidance for Industry For 
Platelet Testing and Evaluation of Platelet Substitute Products, published by the FDA in 
1999 prescribes the recording of bleeding outcomes as a necessary activity.2 However, as a 
consequence of the several different methods for the observation and grading of bleeding 
complications, passive versus active reporting, frequency of bleeding complications and 
differences in patient populations, the reported percentage of patients experiencing 
bleeding complications is highly variable.3 A review of literature shows that the reported 
incidence of major bleeding (WHO grade ≥ 2) varies from 5 to 70% (figure 1).4, 5, 6, 7, 9, 12-32 
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figure 1: Figure 1 shows reported percentages of patients with grade 2 – 4 bleeding complication.  
The error bars reflect the 95% confidence interval. The filled markers represent randomised 
controlled trials, whereas the open markers represent observational studies. 1 = Blumberg et al14;  
2 = Sensebe et al15; 3 = Kerkhoffs et al7; 4 = Oka et al16; 5 = Tinmouth et al17; 6 = Gil-Fernandez et al18; 
7 = Zumberg et al19; 8 = Kerkhoffs et al6; 9 = Mirasol20; 10 = Diedrich et al21; 11 = Wandt et al22;  
12 = Rebulla et al12; 13 = Gmur23; 14 = Nevo et al9; 15 = Wandt et al24; 16 = Sagmeister et al25;  
17 = Murphy et al26; 18 Pihush et al27; 19 = Higby et al28; 20 = Navarro et al29; 21 = Heddle et al5;  
22 = McCullough et al13; 23 = Lawrence et al30; 24 = Friedmann et al31; 25 = Slichter et al4.




















The observation of bleeding complications in hemato-oncological 
patients: results of a pilot study 7
This variability poses a major problem for designing clinical platelet transfusion trials 
using bleeding complications as a primary endpoint. In studies using a rigorous 
bleeding observation and adjudication process to assess bleeding, at least one episode 
of major bleeding (WHO > grade 2) is reported in up to 70% of patients and on 16% of 
thrombocytopenic days.4, 5 In contrast, studies that relied on physician’s bedside assessment 
of bleeding complications reported much lower incidences of major bleeding.6, 7  
Recently, we initiated a platelet transfusion trial studying the haemostatic efficacy of 
transfused platelets treated with an alternative pathogen reduction technique (PREPAReS; 
Pathogen Reduction Evaluation & Predictive Analytical Rating Score). As bleeding 
complications are the intended primary outcome of this study, we performed a pilot study 
to investigate the percentage of patients with major bleeding complications in the Dutch 
situation using a rigorous bleeding observation system. Secondary endpoints were  
the percentage of patients experiencing any bleeding complication (WHO grade 1-4)  
and the percentage of days with WHO grade ≥ 2 bleeding complications. Moreover we 
have compared the data from this pilot study with the bleeding data from a previous study 
(HOVON) testing pathogen reduced platelet products.7
m e t H o D s
We performed a prospective observational study, including patients ≥ 18 years, admitted 
to the hospital for receiving high dose chemotherapy or stem cell transplantation 
for hemato-oncological disease expected to need platelet transfusions during their 
admittance. Exclusion criteria were suspicion of microangiopathic thrombocytopenia,  
the use of anticoagulant drugs or active bleeding (grade > 2) at the time of inclusion.  
The study protocol and consent forms were approved both by a central ethics committee 
and local institutional review boards. In total, four haematological centres participated 
in the study, two academic medical centres and two large general hospitals (HIC, 
Haematological Intensive Care centres). Hospital discharge, death or patients’ refusal 
to continue were reasons to go off protocol. Daily assessment of bleeding symptoms 
for 8 World Health Organisation (WHO) defined sites (oral, nasal; skin, soft tissue, 
musculoskeletal; gastrointestinal; genitourinary; pulmonary; body cavity; central nervous 
system; invasive sites) was performed by trained physicians, nurses or research staff 
members in each of the four hospitals including physical examination and a patient’s 
interview. Adjudication of grades of bleeding according to the WHO criteria was performed 
by two clinicians, independently.8 Platelet transfusions were administered in general if the 
morning platelet count was below the trigger (10 x 109/L) or at the treating physicians’ 
initiative if the patient experienced bleeding or using a higher trigger in certain clinical 
circumstances. Platelet transfusions consisted of a mean of 350 x 109 buffy-coat derived 
platelets. Red cell transfusions were administered below an age-dependent trigger as 
described in national or local transfusion guidelines. Besides bleeding, each day a blood 
cell count and transfusion requirements were recorded. For the comparison with the 
previously published HOVON study, we extracted all bleeding data from the case report 
forms of that study.7 Primary endpoint of the study was the percentage of patients 
experiencing bleeding WHO grade ≥ 2. Secondary outcome measures were the percentage 
of patients experiencing bleeding of any grade and the percentage of days with bleeding 
WHO grade ≥ 2. 
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statistical analysis
Categorical patient characteristics and bleeding complications are reported as 
percentages. Continuous data are presented as the mean with standard deviation (STD) 
for normally distributed variables and the median with (inter)quartile range (IQR) for other 
continuous variables not normally distributed. A univariate comparison of patients with 
and without WHO grade ≥ 2 bleeding was performed. A multivariate logistic regression 
analysis was performed including all parameters associated with bleeding (p<0.1) in the 
univariate analysis. Variables considered as possible consequences of bleeding rather 
than causes (number of platelet and red cell transfusions), were not considered for multi-
variable analyses. All statistical analyses were performed using SSPS (version 15.0, Chicago, 
IL). P values < 0.05 were considered statistically significant.
r e s u lt s
Patients
A total of 68 patients were enrolled at four sites (centre A, B, C and D) with a median follow 
up period of 20 days. The patients were not equally divided: centre A enrolled 10 patients, 
centre B 13 patients, centre C 28 patients and centre D 17 patients. Patient characteristics 
are summarized in table 1. More men than women were included and almost half of the 
patients suffered from acute leukaemia. The composition of the included patients does 
not differ substantially from the patients included in the HOVON trial. A small number of 
patients treated with a reduced intensity conditioning regimen did not reach a level of 
thrombocytopenia indicating a platelet transfusion; they were however not excluded from 
this analysis.
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table 1: Patient characteristics.
n=68
Male / female n / n 46 / 22
Age years, mean(SD) 55 (±13)
Diagnosis
 acute leukemia n (%) 31 (45%)
 myeloma n (%) 14 (21%)
 lymphoma n (%) 12 (18%)
 other n (%) 11 (16%)
Therapy
 chemotherapy n (%) 30 (44%)
 stem cell transplantation n (%) 35 (52%)
 other n (%) 3 (4%)
Follow-up days, median (IQR) 19 (14 - 26)
Mean hemoglobin mmol/l, median (IQR) 5.9 (5.7 - 6.3)
Mean platelet count 109/L, median (IQR) 46 (30 - 74)
Platelet nadir 109/L, median (IQR) 7 (5 - 10)
Red blood cell transfusion (units) n, median (IQR) 3.5 (1.3 - 7.8)
Platelet transfusion* n, median (IQR) 2.0 (1.0 - 5.8)




One or more episodes of grade ≥ 2 bleeding were experienced by 37 patients (54%).  
Five patients (7%) suffered from a grade 3 or 4 bleeding and 1 patient died from a bleeding 
complication. Fifty-nine (87%) patients experienced one or more bleeding complications 
of any grade. Table 2 summarizes the bleeding complications by different bleeding sites 
as defined by the WHO criteria. The vast majority of bleeding complications occurred on 
mucocutaneous sites as expected. Figure 2 shows the comparison for the several bleeding 
sites as reported in the HOVON studies. The striking difference in grade ≥ 2 bleeding 
complications is almost completely explained by the difference in mucocutaneous 
bleeding complications.
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table 2: Bleeding complications (maximal score) by site.
figure 2: Figure 2 shows the comparison between the BOP trial with the HOVON trial of 
patients with bleeding WHO grade ≥ 2 grouped by the anatomical sites. The bars reflect 95% 
confidence intervals.
Bleeding site grade 1 bleeding grade ≥ 2 bleeding
n n
Oral cavity and nose 41 2
Skin, soft tissue and musculoskeletal 25 20
Digestive tract - 14
Urogenital tract - -
Respiratory tract - 6
Body cavity - 3
Central nervous system / retina - 4
Invasive site - 3














































































The percentage of thrombocytopenic days with bleeding of any grade during the 
observation period was 42%. The percentage of days with bleeding grades> 2 for patients 
on study was 18%. Most of the grade > 2 bleedings occurred on the skin.
Including only newly perceived haematomas, the percentage of days with bleeding 
of grade > 2 was only 7.8%. Figure 3 shows the relation between platelet counts and 
percentage of days with grade II – IV bleeding with or without excluding persisting 
haematomas, again illustrating the effect of mucocutaneous bleeding on the total 
incidence of bleeding.
Univariate analysis indicated that patients in academic centers experienced less bleeding 
episodes as compared to patients in general hospitals (p = 0.05). Acute leukaemia 
as indication for treatment (compared to other haematological disorders) and the 
administration of chemotherapy (as opposed to transplantation therapy) resulted in 
significantly higher bleeding frequencies (table 3). A multivariate analysis showed that  
the administration of chemotherapy (remission–induction and consolidation 
chemotherapy) was the only independent predictor of grade > 2 bleeding in patients with 
hemato-oncological diseases receiving myelosuppressive therapy. Although maintained as 
a factor in the model of the backward multivariate analysis, a low mean platelet count only 
showed a trend of an association with bleeding (p = 0.08).
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30 - 39 40 - 49 > 50
Censored for skin bleeding Total grade 2-4 bleeding
figure 3: Figure 3 shows the percentage of days with bleeding grade ≥ 2 with the 95% 
confidence interval according to the platelet count categories based on the days with both  
a platelet count measurement and information on bleeding (n = 901 days). The closed symbols 
represent the percentage of days with bleeding if all the events are included. The open symbols 
show the censored percentage after exclusion of successive days with stable skin bleeds.
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D i s C u s s i o n
This study was designed to explore a rigorous bleeding observation and adjudication 
strategy in the setting of the preparation of a multicenter platelet transfusion trial.  
We observed an incidence of WHO grade > 2 bleeding of 54% in our patient population 
and in 18% of the days, which was in the range of other studies applying rigorous bleeding 
assessment.4, 5 The vast majority of the observed major bleeding complications consisted 
of mucocutaneous bleeding. Moreover, we showed that a different way of assessment by 
taking only newly appearing skin haemorrhages into account had a large impact on the 
percentage of bleeding days. Comparison with the HOVON study, published in 2010, shows 
that the main difference in bleeding score is explained by the difference in mucocutaneous 
bleeding.7 There was some concern that despite the defined rigorous bleeding observation 
strategy variation between centers persisted, as revealed by univariate analyses, but this 
factor disappeared in the multivariable analyses. Likely, different patient populations as 
well as differences in treatment explain for the variation between academic and non-
academic centers. Indeed patients with a newly diagnosed acute myeloid leukemia often 
receive their remission-induction and consolidation therapy in a non-academic center, 
while post remission transplant procedures were only performed in the academic setting. 
Acute leukaemia on treatment with chemotherapy was associated with the highest risk  
of bleeding. 
The relevance of skin bleeding in a daily observation and scoring system requires special 
consideration. Although the presence of a grade > 2 bleeding of the skin might be relevant 
in the above mentioned perspective, it seems less appropriate to include every day a skin 
bleeding is visible as a “bleeding day” in the scoring system. Bruising of the skin takes 
several days to weeks to disappear and counting all those days forms a distorted picture 
of the bleeding tendency. As is shown in figure 3, excluding successive days with stable 
haematomas affects only the percentage but does not affect the curve of the line. There is 
no difference in the percentage of days with grade > 2 bleeding when platelet counts are 
0-9 x 109/L or 10-19 x 109/L or 20-29 x 109/L. Also with higher platelet counts a considerable 
percentage of days remain to be reported where patients suffer from grade > 2 bleedings 
in agreement with the platelet dose trial reported by Slichter et al.4
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table 3: Statistical comparison of patients with bleeding grade ≥ 2 versus no or grade 1 bleeding.
Bleeding site no or grade 1 bleeding grade ≥ 2 bleeding
n = 31 n = 37
Male / female; n / n 23 / 8 23 / 14
Age, years; median (range) 57 (19-70) 59 (23-77)
Acute Leukemia; n (%) 8 (26) 23 (74)#
Stem cell transplant; n (%) 25 (81) 13 (35)#
Academic center; n (%) 18 (58) 12 (32)
Mean Hb, mmol/L; median (range) 6.0 (5.2-7.5) 5.8 (5.2-8.4)
Mean PLT, 109/L; median (range) 67 (14-151) 39 (4-148)#
PLT Nadir, 109/L; median (range) 8 (2-134) 7 (1-22)
n of RBC; median (range) 2 (0-16) 4 (0-17)#
n of PC; median (range) 1 (0-16) 5 (0-18)#
Hb = Hemoglobin; PL T = Platelets; RBC = Red blood cell concentrate; PC = Platelet concentrate; n = number of patients  
or units; #p < 0.05 (univariate); in the multivariate analysis only stem cell transplantation was independently associated 
with a decreased bleeding incidence (p < 0.01).
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Although bleeding complications were found to be associated with survival, the clinical 
relevance of reporting of grade 2 bleeding for platelet transfusion study purposes has been 
called into question.9 Recently, in a commentary Heddle et al discuss the use of grade 2 
bleedings in transfusion studies. This type of bleeding is likely to neither represent a valid 
surrogate for an effect of the intervention (bleeding occurs despite adequate prophylactic 
platelet transfusions), nor a valid composite outcome according to methodological criteria 
lacking reproducibility and accuracy.10 
Our pilot study underscores that slight differences in assessment have a great impact 
on the estimation of bleeding. Although we completely agree on the need for better 
(surrogate) criteria to evaluate platelet transfusion therapy, the pilot study we performed 
had the purpose of investigating the soundness of scoring bleeding tendency in 
anticipation of a large multicenter randomised controlled trial. In this perspective the 
occurrence of an effect on any bleeding tendency, albeit not a surrogate for clinical 
outcome, might be informative. Indeed, there is evidence that certain modifications of  
the platelet product have an adverse effect on the haemostatic capacity.11
To summarize, we have found a comparable incidence of WHO grade ≥ 2 bleeding scores, 
supporting the power calculation of a recently initiated platelet transfusion trial.  
However there are still a number of unresolved issues. In this respect, the term “clinically 
relevant” gives rise to most of these issues. From a patient’s perspective relevance is 
without doubt different, but more important is the discrepancy of the “relevance” concept 
between the clinicians taking care of the patients and blood bank scientists aiming to 
improve platelet products. Every clinician knows the difference between a “wet” patient 
and just an incidental haematoma albeit smaller or greater than 1 inch. Perhaps it is time to 
re-evaluate the current bleeding scales in relation to these different purposes.
7 The observation of bleeding complications in hemato-oncological patients: results of a pilot study
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t H r o m B o C y to P e n i A ,  B l e e D i n g  A n D  s u r V i VA l  – 
t H e  e n D  o r  s tA r t  o f  A  C H A P t e r ?
introduction
The use of platelet concentrates (PC) is generally recommended for the prophylaxis and 
treatment of haemorrhagic complications in patients with thrombocytopenia due to 
myelosuppression.1–4 Based on the observations of Gaydos et al as well as two post mortem 
studies, the concept of prophylactic platelet transfusions became standard practice since 
the late sixties and early seventies of the past century.5–7 Indeed, after the introduction 
of platelet transfusions, the incidence of lethal haemorrhages steadily declined from 
more than 60% in the sixties to less than 5% in the last two decades.6 – 8 Although it has 
to be noted that other supportive care measures as well as leukaemia treatment without 
doubt contributed major to this decline, a Cochrane analysis, which included these older 
studies, showed a small but significant effect of prophylactic platelet transfusions in the 
reduction of severe haemorrhages as compared to therapeutic transfusions.9 Over the 
past three decades several endpoints have been engaged in successive trials starting with 
more patient centred endpoints such as bleeding prevention efficacy and the incidence of 
adverse transfusion reactions (e.g. alloimmunisation, febrile non-haemolytic transfusion 
reactions), as well as transfusion efficacy, a more transfusion product oriented endpoint. 
This thesis is based on the results of two product-based randomised trials, looking at 
transfusion efficacy in terms of increments, with adverse transfusion reactions and 
haemostatic efficacy as secondary outcome measures.10, 11 This discussion reviews the most 
relevant outcomes of these trials and debate the clinical relevance of these (surrogate) 
endpoints, focussed on refractoriness and bleeding incidence. 
 
the trials
The first randomised controlled trial (RCT) we performed aimed to investigate the clinical 
efficacy of a platelet additive solution as compared to conventionally plasma stored 
platelets in non-selected, thrombocytopenic patients in two large hospitals. Despite 
platelets stored in platelet additive solution (PAS2, Trombosol) had a significantly lower 
1- and 24-hour corrected count increment, the wide chosen 30% margin of non-inferiority, 
as well as the fact that a comparable transfusion interval and no difference of hemorrhagic 
consequences were observed has not led to abandoning of platelets stored in PAS2 
for up to five days in clinical practice (Chapter 3).10 The transfusion efficacy results are 
in line with the findings of three other studies using this additive solution.12-14 Adverse 
transfusion reactions occurred less frequently after transfusion with platelets in additive 
solution, consistent with the concept of plasma as important factor in FNHTRs. Platelet 
transfusion refractoriness defined as a 1-hour CCI < 7.5 and/or a 24-hour CCI < 4.5 occurred 
more frequent after transfusions with PAS2-PCs, however a multivariate analysis showed 
that patient factors like enlarged spleen, fever and infection and not product factors 
like storage time and storage solution determined the incidence of non-immunological 
refractoriness.10 
As a consequence of the growing awareness of transfusion-transmitted infections along 
with a public debate, the second randomised trial investigated the transfusion efficacy 
of pathogen-reduced platelet products (PR-PAS3PC, Intercept) as compared to two 
non-pathogen-reduced platelet products (PAS3 PC, Intersol; plasma PC) in a comparable 
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non-selected hospitalised patient population as the first trial. With the chosen 20% margin 
of non-inferiority, inferiority was shown for pathogen-reduced platelets as compared 
to both control arms. Moreover, patients treated with pathogen-reduced platelets had 
significantly more bleeding complications and was reason for the Data Safety Monitoring 
Committee to stop the study arm PR-PAS3PC (Chapter 4).11 Although the overall bleeding 
incidence, scored by clinicians in this trial, was considerably less as compared to other 
trials in which bleeding was scored according to rigorous prescriptive protocols; the 
reported outcome is consistent with these trials.15-17 Whether the increase in haemorrhagic 
complications was due to a difference in platelet dose or impaired platelet function could 
no be determined. Platelet dose, which was significantly lower in the pathogen reduction 
arm, has been suggested as possible explanation for the increase in haemorrhagic 
complications.18 A recently published large trial, however, testing 3 different platelet doses 
showed no difference with regard to the bleeding incidence.19 In vitro studies reported 
that platelets treated with pathogen reduction, especially after prolonged storage, show 
reduced aggregation capacity, reduced glycoprotein expression, increased expression of 
annexin V as well the activation marker P-selectin, suggesting functional alterations that 
may play a role in an increase in bleeding complications.20, 21 Apart from this unresolved 
issue, the outcome of this second trial has lead to both a debate with regard to bleeding as 
an endpoint as well as enormous (legal) consequences of reporting an adverse outcome 
and consequently stopping a study arm. The outcomes of the second trial as well as the 
intention to include bleeding as a primary outcome measure in current trials have led 
to a number of questions. To what extend is an increase in haemorrhagic complications 
acceptable using manipulated platelets to reduce the already very low incidence of 
transfusion-transmitted infections? And, if so what margin of non-inferiority is acceptable? 
What are the clinical consequences of bleeding complications?
 
t H e  e n D P o i n t s :  r e f r AC to r i n e s s  A n D  B l e e D i n g
refractoriness
Although still incompletely understood, the association of refractoriness with several 
clinical factors has been noted and investigated by several studies (table 1). Bishop et 
al showed that the recovery of platelets is affected by several clinical factors, including 
diffuse intravascular coagulation (DIC), administration of amphotericin B, splenomegaly 
and HLA antibodies. Antibiotic therapy, bleeding and temperature were less important 
factors.22-24 Norol et al studied the impact of platelet storage time in the context of clinically 
“stable versus unstable” patients (i.e. patients with bacterial infection, GVHD, veno-
occlusive disease as well as patients with splenomegaly) showing that only stored platelets 
performed worse as compared to fresh platelets in “unstable” patients.25  
Bock et al demonstrated that fever as well as the use of certain antibiotics, either causal or 
as confounder (amphotericin B, ciprofloxacin, vancomycin), significantly influenced platelet 
increment.26 The relation of fever with refractoriness has been explained by circulating 
cytokines, among others IL-1 and TNF, which induce activation of endothelial cells leading 
to the expression of adhesion molecules and induction of procoagulant activity.27, 28 
In line with this,, the association between a higher dose of total body irradiation with 
refractoriness also suggests that endothelial damage could play an important causal role.27 
Heim et al showed in a large group of haemato-oncology patients that patient age, female 
sex and the administration of antithymocyte globulin (ATG) were associated with better 
post-transfusion platelet recovery, whereas increasing storage time, ABO-mismatched 
platelets, additive solution (T-Sol), allogeneic haematopoietic stem cell transplant (HSCT), 
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transfusion sequence > 40 and fever before transfusion had a significant adverse affect.29 
Similar results were found in an analysis using the data of the TRAP trial. In this analysis 
refractoriness was defined as 2 sequential 1-hour post transfusion increments (recovery)  
of less than 11 x 109/L (equalling an average CCI of 5.0). The strongest negative impact 
on 1- as well as 24-hour increment had male sex and females with previous pregnancies. 
Other negative factors were enlarged spleen, amphotericin B, bleeding, fever, infection, 
weight, height and transfusion sequence number. Platelet product factors negatively 
influencing 1- and 24-hour increments were ABO-incompatibility and storage time. 
By estimation, patient factors determined over 80% of the variation of both the 1- and 
24-hour increment. The authors suggested that decreasing transfusion efficacy with 
increasing platelet transfusions might be related to progressive endothelial damage with 
increased platelet adherence and thus a more rapid loss from circulation.30, 31 In our first 
RCT platelet transfusion failure occurred at least once in 49.6% of the patients. Platelet 
transfusion failure was, independent from thrombocytopenia, positively associated with 
bleeding complications, non-transplant related chemotherapy, severe mucosal damage 
and age.10, 32 To summarize, non-immunological refractoriness, a frequent observed 
complication of platelet transfusions, is largely determined by several patient factors 
including bleeding complications, infectious complications and chemo- and radiotherapy 
induced tissue damage, whereas product factors such as storage time and storage solution 
play a minor role. In this sense platelet refractoriness may be a consequence as well as  
an indicator of increasing endothelial activation and damage. 
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table 1: Factors associated with refractoriness22, 24, 25, 26, 29, 31, 32
Bishop Norol Bock Heim Slichter Kerkhoffs
Gender m m m
Age m
BSA m
Enlarged spleen m m m m
Bleeding m m m
Infection m m m







Stem cell Tx m
Chemotherapy m
Antibiotic therapy m m m
Transfusion sequence m m
Storage time m m
ABO mismatch m m
Additive solution m
BSA =Body Surface Area; VOD = Veno Occlusive Disease; GVHD =Graft versus Host Disease; DIC = Diffuse intravascular 
Coagulation; TBI =Total Body Irradiation; ATG =Anti Thymocyte Globulin; Tx = Transplantation
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Bleeding
The reported incidences of grade 2 – 4 bleeding varies from 5 – 70% (figure 1). Clinical 
platelet transfusion studies evaluating platelet products report major bleeding > grade 1 
in 48% of the patients, whereas the incidence of major bleeding in AML RCTs evaluating 
patient outcome is only 7%, comparable with the percentage found in our second RCT. 
These figures reflect the subjectivity of the grading of bleeding. Active versus passive 
reporting of bleeding complications together with the frequency and timing of bleeding 
observation are the main factors explaining for the enormous variation in reported 
bleeding incidences in literature.33 Apparently the difference between platelet product 
driven studies and clinical outcome studies in AML trials is explained by the perception of 
“clinically relevant”, i.e. the perception of “what is meaningful”.34 Adapting the active and 
rigorous bleeding observation of the PLADO trial, which encompasses an active bleeding 
observation of 8 WHO defined sites by trained personnel and an independent adjudication, 
the Bleeding Observation Pilot (BOP) study showed bleeding grade 2 – 4 in 54% of the  
68 participating patients on 18% of the observed days, which is in agreement with reports 
using similar bleeding score systems.19, 35 Comparing the data of the BOP trial with our 
second RCT shows that the large difference in bleeding incidence is mainly due to the 
underreporting of skin- and mucosal bleeding events, underlining the impact of clinical 
perception (Chapter 6) .
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figure 1: Figure 1 shows reported percentages of patients with grade 2 - 4 bleeding complication. 
The error bars reflect the 95% confidence interval. The filled markers represent randomised controlled 
trials, whereas the open markers represent observational studies. 1 = Blumberg et al71; 2 = Sensebe  
et al72; 3 = AML Trials 83 = Kerkhoffs et al11; 4 = Oka et al16; 5 = Tinmouth et al17; 6 = Gil-Fernandez  
et al18; 7 = Zumberg et al19; 8 = Kerkhoffs et al10; 9 = Mirasol76; 10 = Diedrich et al77; 11 = Wandt et al78;  
12 = Rebulla et al52; 13 = Gmur79; 14 = Nevo et al55; 15 = Wandt et al80; 16 = Sagmeister et al81;  
17 = Murphy et al82; 18 Pihush et al53; 19 = Higby et al83; 20 = Navarro et al84; 21 = Heddle et al35;  
22 = McCullough et al16; 23 = Lawrence et al85; 24 = Friedmann et al46; 25 = Slichter et al19.
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The use of bleeding as an endpoint assumes the level of thrombocytopenia to be an 
important etiological factor as well the potency of transfused platelets to correct this 
level to decrease bleeding complications. Despite a preventive platelet transfusion policy 
major bleeding is occurring in half of the patients. We still lack the tools in understanding 
which patients are going to have bleeding complications and to what extend platelet 
transfusions are aiding in their prevention or even may be harmful in certain clinical 
situations.36, 37
experimental studies in thrombocytopenia
In rabbits with severe thrombocytopenia flattening and increased fenestration of the 
endothelium has been shown using electron microscopy.38 Also an increased leaking of 
red cells associated with the level of thrombocytopenia was shown in thrombocytopenic 
rabbits.38, 39 The relation between thrombocytopenia was explored using radio labelled 
red cells in stable thrombocytopenic patients. Substantial faecal loss of radio labelled red 
cells only occurred at platelet counts less than 5 x 109/L.40 In a landmark study using radio 
labelled platelets an endothelium supportive role for platelets was suggested with an 
average consumption of 7 x 103/µL/day.41 Although these studies show that platelets play 
an important role in the maintenance of endothelial integrity, it is likely that increased 
fenestration and flattening of the endothelium causes petechiae and mucosal bleeding, 
but it is unknown whether this explains for the major bleeding complications.  
Using mice experiments, Ho-Tin-Noé et al showed mice deficient of β-integrines, 
which have decreased neutrophil infiltration capabilities, were protected from 
thrombocytopenia-induced tumor hemorrhage. The same group showed that platelet 
adhesion in it self is not required to maintain vascular integrity and that in the absence  
of platelets hemorrhage only occurred in an inflamed microcirculation.42, 43
 
Bleeding susceptibility
Gaydos et al first described the relationship between thrombocytopenia and haemorrhage, 
although no threshold could be recognized and most of the lethal cerebral haemorrhages 
described in this study occurred in patients with cerebral leukaemia involvement. 
Moreover aspirin was frequently used as an antipyretic agent.5 Estey et al studied the 
causes and risk factors of remission induction failure in 378 previously untreated AML 
patients in the period 1973 – 1979. Only 22% of these patients were primary chemotherapy 
resistant, the majority of patients failed coming into remission due to infectious 
complications and in 33% of the patients failure occurred due to fatal haemorrhages 
despite prophylactic platelet transfusion support. The main risk factor for fatal hemorrhage 
were an initial white blood count of ≥ 25 x 109/L (OR 2.7; 95%CI 1.3 – 5.3) and the incidence 
of death from haemorrhage was highest during the initial 2 weeks of treatment. In the 
discussion an etiologic role for leukaemia infiltration of vessel walls is considered as 
also reported by Freireich.44, 45 Friedmann et al studied clinical and laboratory features 
predicting for severe hemorrhage in 2942 patients. 368 patients (12.5%) suffered severe 
bleeding complications. Uraemia, hypoalbuminemia, recent BMT, platelet transfusion, the 
administration of aminocaproic acid and recent bleeding were associated with increased 
bleeding. Platelet count was not significantly associated with bleeding in untransfused 
patients. The main limitation of this retrospective study was the lack of information 
regarding the temporal relationship between platelet count, platelet transfusion and 
bleeding.46 Studying the relationship of thrombocytopenia with bleeding post stem 
cell transplant, Nevo et al compared 321 bleeding BMT patients with 287 non-bleeding 
matched controls. There was a small but significant increased risk for bleeding in patients 
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with more days of platelet counts ≤ 10. However profound thrombocytopenia was present 
in only 8.6% of bleeding patients. Pulmonary hemorrhage was significantly associated  
with thrombocytopenia in contrast to bleeding from other sites.47 This might be associated 
with GVHD and endothelial damage, as has been shown by a post-mortem study.48  
In line with the report of Gil-Fernandez et al, who identified high platelet consumption 
factors (VOD, fever, treatment with amphotericine B and mucosal damage) in most cases 
of bleeding in two transfusion trigger groups (10 vs. 20 x 109/L), Nevo et al showed that 
profound thrombocytopenia was not the primary cause of bleeding in both groups.49, 50 
In contrast, in the re-analysis of the Rebulla trigger trial, including 255 patients with acute 
myeloid leukaemia, six variables were multivariate associated with grade I-II bleeding: 
administration of antifungal medication, steroid administration, a higher platelet count 
and platelet transfusion decreased the risk, whereas the presence of infection and fever 
increased the risk. Grade II – IV bleeding was associated with fever as well as platelet 
count. Grade III – IV bleeding was associated with the administration of antifungal therapy 
(increased risk!). The presence of a grade I bleeding was associated with at 2.6 times 
increased risk of grade II – IV bleeding (95%CI 1.18 – 5.49) and grade I – II bleeding was 
associated with a 3.1 times higher risk of grade III – IV bleeding (95%CI 1.17 – 7.95).51, 
52 Pihusch et al studied hemorrhagic and thrombotic events in 447 transplant patients 
(autologous n = 83; allogeneic n = 364). Haemostatic (thrombotic as well as haemorrhagic) 
events occurred in 83.2% of the patients. Severe haemorrhage occurred in 41.5%  
of the patients and 3.6% suffered lethal bleeding. Intracranial haemorrhage was  
observed in 21 patients (4.7%) and associated in a majority of patients with infection. 
Allogeneic BMT patients had a higher bleeding incidence as compared to autologous BMT 
patients. Patients with GVHD > grade I had a significantly higher incidence of bleeding.  
A strong correlation was found between the duration of thrombocytopenia and bleeding 
events. GVHD and duration of thrombocytopenia were the only “predictors” for the 
occurrence of bleeding. Also a thrombotic event such as microangiopathic haemolytic 
anemia (MAHA) was more frequent in the allogeneic group. Interestingly in 23.5% of 
the MAHA cases a shortened aPTT was found indicating endothelial perturbation and 
activation. In the discussion authors suggest a role for TNF-α, essential in the pathogenesis 
of GVHD, known to modulate endothelial haemostatic function and enhance the 
production of Plasminogen activator inhibitor-1 and Tissue Factor as well as down 
regulating Tissue factor pathway inhibitor.53, 54
To summarize (see also table 2), bleeding is a frequent but variably reported complication 
in patients with thrombocytopenia due to myelosuppression. Apart from the level 
of thrombocytopenia, also inflammation and vascular damage are associated with 
an increased risk of bleeding. It could be postulated that both the dynamics of 
thrombocytopenia as well as hemorrhage are determined by endothelial activation  
and damage, associated with inflammation.
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refractoriness and bleeding in relation to survival
In a study in 1,402 patients, the first 100 days post transplant, Nevo et al showed that 
bleeding was both for allogeneic as well as well autologous patients associated with 
reduced survival.55 Bleeding severity correlated with GVHD severity in 463 allogeneic 
transplant patients studied by Nevo et al. A significant association was found with 
gastrointestinal bleeding, hemorrhagic cystitis and pulmonary bleeding. Acute GVHD 
occurred early in the course post transplant and in 88% of the patients with bleeding 
and GVHD, bleeding episodes started after GVHD initiation. Both bleeding as well as 
GVHD were significantly associated with a reduced survival. Also, survival in non-bleeding 
patients was significantly reduced in patients with more pronounced thrombocytopenia 
perhaps suggesting more extensively injured endothelium.47, 56, 58 The association between 
hemorrhagic complications, reduced survival and GVHD was also shown in another study 
of 807 allogeneic HSCT patients.57 In the study by Pihush et al, haemostatic events  
(both thrombotic as well as hemorrhagic) were associated with an increased mortality 
risk (RR 1.7; 96%CI 1.0 – 3.2).53 Intrigued by these findings, we studied the association of 
platelet refractoriness with patient survival. Surprisingly, patients experiencing one or 
more 24-hour platelet transfusion failures had, as compared to patients always showing 
a sufficient 24-hour increment, a significantly reduced survival, independent of therapy, 
diagnosis and age (Chapter 6).32 As it is unlikely, that bleeding and refractoriness are 
directly causally related to the reduced survival, it is hypothesised that these are both 
confounders for vascular damage and /or microthrombosis.
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table 2: Factors associated with increased bleeding (severity)5, 44, 46, 47, 51, 53, 32










Mucosal damage m m
Platelet count m m m m
Stem cell Tx m m
Chemotherapy m
Antifungal Rx m m
WBC = White Blood cell Count; VOD = Venoocclusive Disease; GVHD = Graft versus Host Disease; Tx = Transplantation;  
Rx = Therapy
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Damaged endothelium: a common pathway?
Haemorrhagic complications, platelet refractoriness and deep, prolonged 
thrombocytopenia are repeatedly observed to define a category of patients with reduced 
survival. Without a logical direct causality, this leads to the hypothesis that these patients 
have more pronounced damage of the vascular endothelium (figure 2). As has been 
mentioned above, although thrombocytopenia in itself leads to endothelial flattening 
and fenestration, in the absence of an inflammatory process thrombocytopenia does 
not lead to haemorrhage in animal models unless deep thrombocytopenia which is 
associated with leakage of erytrocytes. Endothelial damage is regarded as a pathologic 
hallmark of vascular complications after HSCT, such as veno-occlusive disease of the liver, 
thrombotic microangiopathy, and capillary leak syndrome. In GVHD, the vasculature 
is sequentially affected. Endothelial damage is caused by the conditioning regimen, 
followed by neovascularisation and recruitment of inflammatory cells with in the third 
phase alloreactive T-cells targeting the endothelium.59 The intensity of the conditioning 
regimen positively correlates with endothelial damage as measured by plasma levels of 
vWF, sVCAM-1 and sTNF receptor I.60 Cyclic GMP, also a marker for endothelial damage, was 
a negative predictive factor for survival after HSCT.61 Pericapillary hemorrhage was shown 
in areas EC lesions in severe intestinal GVHD and associated with severe hemorrhagic 
enterocolitis.62 Circulating endothelial cells (ECs) are increased with endothelial damage 
and in patients after myeloablative conditioning an increasing number of ECs was found.63, 64 
In patients with GVHD significantly more EC microparticles were found as compared 
to patients without GVDH as are vWF and thrombomodulin.65, 66 Moreover, factors like 
interleukin-1 and TNF-α have been shown to induce ultra structural changes in the blood-
retina barrier.67 Apart from GVHD, which might be a model to study bleeding susceptibility 
also for other conditions, several cytotoxic agents have been shown to cause endothelial 
damage and interestingly treatment with vascular endothelial growth factor inhibitors 
in oncology patients resulted in an increased incidence of both thrombotic as well as 
haemorrhagic complications.68-70 
In conclusion deep aplastic thrombocytopenia causes endothelial fenestration and 
capillary leakage of erythrocyts. Its association with skin and mucous membrane 
bleeding is obvious, but an association with major bleeding is not proven. In contrast 
high blast counts, chemotherapy, irradiation, infection and GVHD associated endothelial 
damage are recognized to be associated with bleeding at varying degrees, as well as 
with thrombocytopenia. Enhanced endothelial damage due to these causes leads to 
increased consumption of both autologous as well as transfused platelets, haemorrhagic 
complications as well as ultimately a decreased patient survival. It is unclear to what extend 
transfused platelets are preventing these complications, although it seems unlikely that 
we will be able to prevent these complications just by transfusing platelets. Future studies 
are needed to test novel grading systems for the bleeding complications, preferentially 
distinguishing between just lack of endothelial repair and endothelial damage associated 
with activation. Endothelial maintenance benefits from platelet substitution and a 
relatively low number of platelets is sufficient. Endothelial damage may need another 
approach and it is questionable whether increase of the transfusion threshold and 
increasing the transfusion dose is the answer. It is challenging to validate  
the corrected count increment as a surrogate outcome parameter for survival as well 
as trying to make an IPSS-like scoring system to predict hemorrhagic complications to 
improve the platelet transfusion strategy on a patient level.
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figure 2: Figure 2 summarizes the hypothesis of endothelial damage in relation to increasing 
platelet (PLT) consumption, haemorrhagic complications and survival. The figure represents 
segments of vascular endothelium showing normal endothelium (segment A), flattened and 
fenestrated endothelium occurring in thrombocytopenia (segment B), activated endothelium due 
to disease, cytotoxic agents, irradiation, GVHD and/or infectious agents (segment C) and damaged, 
apoptotic endothelium (segment D).
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i n t r o D u C t i o n
Background
Platelet transfusions are extensively used for treatment and prophylaxis of bleeding in 
thrombocytopenic patients. Bleeding still is a frequent complication and recommendations 
differ regarding the preferred transfusion regimen, the quantity and quality of transfused 
platelets and strategies to monitor efficacy.1-3 These recommendations regard the platelet 
transfusion triggers for prophylaxis, intervention and bleeding. However, except for the 
upper level of the trigger for prophylaxis, a minority of the recommendations is evidence-
based. 
Several platelet products are in use. Most variations concern the donor origin (random or 
matched), way of collection (whole blood or apheresis), production (platelet rich plasma-
derived, pooled buffy coats, white cell-reduction methods), storage solution (plasma or 
platelet additive solution) and storage duration. For most of these variations, even major 
ones such as prolongation of the storage time and replacement of plasma by additive 
solutions, clinical comparative studies were not or scarcely performed. 
The gap between platelet product developments and even platelet substitutes on one 
hand, and clinical evaluation on the other, was noticed by regulatory bodies, such as the 
FDA. Progress in this respect is however slow, due to a poor correlation between in vitro 
quality tests and clinical efficacy. The FDA has therefore suggested a number of biological 
guidelines. These include documenting the viability of manipulated (autologous) platelets 
in normal volunteers. Using radioisotope studies, recovery should be 67% of fresh 
platelets and survival 58% or more, as compared to a gold standard defined as a fresh 
(<1 day) plasma stored platelet product.4 With these minimal requirement strategy, the 
goal is to protect against the risk of a “downward creep” in quality. There is now general 
agreement that substantial changes in platelet production should also be validated for 
their clinical quality, including assessment of bleeding. Recently it is possible to subject 
platelet products to a pathogen inactivation step. Apart from obvious bacteriological and 
logistic advantages as well as possible immunologic advantages of pathogen-reduced and 
extended stored products as eminent new developments, these new products clearly need 
clinical validation for their haemostatic effectivity. Policymakers, product providers,  
and investigators agree that clinical platelet transfusion studies are essential.
the Dutch situation
In line with international developments, Sanquin Blood Bank explores emerging issues 
as extending storage (storage up to 7 days) of platelet concentrates (PCs) in plasma and 
additive solutions, development and use of additive solutions and methods of pathogen 
inactivation. Recently extended storage for plasma-PCs to 7 days has been approved 
for clinical use requiring a post marketing surveillance phase. This approval is based 
on one trial investigating extended storage of plasma-PCs in a selected population of 
thrombopenic patients.5 In the Netherlands all platelet products undergo aerobic  
and anaerobic culture and approximately 0.44% is found bacterially contaminated.6
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experimental platelet product to be investigated in the proposed study
Both in vitro and clinical studies have been done with the Mirasol system, using riboflavin. 
Riboflavin is a naturally-occurring vitamin (B2) and is postulated to interact with nucleic 
acids which undergo a chemical reaction when exposed to UV light.7 Extensive toxicology, 
mutagenicity, carcinogenicity, photo toxicity, and pharmacological studies established an 
adequate safety for photo-chemically treated PCs.8 The technical file has been evaluated 
by KEMA Notified Body, and they have accepted the file.9 The Mirasol Pathogen Reduction 
System for Platelets has been classified as a Class IIb device and is CE marked.  
Riboflavin-based photo-chemical treatment has shown to be effective against selected 
pathogens, including HIV, WNV, gram positive and gram negative bacteria, obtaining  
a more than 4 log10 reduction, except for S. aureus and B. cereus10 (see Table 1A, 1B and 
1C). Spiking studies in apheresis platelet concentrates showed a high effectiveness of 
inactivating various bacteria, including complete inactivation of the spore-forming B. 
cereus, despite only 1.9 log reduction. A. baumannii showed only partial inactivation, 
despite being spiked at low bacterial dose.11 Although in vitro studies of treated platelets 
show functional13 and metabolic alterations14-16 during storage up to five days, minimal 
requirements (pH, swirl) for issuing PCs are preserved. 
Seven-day storage of platelet concentrates is an important issue in the Netherlands.  
There is limited clinical experience with 7 day-stored Mirasol-treated platelets;  
laboratory data of buffy coat-derived PCs stored for 6 days show comparable in vitro 
quality as apheresis platelets that have been stored for (the currently licensed) 5 days  
(see Table 2). There are differences among the treated versus untreated PCs, but the treated 
units nevertheless conform to current Dutch blood product specifications (which requires 
a pH37°C>6.3)17, with pH22°C>6.8, [Canadian Blood Services, unpublished observations] 
and swirl present. These data show that buffy coat-derived platelets maintain better in 
vitro quality as apheresis platelets during storage and that shelf-life of buffy coat-derived 
platelets can likely be extended to 7 days. The experimental platelet product investigated 
in the current study has to comply with the CCMO (Central Committee on Research 
Involving Human Subjects) guidelines, and the WMO (Medical Research Involving Human 
Subjects Act) is applicable.
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Prevention of allo-immunization and graft versus Host disease
The Mirasol treatment is likely to be effective in reducing allo-antibody formation and 
prevention of transfusion-associated graft versus host disease (TA-GvHD) in transfusion 
recipients. Currently the standard guideline for prevention of TA-GvHD is gamma 
irradiation. As compared to gamma irradiation, Mirasol treatment is more effective 
abolishing the proliferation of lymphocytes as allogeneic responder cells in a mixed 
lymphocyte culture, whereas the reduction of lymphocyte proliferation is the surrogate 
assay for assessment of radiation dose to prevent GvHD.18 The TRAP trial19 indicated that 
UV-B irradiation (1480 mJ/cm2) alone was able to reduce the incidence of HLA-antibody 
mediated refractoriness from 13% in patients receiving unfiltered PRP-derived PCs, to 5%  
in patients that received UV-B irradiated PRP-derived PCs. Leukoreduction by filtration 
of the PCs gave a similar rate of 3% refractoriness. In this study the formation of 
lymphocytotoxic antibodies, not leading to platelet transfusion failure, reduced from 45% 
to 20%, whereas in patients with prior pregnancies the antibodies fell from 65% in the 
control group to 33% in the group that had received UV-B treated platelets. This suggests 
that the primary immune response in naïve individuals and the booster stimulus in primed 
individuals are impaired. A recent study18 suggests that the Mirasol treatment, that uses  
a UV-B dose of 530 mJ/m2 in addition to the presence of riboflavin, induces loss of surface 
expression of HLA class II and co-stimulatory molecules in peripheral blood mononuclear 
cells, similarly as obtained with higher doses of UVB. Furthermore, Mirasol treated 
mononuclear cells had a significant reduction in surface expression levels of a number of 
adhesion molecules as compared to untreated cells and showed virtual absence of cell-cell 
conjugation in vitro. The observed loss of immunogenicity was nearly complete and UV 
irradiated antigen presenting cells (APCs) barely induced measurable IFN-γ production and 
no detectable STAT-3, STAT-5, or CD3-ε phosphorylation in allospecific primed T cells.  
These results suggest that defective cell-cell adhesion prevents UV irradiated cells from 
inducing T cell activation.
Clinical studies
Transfusion of up to 5 day-stored, riboflavin/UV-B-treated apheresis PCs to normal subjects 
revealed that recovery was 50±19%, which was significantly lower as that of control units 
at 67±13%. Also, survival time was shorter, 104±26 h for the treated group versus 142±26 
h for the reference group.15 Although recovery and survival of treated platelets in healthy 
volunteers is impaired, the PCs performance falls within the range as delineated by the 
FDA for new products. One randomized study is available, although not yet peer reviewed. 
In spite of the lower recovery and survival data in volunteers, the Miracle trial, evaluating 
corrected count increments of apheresis- or buffy coat-derived plasma-PCs, showed 
acceptable 1-hour CCI values for both methods of preparation: 15.7±1.0 for buffy coat 
and 13.0±0.6 (mean±SE, p=0.02 [unpublished results]). An unresolved issue was however 
a sudden drop in CCI with riboflavin-UV-B-treated buffy coat platelets halfway the study. 
Prior to the interim analysis, the 1-h CCI was 11.9±0.6 (versus 14.6±1.3 in the untreated 
group), and this value dropped to 7.3±0.5 after the interim analysis (versus 17.4±1.6 in the 
untreated group). This trial showed no difference in red cell or platelet usage, but there 
was a significant difference in the average number of days between the first 8 on-protocol 
transfusions in the Mirasol subjects and Reference subjects: 2.4±0.8 days and 3.3±1.5 days, 
respectively (p<0.001). For greater than 8 on-protocol transfusions, the average number of 
days between transfusions in the Mirasol group was 1.2±0.9 days, versus 2.2±0.9 days in 
the Reference group (p=0.1). 
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rationale for this study
Currently some pathogen-reduced platelet products (PR-PCs) have passed phase III studies, 
are in progress or can be expected in the near future. At present some transfusion centers 
throughout Europe have implemented PR-PCs, but as yet PR-PCs are not formally accepted 
as a standard product that should be applied nation-wide. Because many uncertainties 
currently exist on the “optimal” platelet product, it is in the interest of patients, health 
care providers and the transfusion provider (Sanquin) to decide on evidence. With all 
the current safety measures remaining in place, pathogen reduction provides a safety 
benefit by reducing the number of transfusions of platelet concentrates contaminated 
with bacteria, but which were missed by the screening method. In the Dutch situation, 
morbidity is estimated to be 1:14,000 platelet concentrates.20 In this publication, two cases 
of transmission of B cereus by a platelet transfusion are reported, where both patients 
experience a life-threatening sepsis, but recover eventually. Cases of bacterial transmission 
however often go unnoted, so a frequency as low as 1:130,000 has been reported.21 
The same is true for mortality; this value ranges from 1:50,000 22 to 1:500,000.23 A more 
precautionary benefit is protection against known and unknown pathogens. It is difficult 
to estimate the actual risk, and consequently to estimate the benefit for the patient.  
While in The Netherlands no epidemics have occurred against which no screening tests 
could be developed, including Q-fever,24 there is a small but real risk that an epidemic 
can wipe out the blood supply in a country. This has happened in La Réunion, where an 
epidemic of chikungunya virus urged import of blood products from abroad, followed by 
rapid introduction of a pathogen reduction technology to ensure the blood supply.25  
An outbreak of this virus in Italy resulted in suspension of blood collections in an affected 
area, which led to a low blood inventory as well as a reduced delivery of plasma to 
fractionation institutes.26 
As mentioned above, appreciating the difficulties of extrapolating in vitro tests towards 
in vivo efficacy, platelet products should be tested in clinical trials. Of note, radiolabeling 
techniques in volunteers as required by the FDA, are not used in the Netherlands. For major 
product variations in the Netherlands we depend on studies in patients. Extending storage 
for logistic purposes, combined with maintaining or even improving the safety of platelet 
products, and maintaining clinical efficacy are the main features in the development of 
new platelet products. In this study protocol we aim to investigate transfusion efficacy 
of two different platelet products: plasma-PCs, and pathogen-reduced (PR)-plasma-PCs, 
combining extended storage with or without treatment with a photochemical pathogen 
reduction technique. Prior to the start of the clinical study an in vitro study of the product 
has been performed, showing that the study product meets the current in vitro quality 
requirements for release for transfusion. However, on site implementation validation still 
has to take place. 
Refractoriness to platelet transfusions and bleeding complications are the main clinical 
problems in intensively treated hemato-oncological patients and are essential endpoints 
for transfusion studies as well. In this trial bleeding will be scored according to the World 
Health Organization (WHO) scale as a primary endpoint. Refractoriness is defined as  
a 1-hour CCI <7.5 and/or a 24-hour CCI <4.5 after ABO compatible platelet transfusions 
on at least two successive occasions. Known causes of non-alloimmune refractoriness 
are included in this trial because for the purpose of generalization, relevant to develop 
a national product, testing transfusion efficacy of new platelet products should imply all 
patients in need of a preventive support with platelet transfusions. The 1- and 24-hour CCI 
are commonly used to evaluate platelet transfusions and, albeit not without discussion, 
currently the platelet count is the only parameter in trigger-based transfusion policy.  
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The ratio of both the 1-hour and 24-hour CCI mirrors both platelet recovery immediately 
after transfusion as the 1-hour CCI, and platelet survival one day after transfusion as the 
24-hour CCI. Other secondary clinical endpoints of the trial will be transfusion requirement 
(red cells and platelets), transfusion interval to next transfusion and adverse reactions.
relation between in vitro measures and clinical outcomes
Besides a low pH, resulting from an increased lactate production, there are no laboratory 
measures available that accurately predict platelet recovery, survival or hemostatic function.12 
In vitro data showed that, despite pH and swirl being unaffected, other in vitro measures of 
platelet activation, function and metabolism may show considerable differences between 
products. We hypothesize that a combination of metabolic, activation and functional 
parameters of PCs, combined into one ‘rating’ score, may predict either the 1-hour and/or 
the 24-hour CCI. For such an in vitro rating value we selected assays that can be performed 
shortly before transfusion of the PLTs, to be able to associate the laboratory values with 
clinical endpoints. We selected three parameters for this rating system, each of which could 
play an independent role in predicting in vivo effectiveness of stored PLTs for reasons 
discussed below. First, we considered CD62P expression on the platelet surface. This reflects 
activation of platelets and a higher CD62P expression has been associated with enhanced 
PLT clearance from the circulation.27-31 Impaired PLT survival in animals was found to be 
associated with the apoptosis marker annexin A5 binding32,33 thus warranting inclusion of 
this parameter in our rating system. The third assay is the lactate concentration (as surrogate 
for lactate production). A low lactate production rate is considered as a good indicator of 
mitochondrial function.34,35 However, to calculate a lactate production rate over multiple 
days of storage, a baseline sample has to be taken immediately after production. In reality, 
this baseline sample shows only a small variation, and so the lactate concentration prior 
to transfusion can be used as being representative for lactate metabolism. The in vitro 
outcomes of each of these three parameters can be scored from 0 to 2, where 0 points would 
indicate a poor quality and 2 points a good quality, rated on an arbitrarily chosen linear 
basis. The combined rating then results in a value between 0 (poor quality) and 6 (excellent 
quality). For CD62P expression a value of 2 points can be attributed to an expression <20%,  
1 for 20-30% and 0 points for an expression >30%. For annexin A5, a value of 2 points for  
a binding <10%, 1 for 10-20% and 0 for all PLT concentrates with a binding >20%.  
Finally, lactate levels >20 mM are known to indicate poor PLT quality,35 and score of 2 points 
is proposed for a level <10 mM, 1 for concentrations between 10-20 mM and 0 points for  
a value >20 mM. 
By sampling and analyzing the PCs prior to transfusion and relating the in vitro outcomes 
with CCI values, the relation between a combination of metabolic, activation and functional 
parameters of transfused PCs, and the usefulness of combining these into one ‘rating’ value, 
will be evaluated. Such a rating system may enhance flexibility to search for improvement  
of products by preclinical studies. 
In this study, a PC sample will be taken prior to transfusion, and the above in vitro measures 
will be performed on platelet products that are issued from Monday to Friday, so that in vitro 
analysis can take place on week-days. These will be determined by investigators blinded for 
the product and clinical results and made available to the statistician for comparison with the 
1-hour and 24-hour CCI and analyzed in a multivariate model. Likely, the dichotomous nature 
of the proposed rating score can be replaced by a more continuous scale, and both will be 
validated. This adapted rating model will be validated with the existing database.
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immunological effects
As mentioned, Mirasol treatment is expected to reduce primary and secondary HLA allo-
antibody formation probably because of the lack of cell-cell interaction. It is as yet unknown 
whether such treated mononuclear cells, not recognized by recipient T cells, may show  
a prolonged survival of donor cells.36 A prolonged survival may enhance indirect antigen 
presentation leading to more delayed alloimmunization, while also the establishment 
of regulatory T cells may be affected. To further investigate this hypothesis in the current 
study, samples will be obtained from patients who are negative for HLA-antibodies prior 
to transfusions, and analyzed according to primed and naive immune status, to investigate 
the formation of HLA-antibodies during a longer follow-up period. These samples will be 
collected weekly up till day 28, and then on day 56 and tested in the Luminex assay for 
presence of single antigen HLA-antibodies. Specifically, EDTA samples will be centrifuged  
and the plasma will be aliquoted in 0.5 mL samples and frozen. Part of these (blinded) 
samples will be shipped to the Blood Systems Research Institute (San Francisco, CA, USA) 
on dry ice for antibody detection and identification. In a selected cohort of primed and 
unprimed patients, following the first on-protocol transfusion, the 1-h samples will be 
analyzed for induction of HLA class II molecules on T cells of donor and recipient and at day 
56 blood will be collected and processed for evaluation of persisting donor cells. The buffy 
coat fraction of the EDTA samples will be frozen to study immunological effects in the white 
cell fraction comparing patients who show increased antibody titers with controls.
s t u Dy  o B j e C t i V e s
Primary objective:
To assess the non-inferiority of PR-plasma-PCs compared to plasma-PCs up to  
a storage interval of 5 days in terms of WHO bleeding complications ≥ grade 2.  
The first 8 transfusions with PCs that have been stored for 1-5 days will be used  
to assess the incidence of bleeding complications ≥ grade 2.
secondary objectives:
1. To assess the transfusion failures defined as 1 hour CCI < 7.5 and 24 hour < 4.5,  
 1 and 24 hour CI and CCI of 1-7 days stored platelets of all platelet transfusions,  
 and in relation to the transfusion number.
2. To assess the percentage of days that bleedings ≥ WHO grade 2 occur. 
3. To evaluate whether clinical factors interact with the different study products leading  
 to a difference in platelet refractoriness.
4. To assess the safety (adverse reactions).
5. To assess the transfusion requirement (red cells and platelets).
6. To assess the transfusion interval.
7. To assess the incidence of adverse reactions.
8. To assess the rate of HLA allo-immunization.
9. To evaluate whether in vitro measures relate to in vivo outcomes measures as  
 the 1-hour and the 24-hour CCI.
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s t u Dy  D e s i g n
The study is a prospective, randomized multicenter trial for the evaluation of platelet 
products in hemato-oncological patients with thrombocytopenia or expected to become 
platelet transfusion dependent due to myelosuppressive therapy or malignancy-related 
myelosuppression. In this trial patients will be randomized to receive one of two platelet 
products during a transfusion episode with a maximum of 6 weeks or a total of 8 platelet 
transfusions according to protocol, whichever comes first. 
Because the Mirasol-treated platelet products show a color difference not allowing an 
appropriate placebo, the study will be single-blinded for investigators evaluating the CCI 
and bleeding score.Products will be stored up to 7 days. The primary endpoint is restricted 
to 5 days storage as this implies the most relevant information. Secondary endpoint 
evaluation requires that the patient continues treatment in the assigned study arm.
Arm A: Plasma stored platelet concentrates (Plasma-PCs)
Arm B: Pathogen reduced plasma-stored platelet concentrates (PR-plasma-PCs)














 i.e. patients with known severe allergic reactions and documented  





Indications for platelet transfusions are distinguished into platelet count-related 
prophylaxis (PP), intervention related prophylaxis (IP) and treatment of bleeding (TB).  
For each transfusion the indication shall be recorded. The CBO guidelines1 will be used as 
guidance for the indication of platelet transfusions, these imply: trigger for PP 10 x 109/L; 
for IP 50 x109/L; and for TB stopping of bleeding or at PLT counts >100 x109/L, although  
the treating physician determines if or when a transfusion is ordered.
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All products are produced by Sanquin Blood Banks. Logistics will be organized to assure 
a seven day coverage of availability for all study products. All platelet products will fulfill 
standard quality requirements prior to release. PCs are prepared from pooled BCs.  
The pooled PCs are leukoreduced by filtration. Platelets will then be resuspended in a unit 
of plasma from one of the buffy coat donors who has not been pregnant or has received 
prior transfusions. In case of photochemical pathogen reduction, 500 mM riboflavin is 
added to the leukoreduced plasma-PCs within 28 hours of platelet collection, mixed and 
exposed to UV-B light (wavelength 265-370 nm) during five to ten minutes (depending on 
the volume of the PC) with constant agitation at 120 rpm, giving a total dose of 6.2 J/mL. 
All platelet products will be stored with gentle agitation at 20-24˚C up to 7 days. Products 
will be γ-irradiated if indicated by the requesting center.
Apart from routine testing (platelet count, swirl and BacT/Alert screening), PCs of each arm 
will be subjected to additional quality control (QC) tests immediately before transfusion 
with respect to platelet metabolism, activation markers and platelet function.  
The four blood bank divisions have determined the inter-laboratory variation of these QC 
parameters by regular contingency exercises. A swirling effect is present and the bacterial 
screening “negative to date”.
e n D  o f  P r oto Co l  t r e At m e n t






e n D P o i n t s
Primary endpoint
•	 Incidence	of	WHO	bleeding	complications	≥	grade	2	after	transfusion	of	PCs	 
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sample size and power considerations
This one-sided, non-inferiority study will compare the mean incidences of WHO bleeding 
complications ≥ grade 2 in patients receiving platelets stored in plasma with or without 
pathogen reduction. Results of a previous study37 show that on average 50% of the patients 
had bleeding complications ≥ grade 2. The margin of non-inferiority is set at an
absolute difference of 12.5%: thus from 50% increasing to 62.5%. With alpha at 0.025,  
a power of 80% and tested one-sided, the required number of patients to demonstrate non-
inferiority is at most 618 patients (309 patients per arm, which includes a 7% drop out rate).
A flexible study design, based on a pre specified alpha and beta spending function is used, 
which allows early study termination at any of the 9 interim analyses currently scheduled 
using the above mentioned parameters. Interim analyses will be performed after inclusion 
of each one-tenth of the number of patients. However, due to the alpha and beta spending 
functions, additional interim analyses do not jeopardize the design, for example when 
requested by the DSMB. Both efficacy and safety will be tested. 
At each interim analysis the hypothesis (H0) will be tested. If the difference in outcome 
between the groups favors the treatment group sufficiently (see upper boundary 
specification in the figure below) the study can be terminated early by showing efficacy (non-
inferiority in this case). On the other hand, if the treatment group is sufficiently worse than 
the control group (the difference is crossing the boundary for futility) than the trial can be 
stopped because non-inferiority is very unlikely to be reached when continuing the trial. 
The table included provides estimates of the likelihood of an early stopping of this trial both 
when the null-hypothesis is true (inferiority) and the alternative is true (in the current study 
implying equality of the treatments). If neither boundary is crossed, the trial continues until 
the next interim analysis or the final one when the total maximum required number of  
618 patients has been accrued.
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Decision rules, based on percentage difference in the bleeding score: 
 The study will be terminated (see above): 
1. When the effect at interim analysis meets the pink boundary area showing that the study 
 has proven inferiority beyond the boundary of 12.5%. 
2. When the interim analysis demonstrates an effect within the blue area (i.e. demonstrated 
 non-inferiority). 
The final analysis yields an effect estimate and its associated 95% confidence intervals.  
In the case of a confidence interval of which the left hand side not only exceeds the 
boundary of 12.5% inferiority but actually exceeds the 0% difference, we will claim 
superiority. Given an average of eight protocolled transfusions per patient and the 
continuation in the assigned arm for secondary endpoint analysis, the minimum number 
of platelet transfusions will be n=5,000.
 
Prior to the PREPAReS study, a pilot study will be conducted (the Bleeding Observation 
Pilot Study, BOPS) to accurately assess bleeding in patients that received Sanquin’s current 
standard platelet products. The rationale is that in the hitherto published studies,37,38  
the percentage of 3 grade 2 bleeding in patients is considerably higher (49.2%37 to 69%38) 
as in earlier studies conducted by Sanquin (16.1%39). The reason for this discrepancy is not 
entirely clear, but the thoroughness of assessing the bleeding sites is a likely explanation. 
In this pilot study, bleeding will be assessed actively by trained nurses. If this pilot study 
shows that the percentage of bleeding is more than 10% different from the 50% value 
obtained from the SToP trial, then a new power calculation will be conducted.  
This modification will be submitted to the Ethics Committee for approval as amendment  
to this protocol.

































r e f e r e n C e s
1. CBO, Kwaliteitsinstituut voor de Gezondheidszorg. Richtlijn Bloedtransfusie. Utrecht, 2004.
2. Slichter SJ. Platelet transfusion: future directions. Vox Sang 2004; 87(Suppl 2): S47-S51.
3. Novotny VMJ. Trombocytentransfusies binnen de hemato-oncologie: een overzicht.  
Tijdschrift voor Hematologie 2004; 4,131-8.
4. Murphy S. Radiolabeling of PLTs to assess viability: a proposal for a standard. Transfusion 2004;44:131-3. 
5. Dijkstra-Tiekstra MJ, Pietersz RN, Hendriks EC, Reesink HW, Huijgens PC. In vivo PLT increments after 
transfusions of WBC-reduced PLT concentrates stored for up to 7 days. Transfusion 2004; 44:330-6.
6. Koopman MM, Van’t Ende E, Lieshout-Krikke R, Marcelis J, Smid WM, de Korte D. Bacterial screening of 
platelet concentrates: results of 2 years active surveillance of transfused positive cultured units released 
as negative to date. Vox Sang 2009; 97:355-7.
7. Dardare N, Platz MS. Binding affinities of commonly employed sensitizers of viral inactivation. 
Photochem Photobiol 2002; 75:561-4.
8. Reddy HL, Dayan AD, Cavagnaro J, Gad S, Li J, Goodrich RP. Toxicity testing of a novel riboflavin-based 
technology for pathogen reduction and white blood cell inactivation. Transfus Med Rev 2008;22:133-53. 
9. KEMA. Review of technical file for CE marking of Mirasol PRT System for Platelets (class IIb) in accordance 
with the requirements of Annex III of the MDD 93/42/EEC. Arnhem, the Netherlands. April 14, 2008.
10. Ruane PH, Edrich R, Gampp D, Keil SD, Leonard RL, Goodrich RP. Photochemical inactivation of selected 
viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004; 44:877-85.
11. Goodrich RP, Gilmour D, Hovenga N, Keil SD. A laboratory comparison of pathogen reduction technology 
treatment and culture of platelet products for addressing bacterial contamination concerns.  
Transfusion 2009; 49:1205-16.
12. Goodrich RP, Edrich RA, Li J, Seghatchian J. The Mirasol PRT system for pathogen reduction of platelets 
and plasma: an overview of current status and future trends. Transfus Apher Sci 2006; 35:5-17.
13. Perez-Pujol S, Tonda R, Lozano M, Fuste B, Lopez-Vilchez I, Galan AM, Li J, Goodrich R, Escolar G.  
Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet 
concentrates. Transfusion 2005; 45:911-9.
14. Li J, Lockerbie O, de Korte D, Rice J, McLean R, Goodrich RP. Evaluation of platelet mitochondria integrity 
after treatment with Mirasol pathogen reduction technology. Transfusion 2005; 45:920-6.
15. AuBuchon JP, Herschel L, Roger J, Taylor H, Whitley P, Li J, Edrich R, Goodrich RP. Efficacy of apheresis 
platelets treated with riboflavin and ultraviolet light for pathogen reduction.  
Transfusion 2005;45:1335-41.
16. Picker SM, Steisel A, Gathof BS. Effects of Mirasol PRT treatment on storage lesion development  
in plasma-stored apheresis-derived platelets compared to untreated and irradiated units.  
Transfusion 2008; 48:1685-92.
17. Sanquin Bloedvoorziening. Richtlijn Bloedproducten. Document PT009.RL. SQ_003.  
Amsterdam, March 2008. 
18. Jackman RP, Heitman JW, Marschner S, Goodrich RP, Norris PJ. Understanding loss of donor white blood 
cell immunogenicity after pathogen reduction: mechanisms of action in ultraviolet illumination  
and riboflavin treatment. Transfusion 2009; 49:2686-99.
19. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B 
irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions.  
N Engl J Med 1997; 337:1861-69.
20. Te Boekhorst PA, Beckers EA, Vos MC, Vermeij H, van Rhenen DJ. Clinical significance of bacteriologic 
screening in platelet concentrates. Transfusion 2005; 45:514-9.
21. Dumont LJ, Kleinman S, Murphy JR, Lippincott R, Schuyler R, Houghton J, Metzel P. Screening of  
single-donor apheresis platelets for bacterial contamination: the PASSPORT study results.  
Transfusion 2010; 50:589-99.
22. Fatal bacterial infections associated with platelet transfusions--United States, 2004.  
MMWR Morb Mortal Wkly Rep. 2005 Feb 25; 54(7):168-70.
9 The continuing story:  The PREPAReS study
143
23. Walther-Wenke G, Schrezenmeier H, Deitenbeck R, Geis G, Burkhart J, Höchsmann B, Sireis W,  
Schmidt M, Seifried E, Gebauer W, Liebscher UM, Weinauer F, Müller TH. Screening of platelet 
concentrates for bacterial contamination: spectrum of bacteria detected, proportion of transfused units, 
and clinical follow-up. Ann Hematol. 2009 May 30. [Epub ahead of print].
24. http://www.intra.sanquin.nl/sanquin-startintra/sqn_startintra_actueel.nsf/All/Invoering-Q-Koorts-Test.
html?opendocument&highlight=Q-koorts
25. Rasonglès P, Angelini-Tibert MF, Simon P, Currie C, Isola H, Kientz D, Slaedts M, Jacquet M, Sundin D,  
Lin L, Corash L, Cazenave JP. Transfusion of platelet components prepared with photochemical  
pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Réunion.  
Transfusion 2009; 49:1083-91.
26. Liumbruno GM, Catalano L, Piccinini V, Pupella S, Grazzini G. Reduction of the risk of bacterial 
contamination of blood components through diversion of the first part of the donation of blood  
and blood components. Blood Transfus 2009;7:86-93.
27. Rinder HM, Murphy M, Mitchell JG, Stocks J, Ault KA, Hillman RS. Progressive platelet activation  
with storage: evidence for shortened survival of activated platelets after transfusion.  
Transfusion 1991; 31:409-14.
28. Michelson AD, Barnard MR, Hechtman HB, MacGregor H, Connolly RJ, Loscalzo J, Valeri CR.  
In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin  
but continue to circulate and function. Proc Natl Acad Sci U S A. 1996; 93:11877-82.
29. Berger G, Hartwell DW, Wagner DD. P-Selectin and platelet clearance. Blood. 1998; 92:4446-52.
30. Leytin V, Allen DJ, Gwozdz A, Garvey B, Freedman J. Role of platelet surface glycoprotein Ibalpha  
and P-selectin in the clearance of transfused platelet concentrates. Transfusion 2004; 44:1487-95.
31. Goodrich RP, Li J, Pieters H, Crookes R, Roodt J, Heyns Adu P. Correlation of in vitro platelet quality 
measurements with in vivo platelet viability in human subjects. Vox Sang 2006;90:279-85.
32. Pereira J, Soto M, Palomo I, Ocqueteau M, Coetzee LM, Astudillo S, Aranda E, Mezzano D.  
Platelet aging in vivo is associated with activation of apoptotic pathways: studies in a model of 
suppressed thrombopoiesis in dogs. Thromb Haemost 2002; 87:905-9.
33. Rand ML, Wang H, Bang KW, Poon KS, Packham MA, Freedman J. Procoagulat surface exposure  
and apoptosis in rabbit platelets: association with shortened survival and steady-state senescence.  
J Thromb Haemost 2004; 2:651-9.
34. D’Aurelio M, Merlo Pich M, Catani L, Sgarbi GL, Bovina C, Fomiggini G, Parenti Castlli G, Baum H, Tura S, 
Lenaz G. Decreased Pasteur effect in platelets of aged individuals. Mech Ageing Dev 2001; 122:823-33.
35. Bertolini F, Porretti L, Lauri E, Rebulla P, Sirchia G. Role of lactate in platelet storage lesion.  
Vox Sang 1993; 55:194-8.
36. Fast LD. Recipient elimination of allogeneic lymphoid cells: donor CD4(+) cells are effective  
alloantigen-presenting cells. Blood 2000; 96:1144-9.
37. Heddle NM, Cook RJ, Tinmouth A, Kouroukis CT, Hervig T, Klapper E, Brandwein JM,  
Szczepiorkowski ZM, AuBuchon JP, Barty RL, Lee KA; SToP Study Investigators of the BEST Collaborative. 
A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets 
(SToP) to patients with thrombocytopenia. Blood 2009; 113:1564-73.
38. Slichter SJ, Kaufman RM, Assmann SF, McCullough J, Triulzi DJ, Strauss RG, Gernsheimer TB, Ness PM, 
Brecher ME, Josephson CD, Konkle BA, Woodson RD, Ortel TL, Hillyer CD, Skerrett DL, McCrae KR,  
Sloan SR, Uhl L, George JN, Aquino VM, Manno CS, McFarland JG, Hess JR, Leissinger C, Granger S.  
Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010; 362:600-13.
39. Kerkhoffs JL, Eikenboom JC, Schipperus MS, van Wordragen-Vlaswinkel RJ, Brand R, Harvey MS,  
de Vries RR, Barge R, van Rhenen DJ, Brand A. A multicenter randomized study of the efficacy of 
transfusions with platelets stored in platelet additive solution II versus plasma. Blood 2006; 108:3210-5.
9The continuing story: The PREPAReS study

APPENDIX A 





AML Trials reviewed for the discussion  
of the thesis
1. Amadori S, Suciu S, Jehn U, Stasi R, Thomas X, Marie JP, Muus P, Lefrere F, Berneman Z, Fillet G, et al.  
Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction 
chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, 
a randomized phase-3 study. Blood 2005 Jul 1;106(1):27-34.
2. Anderson JE, Kopecky KJ, Willman CL, Head D, O’Donnell MR, Luthardt FW, Norwood TH, Chen IM, 
Balcerzak SP, Johnson DB, et al. Outcome after induction chemotherapy for older patients with acute 
myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and 
daunorubicin: a Southwest Oncology Group study. Blood 2002 Dec 1;100(12):3869-76.
3. Archimbaud E, Ottmann OG, Yin JA, Lechner K, Dombret H, Sanz MA, Heil G, Fenaux P, Brugger W,  
Barge A, et al. A randomized, double-blind, placebo-controlled study with pegylated recombinant 
human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy 
for adults with de novo acute myeloid leukemia. Blood 1999 Dec 1;94(11):3694-701.
4. Baer MR, George SL, Dodge RK, O’Loughlin KL, Minderman H, Caligiuri MA, Anastasi J, Powell BL, Kolitz JE, 
Schiffer CA, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated 
patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 
9720. Blood 2002 Aug 15;100(4):1224-32.
5. Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S, Gulati S, Andreeff M, Kolitz J, Gabrilove J,  
et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin  
and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia.  
Blood 1991 Apr 15; 77(8):1666-74.
6. Bishop JF, Lowenthal RM, Joshua D, Matthews JP, Todd D, Cobcroft R, Whiteside MG, Kronenberg H,  
Ma D, Dodds A, et al. Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. 
Blood 1990 Jan 1; 75(1):27-32.
7. Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, Bradstock K, Enno A, Wolf MM, Fox R, et al.  
A randomized study of high-dose cytarabine in induction in acute myeloid leukemia.  
Blood 1996 Mar 1; 87(5):1710-7.
8. Blaise D, Maraninchi D, Archimbaud E, Reiffers J, Devergie A, Jouet JP, Milpied N, Attal M, Michallet M, 
Ifrah N, et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission:  
a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen:  
a report from the Group d’Etudes de la Greffe de Moelle Osseuse. Blood 1992 May 15; 79(10):2578-82.
9. Bradstock KF, Matthews JP, Lowenthal RM, Baxter H, Catalano J, Brighton T, Gill D, Eliadis P, Joshua D,  
Cannell P, et al. A randomized trial of high-versus conventional-dose cytarabine in consolidation 
chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy 
containing high-dose cytarabine. Blood 2005 Jan 15;105(2):481-8.
10. Buchner T, Hiddemann W, Wormann B, Loffler H, Gassmann W, Haferlach T, Fonatsch C, Haase D, 
Schoch C, Hossfeld D, et al. Double induction strategy for acute myeloid leukemia: the effect of 
high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin 
and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood 1999 Jun 15; 
93(12):4116-24.
11. Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, Wheatley K. A comparison of 
low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia 
and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment.  
Cancer 2007 Mar 15; 109(6):1114-24.
12. Cassileth PA, Lynch E, Hines JD, Oken MM, Mazza JJ, Bennett JM, McGlave PB, Edelstein M, Harrington DP, 
O’Connell MJ. Varying intensity of postremission therapy in acute myeloid leukemia.  
Blood 1992 Apr 15; 79(8):1924-30.
148
13. Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E, Willman C, Hurd DD, 
Bennett JM, Blume KG, et al. Chemotherapy compared with autologous or allogeneic bone marrow 
transplantation in the management of acute myeloid leukemia in first remission.  
N.Engl.J.Med. 1998 Dec 3; 339(23):1649-56.
14. Castaigne S, Chevret S, Archimbaud E, Fenaux P, Bordessoule D, Tilly H, de RT, Simon M, Dupriez B, 
Renoux M, et al. Randomized comparison of double induction and timed-sequential induction to  
a “3 + 7” induction in adults with AML: long-term analysis of the Acute Leukemia French Association 
(ALFA) 9000 study. Blood 2004 Oct 15; 104(8):2467-74.
15. Clift RA, Buckner CD, Appelbaum FR, Bearman SI, Petersen FB, Fisher LD, Anasetti C, Beatty P,  
Bensinger WI, Doney K, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia 
in first remission: a randomized trial of two irradiation regimens. Blood 1990 Nov 1; 76(9):1867-71.
16. Cortes J, Kantarjian H, Albitar M, Thomas D, Faderl S, Koller C, Garcia-Manero G, Giles F, Andreeff M,  
O’Brien S, et al. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal 
daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor 
prognosis acute myelogenous leukemia or myelodysplastic syndrome. Cancer 2003 Mar 1; 97(5):1234-41.
17. Couban S, Simpson DR, Barnett MJ, Bredeson C, Hubesch L, Howson-Jan K, Shore TB, Walker IR, Browett P,  
Messner HA, et al. A randomized multicenter comparison of bone marrow and peripheral blood in 
recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002 Sep 1; 
100(5):1525-31.
18. Dillman RO, Davis RB, Green MR, Weiss RB, Gottlieb AJ, Caplan S, Kopel S, Preisler H, McIntyre OR,  
Schiffer C. A comparative study of two different doses of cytarabine for acute myeloid leukemia:  
a phase III trial of Cancer and Leukemia Group B. Blood 1991 Nov 15; 78(10):2520-6.
19. Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R, Mandelli F, Ferrant A, 
Auzanneau G, Tilly H, et al. A controlled study of recombinant human granulocyte colony-stimulating 
factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study 
Group. N.Engl.J.Med. 1995 Jun 22; 332(25):1678-83.
20. Estey EH, Thall PF, Pierce S, Cortes J, Beran M, Kantarjian H, Keating MJ, Andreeff M, Freireich E. 
Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid 
+/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia 
and myelodysplastic syndrome. Blood 1999 Apr 15; 93(8):2478-84.
21. Estey EH, Thall PF, Cortes JE, Giles FJ, O’Brien S, Pierce SA, Wang X, Kantarjian HM, Beran M.  
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens 
in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in 
transformation, or refractory anemia with excess blasts. Blood 2001 Dec 15; 98(13):3575-83.
22. Estey EH, Thall PF, Giles FJ, Wang XM, Cortes JE, Beran M, Pierce SA, Thomas DA, Kantarjian HM. 
Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with 
untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin 
plus continuous-infusion, high-dose cytosine arabinoside. Blood 2002 Jun 15; 99(12):4343-9.
23. Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, Borthakur G, Verstovsek S,  
Thomas DA, Kwari M, et al. A randomized study of clofarabine versus clofarabine plus low-dose 
cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia  
and high-risk myelodysplastic syndrome. Blood 2008 Sep 1; 112(5):1638-45.
24. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, Racevskis J, Dewald GW, Ketterling RP, 
Bennett JM, et al. Anthracycline dose intensification in acute myeloid leukemia.  
N.Engl.J.Med. 2009 Sep 24; 361(13):1249-59.
25. Giles F, Vey N, DeAngelo D, Seiter K, Stock W, Stuart R, Boskovic D, Pigneux A, Tallman M, Brandwein J, 
et al. Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion 
cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first 
relapse. Blood 2009 Nov 5; 114(19):4027-33.
APPENDIX A 
AML Trials reviewed for the discussion of the thesis
149
26. Godwin JE, Kopecky KJ, Head DR, Willman CL, Leith CP, Hynes HE, Balcerzak SP, Appelbaum FR.  
A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients  
with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031).  
Blood 1998 May 15; 91(10):3607-15.
27. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE. Attempts to improve 
treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United 
Kingdom Medical Research Council AML11 trial. Blood 2001 Sep 1; 98(5):1302-11.
28. Hann IM, Stevens RF, Goldstone AH, Rees JK, Wheatley K, Gray RG, Burnett AK. Randomized comparison 
of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid 
leukemia. Results of the Medical Research Council’s 10th AML trial (MRC AML10). Adult and Childhood 
Leukaemia Working Parties of the Medical Research Council. Blood 1997 Apr 1; 89(7):2311-8.
29. Harousseau JL, Cahn JY, Pignon B, Witz F, Milpied N, Delain M, Lioure B, Lamy T, Desablens B, Guilhot F,  
et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as 
postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues 
Myeloblastiques (GOELAM). Blood 1997 Oct 15; 90(8):2978-86.
30. Harousseau JL, Martinelli G, Jedrzejczak WW, Brandwein JM, Bordessoule D, Masszi T, Ossenkoppele GJ, 
Alexeeva JA, Beutel G, Maertens J, et al. A randomized phase 3 study of tipifarnib compared with best 
supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia  
in patients 70 years or older. Blood 2009 Aug 6; 114(6):1166-73.
31. Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin JA, Papa G, Noens L, Szer J, Ganser A, O’Brien C, et al.  
A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction  
and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute 
Myeloid Leukemia Study Group. Blood 1997 Dec 15; 90(12):4710-8.
32. Kern W, Behre G, Rudolf T, Kerkhoff A, Grote-Metke A, Eimermacher H, Kubica U, Wormann B, Buchner T, 
 Hiddemann W. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic 
amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective 
randomized phase III study. German AML Cooperative Group. Cancer 1998 Jul 15; 83(2):291-301.
33. Lange BJ, Smith FO, Feusner J, Barnard DR, Dinndorf P, Feig S, Heerema NA, Arndt C, Arceci RJ, Seibel N,  
et al. Outcomes in CCG-2961, a children’s oncology group phase 3 trial for untreated pediatric acute 
myeloid leukemia: a report from the children’s oncology group. Blood 2008 Feb 1; 111(3):1044-53.
34. List AF, Kopecky KJ, Willman CL, Head DR, Persons DL, Slovak ML, Dorr R, Karanes C, Hynes HE,  
Doroshow JH, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk 
acute myeloid leukemia: a Southwest Oncology Group study. Blood 2001 Dec 1; 98(12):3212-20.
35. Lowenberg B, Suciu S, Archimbaud E, Ossenkoppele G, Verhoef GE, Vellenga E, Wijermans P,  
Berneman Z, Dekker AW, Stryckmans P, et al. Use of recombinant GM-CSF during and after remission 
induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report 
of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation 
for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. 
Blood 1997 Oct 15; 90(8):2952-61.
36. Lowenberg B, van PW, Theobald M, Gmur J, Verdonck L, Sonneveld P, Fey M, Schouten H, de GG,  
Ferrant A, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of 
chemotherapy for acute myeloid leukemia. N.Engl.J.Med. 2003 Aug 21; 349(8):743-52.
37. Lowenberg B, Ossenkoppele GJ, van PW, Schouten HC, Graux C, Ferrant A, Sonneveld P, Maertens J, 
Jongen-Lavrencic M, von Lilienfeld-Toal M, et al. High-dose daunorubicin in older patients with acute 
myeloid leukemia. N.Engl.J.Med. 2009 Sep 24; 361(13):1235-48.
38. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E, 
III. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia 
Group B. N.Engl.J.Med. 1994 Oct 6; 331(14):896-903.
39. Milligan DW, Wheatley K, Littlewood T, Craig JI, Burnett AK. Fludarabine and cytosine are less effective 
than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA 
are not beneficial: results of the MRC AML-HR randomized trial. Blood 2006 Jun 15; 107(12):4614-22.
APPENDIX A 
AML Trials reviewed for the discussion of the thesis
150
40. Miyawaki S, Sakamaki H, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y,  
Asou N, et al. A randomized, postremission comparison of four courses of standard-dose consolidation 
therapy without maintenance therapy versus three courses of standard-dose consolidation with 
maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group 
AML 97 Study. Cancer 2005 Dec 15; 104(12):2726-34.
41. Moore JO, George SL, Dodge RK, Amrein PC, Powell BL, Kolitz JE, Baer MR, Davey FR, Bloomfield CD, 
Larson RA, et al. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as 
postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age:  
Cancer and Leukemia Group B Study 9222. Blood 2005 May 1; 105(9):3420-7.
42. Ohno R, Naoe T, Kanamaru A, Yoshida M, Hiraoka A, Kobayashi T, Ueda T, Minami S, Morishima Y, Saito Y, 
et al. A double-blind controlled study of granulocyte colony-stimulating factor started two days before 
induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group.  
Blood 1994 Apr 15; 83(8):2086-92.
43. Ossenkoppele GJ, Graveland WJ, Sonneveld P, Daenen SM, Biesma DH, Verdonck LF, Schaafsma MR, 
Westveer PH, Peters GJ, Noordhuis P, et al. The value of fludarabine in addition to ARA-C and G-CSF  
in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients.  
Blood 2004 Apr 15; 103(8):2908-13.
44. Rai KR, Holland JF, Glidewell OJ, Weinberg V, Brunner K, Obrecht JP, Preisler HD, Nawabi IW, Prager D, 
Carey RW, et al. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B.  
Blood 1981 Dec;58(6):1203-12.
45. Ravindranath Y, Yeager AM, Chang MN, Steuber CP, Krischer J, Graham-Pole J, Carroll A, Inoue S,  
Camitta B, Weinstein HJ. Autologous bone marrow transplantation versus intensive consolidation 
chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. N.Engl.J.Med. 1996 
May 30; 334(22):1428-34.
46. Ringden O, Ruutu T, Remberger M, Nikoskelainen J, Volin L, Vindelov L, Parkkali T, Lenhoff S, Sallerfors B,  
Ljungman P, et al. A randomized trial comparing busulfan with total body irradiation as conditioning 
in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow 
Transplantation Group. Blood 1994 May 1; 83(9):2723-30.
47. Rowe JM, Andersen JW, Mazza JJ, Bennett JM, Paietta E, Hayes FA, Oette D, Cassileth PA, Stadtmauer EA,  
Wiernik PH. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-
stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia:  
a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995 Jul 15; 86(2):457-62.
48. Rowe JM, Neuberg D, Friedenberg W, Bennett JM, Paietta E, Makary AZ, Liesveld JL, Abboud CN,  
Dewald G, Hayes FA, et al. A phase 3 study of three induction regimens and of priming with GM-CSF  
in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group.  
Blood 2004 Jan 15; 103(2):479-85.
49. Schiffer CA, Miller K, Larson RA, Amrein PC, Antin JH, Zani VJ, Stone RM. A double-blind, placebo-
controlled trial of pegylated recombinant human megakaryocyte growth and development factor as  
an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia.  
Blood 2000 Apr 15; 95(8):2530-5.
50. Solary E, Drenou B, Campos L, de CP, Mugneret F, Moreau P, Lioure B, Falkenrodt A, Witz B, Bernard M,  
et al. Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult  
de novo acute myelogenous leukemia. Blood 2003 Aug 15; 102(4):1202-10.
51. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P, Lee EJ, Moore JO, Powell BL,  
Schiffer CA. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly 
patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N.Engl.J.Med. 1995 
Jun 22; 332(25):1671-7.
52. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman PP, Lee EJ, Moore JO, Powell BL, Baer MR, 
et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial 
comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine.  
Blood 2001 Aug 1; 98(3):548-53.
APPENDIX A 
AML Trials reviewed for the discussion of the thesis
151
53. Tsimberidou AM, Stavroyianni N, Viniou N, Papaioannou M, Tiniakou M, Marinakis T, Skandali A, Sakellari I, 
Yataganas X. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous 
peripheral stem cell transplantation as postremission treatment in patients with de novo acute 
myelogenous leukemia. Cancer 2003 Apr 1; 97(7):1721-31.
54. Vogler WR, Winton EF, Gordon DS, Raney MR, Go B, Meyer L. A randomized comparison of postremission 
therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial. Blood 1984 May; 
63(5):1039-45.
55. Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP, Bickers JN, Hynes HE,  
Welborn JL, Simon SR, et al. A randomized investigation of high-dose versus standard-dose cytosine 
arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia:  
a Southwest Oncology Group study. Blood 1996 Oct 15; 88(8):2841-51.
56. Wiernik PH, Banks PL, Case DC, Jr., Arlin ZA, Periman PO, Todd MB, Ritch PS, Enck RE, Weitberg AB. 
Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously 
untreated adult patients with acute myeloid leukemia. Blood 1992 Jan 15; 79(2):313-9.
57. Witz F, Sadoun A, Perrin MC, Berthou C, Briere J, Cahn JY, Lioure B, Witz B, Francois S, Desablens B, et al. 
A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor 
administered during and after induction treatment for de novo acute myelogenous leukemia in elderly 
patients. Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 1998 Apr 15; 91(8):2722-30.
58. Woods WG, Kobrinsky N, Buckley JD, Lee JW, Sanders J, Neudorf S, Gold S, Barnard DR, DeSwarte J, 
Dusenbery K, et al. Timed-sequential induction therapy improves postremission outcome in acute 
myeloid leukemia: a report from the Children’s Cancer Group. Blood 1996 Jun 15; 87(12):4979-89.
59. Woods WG, Neudorf S, Gold S, Sanders J, Buckley JD, Barnard DR, Dusenbery K, DeSwarte J, Arthur DC, 
Lange BJ, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow 
transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. 
Blood 2001 Jan 1; 97(1):56-62.
60. Yates J, Glidewell O, Wiernik P, Cooper MR, Steinberg D, Dosik H, Levy R, Hoagland C, Henry P, Gottlieb A, 
et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia:  
a CALGB study. Blood 1982 Aug; 60(2):454-62.
61. Zittoun R, Jehn U, Fiere D, Haanen C, Lowenberg B, Willemze R, Abels J, Bury J, Peetermans M, Hayat M,  
et al. Alternating v repeated postremission treatment in adult acute myelogenous leukemia: a randomized 
phase III study (AML6) of the EORTC Leukemia Cooperative Group. Blood 1989 Mar; 73(4):896-906.
62. Zittoun RA, Mandelli F, Willemze R, De WT, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G, et al. 
Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute 
myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the 
Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) Leukemia Cooperative Groups. 
N.Engl.J.Med. 1995 Jan 26; 332(4):217-23.
APPENDIX A 









According to current guidelines, patients with thrombocytopenia due to myelosuppression 
are supported with platelet concentrates in order to prevent and treat bleeding 
complications using algorithms which include the level of thrombocytopenia as well as 
varying clinical parameters, e.g. concomitant infection, the use of anticoagulant drugs, 
specific interventions. In the last three decades, mainly driven by safety issues, several 
platelet product changes were made with leukoreduction in the eighties of the previous 
century, plasma reduction and the use of additive solution in the nineties and the use of 
pathogen reduction in the first decade of this century (chapter 1). Pre-transfusion in-vitro 
quality testing, considered essential by the FDA draft guidance, shows several significant 
differences during storage, however the used tests do not predict clinical efficacy.  
It is hypothesized that a combination of tests using a rating score could be a better 
alternative for the prediction of clinical efficacy (chapter 2). This thesis is mainly based on 
two randomised controlled trials testing the clinical efficacy of the use of additive solutions 
and pathogen reduction, essentially showing a decreased clinical efficacy as well as  
a decrease in adverse transfusion events (chapter 3-5). Platelet transfusion refractoriness 
occurred very frequent, but more importantly it was mainly if not solely caused by 
clinical factors (chapter 3) and associated with bleeding and a decreased patient survival 
(chapter 6). The second trial emphasising the difficulty of measuring and grading bleeding 
complications, nowadays considered as an essential endpoint in platelet transfusion trials, 
resulted in the performance of a pilot study showing that despite platelet transfusion 
support bleeding occurred in the vast majority (87%!) of patients (chapter 7). Similar 
studies from other investigators as well as these observations are leading to an era of 
“rethinking” the pathophysiology of bleeding and the role of platelet transfusion support: 
endothelial damage as a common pathway (chapter 8). As the development of novel 
platelet products continues recently a randomised controlled trial started, comparing 
conventional plasma stored platelets with riboflavin-UVB treated platelets using bleeding 
as primary outcome. In addition, this trial allows for several side studies, including HLA-
immunisation as well as testing patient and product parameters in relation to clinical 
efficacy and the occurrence of bleeding (chapter 9). A better understanding of the 
pathophysiology of bleeding, thrombocytopenia and platelet transfusion refractoriness 




Volgens de huidige richtlijnen worden patiënten met een trombocytopenie als gevolg 
van beenmergsuppressie ondersteund met plaatjes concentraten ter preventie en 
behandeling van bloedingen, gebruikmakend van algoritmes welke rekening houden 
met de mate van trombocytopenie als ook een variërend aantal klinische parameters, b.v. 
infectie, het gebruik van bloedverdunnende medicatie, specifieke interventies. In de laatste 
drie decennia, vooral gedreven door veiligheidsaspecten, hebben plaatjes concentraten 
veranderingen ondergaan met leukoreductie in de tachtiger jaren van de vorige eeuw, 
plasma reductie en de toepassing van synthetische bewaarmedia in de negentiger jaren 
en het gebruik van pathogeen reductie in het eerste decennium van deze eeuw  
(hoofdstuk 1). Pre transfusie in-vitro kwaliteitstesten, als essentieel gezien door de FDA 
richtlijn, toont verschillende significante verschillen gedurende de bewaarperiode,  
echter geen van deze testen voorspellen de klinische effectiviteit. Er wordt een hypothese 
geponeerd dat wellicht een combinatie van testen resulterend in een punten schaal een 
alternatief vormt om klinische effectiviteit te voorspellen (hoofdstuk 2). Dit proefschrift 
is vooral gebaseerd op twee gerandomiseerde studie welke de klinische effectiviteit 
onderzochten van bewaarmedia en pathogeen reductie, en in essentie een afname van 
klinische effectiviteit maar ook een afname van nadelige transfusiereacties laten zien 
(hoofdstuk 3-5). Transfusiefalen bleek zeer frequent voor te komen en belangrijker nog 
vooral zoniet volledig te worden verklaard door klinische factoren (hoofdstuk 3)  
en geassocieerd te zijn met bloeden en een verminderde overleving van patienten 
(hoofdstuk 6). De tweede studie, de moeilijkheid van het meten en graderen van 
bloedingen, tegenwoordig als essentieel eindpunt van plaatjestransfusie studies 
beschouwt, benadrukkend, resulteerde in het verrichten van een voorstudie die liet zien 
dat, ondanks plaatjestransfusies, bloedingen in de overgrote meerderheid (87%!) van de 
patienten optraden (hoofdstuk 7). Vergelijkbare studies van andere onderzoekers als ook 
deze observaties leiden tot het “overdenken” van het mechanisme van bloeden en de rol 
van plaatjestransfusies: Endotheelschade als “common pathway” (hoofdstuk 8).  
Omdat de ontwikkeling van nieuwe plaatjes producten verder gaat, werd in 2011  
met een derde gerandomiseerde studie gestart, welke conventionele in plasma 
bewaarde plaatjes vergelijkt met riboflavine-UVB behandelde plaatjes met bloeden als 
primaire uitkomstmaat. Daarnaast fungeert deze studie als platvorm voor verschillende 
zijstudies, waaronder onderzoek naar HLA-immunisatie als ook het testen van patient- 
en productfactoren in relatie tot het optreden van bloedingen (hoofdstuk 9). Een beter 
begrip over de achtergrond van bloedingen, trombocytopenie en het optreden van 
transfusiefalen zal uiteindelijk leiden tot verbeteringen in de ondersteunende zorg  
en overleving van de patiënt, het gemeenschappelijke doel voor alle behandelaren.
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Na een gevoelsmatig lange weg is er dan nu toch een proefschrift. Hieraan werd ik telkens 
herinnerd door de jaarlijks terugkerende kerstboodschap van Christl Vermeij-Keers. 
Eigenlijk staat zij aan de basis van mijn interesse voor het doen van wetenschappelijk 
onderzoek. Ik zie mij zelf nog staan in de kelder van het oude Anatomiegebouw van de 
Leidse Universiteit. Vreugdevol was ik dan ook dat ik haar op de kerstkaart kon schrijven 
dat de promotie in 2012 echt zal plaatsvinden. 
Het tweede bepalende moment is mijn kennismaking met Anneke Brand, die mij 
op een bank naast het transfusielaboratorium enthousiast maakte voor klinisch 
transfusieonderzoek. Dankbaar ben ik voor de drempelloze begeleiding, die zij mij al die 
jaren gaf en nog geeft. Mijn eerste studie had ik niet kunnen doen zonder de medewerking 
van het transfusielaboratorium in Leiden, de verpleegkundigen en niet in het minst de 
secretaresses van de hematologie afdeling van het LUMC. Zonder enige kennis van GCP 
werd er nog gerandomiseerd met envelopjes en de afdeling gedecoreerd met oranje 
stickers. In die tijd leerde ik ook Rinie kennen als een trouwe steun en toeverlaat. De studie 
toen, maar ook de daaropvolgende studies had ik niet kunnen volbrengen zonder haar 
toewijding. Zij is in de afgelopen jaren gegroeid als datamanager en bovenal als vriendin. 
Wat mij brengt op Henk, de andere paranimf. Hoewel ik Henk al kende van mijn 
opleidingsjaren in het Leyenburg ziekenhuis, leerde ik hem vooral kennen toen hij 
voor Sanquin ging werken. Mijn allereerste bloedtransfusiecongres in Seattle maakte 
ik met hem mee. Waar Anneke, Jeroen, Henk en vele anderen mijn wetenschappelijke 
vorderingen ondersteunden, was er ook een collega en vriend, die mij als hematoloog  
het vertouwen gaf en geeft, Pierre. Er zijn weinigen, die zo vol overgave en visie met 
mensen kunnen werken als hij, zowel als dokter, opleider en collega. Ik ben er trots op  
te mogen werken met collega’s als Pierre, Martin, Paula, Lara en Danielle.  
Hoewel het zeker niet al tijd ‘koek en ei’ is, zorgen zij er al jaren voor dat ik op een 
topklinische hematologieafdeling kan werken en onderzoek kan doen. Een andere 
hematoloog die ik dankbaar ben, is Peter Huijgens. Hij stond voor en naast me toen  
het recht om wetenschappelijk onderzoek te publiceren werd bedreigd.
Dankbaar ben ik voor de steun die ik kreeg van mijn collega’s van de KCD: Bert, Edward, 
Kees, Ella, Cynthia, Judith, Annemieke, Tanneke, Dick en Ivan. De woensdag-overdracht is 
één van ‘sweeks hoogtepunten! Naast deze mensen, is er nog een lange lijst met personen 
die mijn dankbaarheid zijn verschuldigd en ik ben helaas niet in staat om deze lijst 
compleet op te noemen zonder mensen te vergeten. Daarom beperk ik mij  
tot drie personen, Anne, Lucia en Gonul. Zij hebben mij al die jaren secretarieel, maar ook 
vriendschappelijk ondersteund. Ze delen één belangrijke eigenschap: je kunt altijd bij ze 
terecht ook als het, zoals zo vaak bij dokters, “tussendoor” moet.
De laatste alinea van dit proefschrift (hoewel het ook de eerste had kunnen zijn) wil ik 
gebruiken om mijn maatje Corine te bedanken. Zij is al meer dan 20 jaar mijn steun en 
toeverlaat. Zonder haar had ik dit alles niet kunnen bereiken. Zij was, is en zal altijd zijn: 
een klankbord en een knuffel. Amo ergo sum!
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Current projects:
 PrePAres study: Clinical effectiveness of standard versus pathogen-reduced buffy coat-derived platelet 
concentrates in plasma in hemato-oncological patients. A multicenter randomised controlled trial. 
 Aml study: a retrospective cohort study investigating the association between bleeding and survival  
in 160 AML patients treated from 2000 – 2004 in two large hospitals. 
 Albumen study: a prospective pilot study testing albuminuria and CRP as markers for endothelial 
damage in AML patients (n = 10) undergoing cytotoxic treatment.
 itP-ttP study: a case-control study testing the occurrence of thromboembolic and cardiovascular 
complications during the follow-up of patients with TTP in remission
